

**CUMULATIVE
SUPPLEMENT 9
JAN'97-SEP'97**

APPROVED DRUG PRODUCTS

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

17TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

PUBLIC HEALTH SERVICE


FOOD AND DRUG ADMINISTRATION

CENTER FOR DRUG EVALUATION AND RESEARCH

OFFICE OF INFORMATION TECHNOLOGY

DIVISION OF DATA MANAGEMENT AND SERVICES

1997



RM
301.45
.A66
1997
Sep 19
Suppl

Prepared By
Division of Data Management and Services
Office of Information Technology
Center for Drug Evaluation and Research, FDA

SUBSCRIBE NOW!

Available in March 1998

New 18th Edition



**APPROVED
DRUG PRODUCTS**

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

**18TH EDITION
1998**

Library Use Only

CONTENTS

- Prescription Drug Product List
- OTC Drug Product List
- Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List
- Discontinued Drug Product List
- Orphan Drug Product Designations
- Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution
- Patent and Exclusivity Information

See Subscription Form Inside Back Cover

Approved drug products with
therapeutic equivalence

C:355661 M:174736 O:12937927

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

17TH EDITION

Cumulative Supplement 9

SEPTEMBER 1997

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to Use the Cumulative Supplement	iii
1.2 Court Order Affecting Uruguay Round Agreements Act-Extended Patents	iv
1.3 Applicant Name Changes	v
1.4 Acyclovir 200 mg Tablet-Reference Listed Drug	vii
1.5 Follitropin Alfa and Beta	viii
1.6 Availability of the Publication and Updating Procedures	viii
1.7 Report of Counts for the Prescription Drug Product List	ix
2.0 DRUG PRODUCT LISTS	
2.1 Prescription Drug Product List	1
2.2 OTC Drug Product List	69
2.3 Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	73
2.4 Orphan Product Designations and Approvals List	74
2.5 Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	82
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Terms	83
B. Patent and Exclusivity Lists	86

LIBRARY
ST. LOUIS COLLEGE OF PHARMACY
4588 PARKVIEW PL
ST. LOUIS, MO. 63110

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

17TH EDITION

**CUMULATIVE SUPPLEMENT 9
SEPTEMBER 1997**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 17th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Patent and Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the patent and/or exclusivity expires. Refer to the Patent and Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

New additions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >DLT> (DELETE) to the left of the line. The >DLT> symbol is dropped in subsequent Cumulative Supplements for that item. The shaded print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements (hard copy only) for this edition. However, the overstruck data in the Patent and Exclusivity Data is dropped in subsequent Cumulative Supplements (hard copy).

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 17th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 18th Edition.

1.2 COURT ORDER AFFECTING URUGUAY ROUND AGREEMENTS ACT-EXTENDED PATENTS

As a result of the April 4, 1996, decision of the United States Court of Appeals for the Federal Circuit in Merck, et al. v. Kessler, patent expiration dates for certain patents subject to patent term extensions under the Uruguay Round Agreements Act and to the patent term extension provisions at 35 U.S.C. § 156 may be changed. FDA has published a notice in the March 14, 1997, *Federal Register* advising NDA and NADA

applicants that patent expiration dates changed by the Merck decision must be submitted within 60 days. Because there may be changes in listed patents as a result of the Merck decision, users of this publication should consult the most recent supplement, and are encouraged to confirm that patent information upon which they intend to rely is current. (See the *Patent and Exclusivity Addendum to the Approved Drug Products with Therapeutic Equivalence Evaluations*, 17th Edition that explains the background information on this court decision).

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will automatically reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. However, when the applicant name change is one which may not be easily recognized or located in the listing (e.g., White Towne Paulsen [Former Abbreviated Name] is changed to Whiteworth Towne PLSN [New Abbreviated Name], the name change will appear in this section and will be identified with an asterisk.

APPLICANT NAME CHANGES

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

CIBA GEIGY CORP
(CIBA GEIGY)

NOVARTIS PHARMACEUTICALS CORP
(NOVARTIS)

APPLICANT NAME CHANGES

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

CIBA GEIGY CORP PHARMACEUTICALS DIV
(CIBA GEIGY)

NOVARTIS PHARMACEUTICALS CORP
(NOVARTIS)

CIBA PHARMACEUTICAL CO
DIV CIBA GEIGY CORP
(CIBA)

NOVARTIS PHARMACEUTICALS CORP
(NOVARTIS)

CIBA SELF MEDICATION INC
DIV CIBA GEIGY CORP
(CIBA)

NOVARTIS CONSUMER HEALTH INC
(NOVARTIS)

CIBA VISION CORP
(CIBA)

CIBA VISION CORPORATION A
NOVARTIS COMPANY
(CIBA)

CIBA VISION OPHTHALMICS
DIV CIBA VISION CORP
(CIBA)

CIBA VISION CORPORATION A
NOVARTIS COMPANY
(CIBA)

FERRING LABORATORIES INC
(FERRING)

FERRING PHARMACEUTICALS INC
(FERRING)

GEIGY PHARMACEUTICALS
DIV CIBA GEIGY CORP
(GEIGY)

NOVARTIS PHARMACEUTICALS CORP
(NOVARTIS)

LEMMON CO SUB TAG PHARMACEUTICAL INC
(LEMMON)

BIOCRAFT LABORATORIES INC
(BIOCRAFT)
THEN CHANGED TO
TEVA PHARMACEUTICALS USA
(TEVA)

REXAR PHARMACAL
(REXAR)

SHIRE RICHWOOD INC
(SHIRE RICHWOOD)

RICHWOOD PHARMACEUTICAL CO INC
(RICHWOOD PHARM)

SHIRE RICHWOOD INC
(SHIRE RICHWOOD)

APPLICANT NAME CHANGES

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

SANDOZ CONSUMER HEALTH
CARE GROUP DIV SANDOZ PHARMACEUTICALS
(SANDOZ)

NOVARTIS CONSUMER HEALTH INC
(NOVARTIS)

SANDOZ PHARMACEUTICALS
CORP DIV SANDOZ INC
(SANDOZ)

NOVARTIS PHARMACEUTICALS CORP
(NOVARTIS)

SANDOZ RESEARCH INSTITUTE INC
(SANDOZ)

NOVARTIS PHARMACEUTICALS CORP
(NOVARTIS)

SANOFI WINTHROP INC
(SANOFI WINTHROP)

SANOFI PHARMACEUTICAL INC
(SANOFI)

SURVIVAL TECHNOLOGY INC
(SURVIVAL TECH)

MERIDIAN MEDICAL TECHNOLOGIES INC
(MERIDIAN MEDCL TECHN)

1.4 ACYCLOVIR 200MG TABLET-REFERENCE LISTED DRUG

Novapharm's single source acyclovir tablets have been declared to be a reference listed drug for the 200 mg tablet in addition to the acyclovir (Zovirax) 800 mg tablet of the innovator. A generic firm wishing to submit an ANDA for a duplicate of the 200 mg acyclovir tablet will be eligible for a waiver of the *in vivo* determination of bioequivalence (1) if their product is proportionally similar in its active and inactive ingredients to their own 800 mg acyclovir tablet and (2) by doing an acceptable comparative dissolution test (dissolution profile) against Novopharm's 200 mg acyclovir reference listed drug.

Before a waiver of the *in vivo* determination of bioequivalence can be granted for the 200 mg acyclovir tablet, the generic firm must have completed an acceptable fasting and fed study comparing their acyclovir 800 mg tablet against the Zovirax 800 mg tablet.

For further information on the study designs, you should contact the Division of Bioequivalence, Office of Generic Drugs.

1.5 FOLLITROPIN ALFA AND BETA

Based on available data derived from physico-chemical tests and bioassay, follitropin alfa and follitropin beta are indistinguishable.

1.6 AVAILABILITY OF THE PUBLICATION AND UPDATING PROCEDURES

The *Approved Drug Products with Therapeutic Equivalence Evaluations* (Prescription Drug Products, OTC Drug Products and the Discontinued Drug Product Lists) is available on diskette, on a quarterly basis, from the National Technical Information Service. The telephone number for the Subscription Department is (703) 487-6430. Written inquiries regarding this subscription may be forwarded to 5285 Port Royal Road Springfield, VA 22161.

The following *Approved Drug Products with Therapeutic Equivalence Evaluations* files are now available on Internet and are updated each October and April: Prescription Drug Product List; OTC Drug Products; Discontinued Drug Products; Prescription and OTC Drug Product Patent and Exclusivity Data; and Appendices. The update in October will include drug products that have been approved through August and the update in April will include drug products that have been approved through December.

These files may be accessed on the Internet's World Wide Web. FDA's Internet site replaced the Agency's electronic bulletin board. To access the CDER Home Page, use this Uniform Resource Locator (URL): <http://www.fda.gov/cder>. You do not need an Internet connection to reach the FDA Home Page; you can use the free dial-up connection (800) 222-0185 for text based, non-graphical use only. For further assistance, please call (301) 443-4908.

1.7 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1996) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC. 1996*</u>	<u>MAR. 1997</u>	<u>JUN. 1997</u>	<u>SEP. 1997</u>
DRUG PRODUCTS LISTED	9392	9493	9533	9501
SINGLE SOURCE	2383 (25.4%)	2387 (25.1%)	2388 (25.0%)	2420 (25.5%)
MULTISOURCE	6905 (73.5%)	6991 (73.7%)	7031 (73.8%)	6970 (73.3%)
THERAPEUTICALLY EQUIVALENT	6463 (68.8%)	6549 (69.0%)	6626 (69.5%)	6587 (69.3%)
NOT THERAPEUTICALLY EQUIVALENT	442 (4.7%)	442 (4.7%)	405 (4.3%)	383 (4.0%)
EXCEPTIONS ¹	104 (1.1%)	115 (1.2%)	114 (1.2%)	111 (1.2%)
NEW MOLECULAR ENTITIES APPROVED	--	6	8	14
NUMBER OF APPLICANTS	650	662	682	701

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

*Exceptions were originally included in the total count of the Multisource Drug Products. Beginning with December 1996, exceptions were no longer included in the Multisource Drug Products total count, but included in the total count of the Drug Products Listed.

ACETAMINOPHEN; HYDROCODONE BITARTRATE
 TABLET; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN
 @ BARR

AA	EON	500MG; 5MG	N88577 001 DEC 21, 1984
AA		500MG; 5MG	N40149 001
AA	HALSEY	750MG; 7.5MG	JAN 27, 1997
AA		500MG; 5MG	N40149 002
AA		750MG; 7.5MG	JAN 27, 1997
AA	PEACHTREE	500MG; 10MG	SEP 25, 1997
AA		500MG; 10MG	N40236 001
AA	VINTAGE PHARMS	500MG; 2.5MG	SEP 25, 1997
AA		500MG; 2.5MG	N40236 002
AA		650MG; 7.5MG	SEP 25, 1997
AA	WATSON LABS	500MG; 10MG	AUG 13, 1997
AA		500MG; 10MG	N40210 001
AA		500MG; 10MG	APR 14, 1997
AA		500MG; 5MG	N40155 001
AA		500MG; 5MG	APR 14, 1997
AA		500MG; 5MG	N40148 002
AA		500MG; 5MG	FEB 14, 1997
AA		500MG; 10MG	N88577 001
AA		500MG; 10MG	DEC 21, 1984
AA		500MG; 10MG	N40160 001
AA		500MG; 5MG	JAN 26, 1996
AA		500MG; 5MG	N87722 001
AA		500MG; 10MG	JUL 09, 1982
AA		325MG; 5MG	N40100 001
AA		325MG; 5MG	JAN 26, 1996
AA		325MG; 10MG	N40099 001
AA		325MG; 10MG	JUN 25, 1997
AA		325MG; 5MG	N40148 001
AA		325MG; 5MG	FEB 14, 1997

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE
 TABLET; ORAL
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN
 @ BARR

AA	VINTAGE PHARMS	650MG; 100MG	N74843 001 FEB 12, 1997
AA		650MG; 100MG	N40195 001
AA		125MG	MAY 28, 1997
AA		250MG	N40195 002
AA		250MG	MAY 28, 1997
AA		500MG BASE/VIAL	N40108 001
AA		500MG BASE/VIAL	OCT 30, 1995
AA		500MG BASE/VIAL	N40108 001
AA		500MG BASE/VIAL	OCT 30, 1995

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE
 TABLET; ORAL
PERCOCET
 @ BARR

AA	DUPONT MERCK	325MG; 5MG	N85106 002
AA		325MG; 5MG	N85106 002

ACETIC ACID, GLACIAL; DESONIDE
 SOLUTION/DROPS; AURICULAR (OTIC)
 @ BAYER

AA		2%; 0.05%	N17914 001
----	--	-----------	------------

ACETAZOLAMIDE SODIUM
 INJECTABLE; INJECTION
 @ ABBOTT

AP		EQ 500MG BASE/VIAL	N40108 001
AP		EQ 500MG BASE/VIAL	OCT 30, 1995
AP		EQ 500MG BASE/VIAL	N40108 001
AP		EQ 500MG BASE/VIAL	OCT 30, 1995

ACETAZOLAMIDE SODIUM
 SOLUTION/DROPS; OTIC
 @ BAYER

AA		2%; 0.05%	N17914 001
----	--	-----------	------------

ACYCLOVIR
 CAPSULE; ORAL
 @ AESGEN

AB		200MG	N74833 001
AB		200MG	APR 22, 1997
AB		200MG	N74872 001
AB		200MG	APR 22, 1997
AB		200MG	N74750 001
AB		200MG	APR 22, 1997

ACYCLOVIR

CAPSULE; ORAL

AB ACYCLOVIR
LEMMON

200MG

N74828 001
APR 22, 1997

AB MYLAN

200MG

N74727 001
APR 22, 1997

AB NOVOPHARM

200MG

N74578 001
APR 22, 1997

AB PUREPAC PHARM

200MG

N74906 001
AUG 26, 1997

AB ROXANE

200MG

N74570 002
APR 22, 1997

AB TEVA

200MG

N74828 001
APR 22, 1997

AB ZENITH GOLDLINE

200MG

N74674 001
APR 22, 1997

AB ZOVIRAX
+ GLAXO WELLCOME

200MG

N18828 001
JAN 25, 1985

SUSPENSION; ORAL

AB ACYCLOVIR
ALPHARMA

200MG/5ML

N74738 001
APR 28, 1997

AB ZOVIRAX
+ GLAXO WELLCOME

200MG/5ML

N19909 001
DEC 22, 1989

TABLET; ORAL

AB ACYCLOVIR
ESI LEDELERLE

400MG

N74834 001
APR 24, 1997

AB LEK PHARM

800MG

N74834 002
APR 24, 1997

AB NOVOPHARM

400MG

N74658 001
APR 22, 1997

AB NOVOPHARM

800MG

N74658 002
APR 22, 1997

AB NOVOPHARM

400MG

N74556 002
APR 22, 1997

AB NOVOPHARM

800MG

N74556 003
APR 22, 1997

AB PUREPAC PHARM

200MG

N74556 001
APR 22, 1997

AB PUREPAC PHARM

400MG

N74870 001
JUN 05, 1997

ACYCLOVIR

TABLET; ORAL

AB ACYCLOVIR
PUREPAC PHARM

800MG

N74870 002
JUN 05, 1997

AB ZENITH GOLDLINE

400MG

N74836 001
APR 22, 1997

AB ZOVIRAX
GLAXO WELLCOME

800MG

N74836 002
APR 22, 1997

AB ZOVIRAX
GLAXO WELLCOME

400MG

N20089 001
APR 30, 1991

AB +

800MG

N20089 002
APR 30, 1991

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

AP ACYCLOVIR SODIUM
ABBOTT

EQ 500MG BASE/VIAL

N74663 001
APR 22, 1997

AP EQ 500MG BASE/VIAL

N74758 001
APR 22, 1997

AP EQ 1GM BASE/VIAL

N74663 002
APR 22, 1997

AP EQ 1GM BASE/VIAL

N74758 002
APR 22, 1997

AP EQ 500MG BASE/VIAL

N74596 002
APR 22, 1997

AP EQ 1GM BASE/VIAL

N74596 001
APR 22, 1997

AP EQ 25MG BASE/ML

N74720 001
APR 22, 1997

AP EQ 500MG BASE/VIAL

N74969 001
AUG 26, 1997

AP EQ 1GM BASE/VIAL

N74969 002
AUG 26, 1997

AP EQ 500MG BASE/VIAL

N74663 001
APR 22, 1997

AP EQ 1GM BASE/VIAL

N74663 002
APR 22, 1997

AP EQ 500MG BASE/VIAL

N18603 001
OCT 22, 1982

AP EQ 1GM BASE/VIAL

N18603 002
JUN 29, 1989

RX DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 9 / JAN '97 - SEP '97

<u>ALBUTEROL</u>					
AEROSOL, METERED; INHALATION					
<u>ALBUTEROL</u>					
ALPHARMA	<u>0.09MG/INH</u>	N73045 001			
		AUG 19, 1997			
<u>ALBUTEROL SULFATE</u>					
SOLUTION; INHALATION					
<u>ALBUTEROL SULFATE</u>					
NEPHRON	<u>EQ 0.083% BASE</u>	N74880 001			
		SEP 17, 1997			
> ADD >					
> ADD >					
<u>ALENDRONATE SODIUM</u>					
TABLET; ORAL					
FOSAMAX					
MERCK	EQ 5MG BASE	N20560 003			
		APR 25, 1997			
<u>ALPRAZOLAM</u>					
TABLET; ORAL					
<u>ALPRAZOLAM</u>					
ROYCE LABS	<u>0.25MG</u>	N74479 001			
		JAN 21, 1997			
<u>AB</u>	<u>0.5MG</u>	N74479 002			
		JAN 21, 1997			
<u>AB</u>	<u>1MG</u>	N74479 003			
		JAN 21, 1997			
<u>ALPROSTADIL</u>					
INJECTABLE; INJECTION					
<u>CAVERJECT</u>					
PHARMACIA AND UPJOHN	<u>0.005MG/VIAL</u>	N20379 003			
		JUN 27, 1996			
<u>AP</u>	<u>0.01MG/VIAL</u>	N20379 001			
		JUL 06, 1995			
<u>AP</u>	<u>0.02MG/VIAL</u>	N20379 002			
		JUL 06, 1995			
<u>AP</u>	<u>0.04MG/VIAL</u>	N20379 004			
		MAY 19, 1997			
<u>ALPROSTADIL</u>					
INJECTABLE; INJECTION					
<u>EDEX</u>					
SCHWARZ PHARMA	<u>0.005MG/VIAL</u>	N20649 001			
		JUN 12, 1997			
<u>AP</u>	<u>0.01MG/VIAL</u>	N20649 002			
		JUN 12, 1997			
<u>AP</u>	<u>0.02MG/VIAL</u>	N20649 003			
		JUN 12, 1997			
<u>AP</u>	<u>0.04MG/VIAL</u>	N20649 004			
		JUN 12, 1997			
<u>AMANTADINE HYDROCHLORIDE</u>					
TABLET; ORAL					
SYMMETREL					
DU PONT MERCK	100MG	N18101 001			
ENDO PHARMS	100MG	N18101 001			
<u>AMIKACIN SULFATE</u>					
INJECTABLE; INJECTION					
<u>AMIKACIN SULFATE</u>					
ABBOTT	<u>EQ 250MG BASE/ML</u>	N64098 001			
		JUN 26, 1995			
<u>AP</u>	<u>EQ 250MG BASE/ML</u>	N64099 001			
		JUN 20, 1995			
<u>AP</u>	<u>EQ 50MG BASE/ML</u>	N63274 001			
		MAY 18, 1992			
<u>AP</u>	EQ 50MG BASE/ML	N63274 001			
		MAY 18, 1992			
<u>AP</u>	<u>EQ 250MG BASE/ML</u>	N64098 001			
		JUN 26, 1995			
<u>AP</u>	<u>EQ 250MG BASE/ML</u>	N64099 001			
		JUN 20, 1995			
AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
ABBOTT	EQ 500MG BASE/100ML	N64146 001			
		APR 02, 1997			
<u>AMINO ACIDS</u>					
INJECTABLE; INJECTION					
AMINOSYN II 5%					
ABBOTT	5%	N19438 002			
		APR 03, 1986			

AMINO ACIDS

INJECTABLE; INJECTION
AMINOSYN II 5%

5% N19438 002
APR 03, 1986

@ ABBOTT

> DLT >
> DLT >

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE;
POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM
CHLORIDE

INJECTABLE; INJECTION
AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM
IN PLASTIC CONTAINER
ABBOTT

5%; 36.8MG/100ML; 25GM/100ML;
51MG/100ML; 22.4MG/100ML; 261MG/100ML;
205MG/100ML N19683 004
NOV 07, 1988

5%; 36.8MG/100ML; 25GM/100ML;
51MG/100ML; 22.4MG/100ML; 261MG/100ML;
205MG/100ML N19714 003
SEP 12, 1988

5%; 36.8MG/100ML; 25GM/100ML;
51MG/100ML; 22.4MG/100ML; 261MG/100ML;
205MG/100ML N19683 004
NOV 07, 1988

5%; 36.8MG/100ML; 25GM/100ML;
51MG/100ML; 22.4MG/100ML; 261MG/100ML;
205MG/100ML N19714 003
SEP 12, 1988

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE;
POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM
CHLORIDE

INJECTABLE; INJECTION
AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM
IN PLASTIC CONTAINER
ABBOTT

3.5%; 36.8MG/100ML; 25GM/100ML;
51MG/100ML; 22.4MG/100ML; 261MG/100ML;
205MG/100ML N19714 001
SEP 12, 1988

3.5%; 36.8MG/100ML; 25GM/100ML;
51MG/100ML; 22.4MG/100ML; 261MG/100ML;
205MG/100ML N19714 001
SEP 12, 1988

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/
CALCIUM IN PLASTIC CONTAINER
ABBOTT

4.25%; 36.8MG/100ML; 20GM/100ML;
51MG/100ML; 22.4MG/100ML; 261MG/100ML;
205MG/100ML N19714 002
SEP 12, 1988

4.25%; 36.8MG/100ML; 20GM/100ML;
51MG/100ML; 22.4MG/100ML; 261MG/100ML;
205MG/100ML N19714 002
SEP 12, 1988

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/
CALCIUM IN PLASTIC CONTAINER
ABBOTT

4.25%; 36.8MG/100ML; 25GM/100ML;
51MG/100ML; 22.4MG/100ML; 261MG/100ML;
205MG/100ML N19714 004
SEP 12, 1988

4.25%; 36.8MG/100ML; 25GM/100ML;
51MG/100ML; 22.4MG/100ML; 261MG/100ML;
205MG/100ML N19714 004
SEP 12, 1988

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE;
POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

CLINIMIX E 2.75/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/
CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE
2.75%; 33MG/100ML; 10GM/100ML;
51MG/100ML; 261MG/100ML; 217MG/100ML;
112MG/100ML N20678 002
MAR 26, 1997

CLINIMIX E 2.75/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/
CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE
2.75%; 33MG/100ML; 25GM/100ML;
51MG/100ML; 261MG/100ML; 217MG/100ML;
112MG/100ML N20678 005
MAR 26, 1997

CLINIMIX E 2.75/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/
CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE
2.75%; 33MG/100ML; 5GM/100ML;
51MG/100ML; 261MG/100ML; 217MG/100ML;
112MG/100ML N20678 001
MAR 26, 1997

> DLT >
> DLT >
> DLT >
> DLT >
> ADD >
> ADD >
> ADD >

> DLT >
> DLT >
> DLT >
> DLT >
> ADD >
> ADD >
> ADD >

> DLT >
> DLT >
> DLT >
> DLT >
> ADD >
> ADD >
> ADD >

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE;
 POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
 CLINIMIX E 4.25/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/
 CALCIUM IN PLASTIC CONTAINER
 + BAXTER HLTHCARE
 4.25%; 33MG/100ML; 10GM/100ML;
 51MG/100ML; 261MG/100ML; 297MG/100ML;
 77MG/100ML
 N20678 009
 MAR 26, 1997

CLINIMIX E 4.25/20 SULFITE-FREE W/ ELECT IN DEXTROSE 20% W/
 CALCIUM IN PLASTIC CONTAINER
 + BAXTER HLTHCARE
 4.25%; 33MG/100ML; 20GM/100ML;
 51MG/100ML; 261MG/100ML; 297MG/100ML;
 77MG/100ML
 N20678 011
 MAR 26, 1997

CLINIMIX E 4.25/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/
 CALCIUM IN PLASTIC CONTAINER
 + BAXTER HLTHCARE
 4.25%; 33MG/100ML; 25GM/100ML;
 51MG/100ML; 261MG/100ML; 297MG/100ML;
 77MG/100ML
 N20678 012
 MAR 26, 1997

CLINIMIX E 4.25/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/
 CALCIUM IN PLASTIC CONTAINER
 + BAXTER HLTHCARE
 4.25%; 33MG/100ML; 5GM/100ML;
 51MG/100ML; 261MG/100ML; 297MG/100ML;
 77MG/100ML
 N20678 008
 MAR 26, 1997

CLINIMIX E 5/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/
 CALCIUM IN PLASTIC CONTAINER
 + BAXTER HLTHCARE
 5%; 33MG/100ML; 10GM/100ML; 51MG/100ML;
 261MG/100ML; 340MG/100ML;
 59MG/100ML
 N20678 016
 MAR 26, 1997

CLINIMIX E 5/15 SULFITE-FREE W/ ELECT IN DEXTROSE 15% W/
 CALCIUM IN PLASTIC CONTAINER
 + BAXTER HLTHCARE
 5%; 33MG/100ML; 15GM/100ML; 51MG/100ML;
 261MG/100ML; 340MG/100ML;
 59MG/100ML
 N20678 017
 MAR 26, 1997

CLINIMIX E 5/20 SULFITE-FREE W/ ELECT IN 20% DEXTROSE W/
 CALCIUM IN PLASTIC CONTAINER
 + BAXTER HLTHCARE
 5%; 33MG/100ML; 20GM/100ML; 51MG/100ML;
 261MG/100ML; 340MG/100ML;
 59MG/100ML
 N20678 018
 MAR 26, 1997

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE;
 POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
 CLINIMIX E 5/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/
 CALCIUM IN PLASTIC CONTAINER
 + BAXTER HLTHCARE
 5%; 33MG/100ML; 25GM/100ML; 51MG/100ML;
 261MG/100ML; 340MG/100ML;
 59MG/100ML
 N20678 019
 MAR 26, 1997

CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/
 CALCIUM IN PLASTIC CONTAINER
 + BAXTER HLTHCARE
 5%; 33MG/100ML; 35GM/100ML; 51MG/100ML;
 261MG/100ML; 340MG/100ML;
 59MG/100ML
 N20678 021
 MAR 26, 1997

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER
 ABBOTT
 3.5%; 25GM/100ML
 N19505 002
 NOV 07, 1986

AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER
 ABBOTT
 3.5%; 25GM/100ML
 N19713 006
 SEP 09, 1988

AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER
 ABBOTT
 3.5%; 25GM/100ML
 N19505 002
 NOV 07, 1986

AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER
 ABBOTT
 3.5%; 25GM/100ML
 N19713 006
 SEP 09, 1988

AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER
 ABBOTT
 3.5%; 5GM/100ML
 N19506 001
 NOV 07, 1986

AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER
 ABBOTT
 3.5%; 5GM/100ML
 N19713 002
 SEP 09, 1988

AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER
 ABBOTT
 3.5%; 5GM/100ML
 N19506 001
 NOV 07, 1986

AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER
 ABBOTT
 3.5%; 5GM/100ML
 N19713 002
 SEP 09, 1988

AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER
 ABBOTT
 4.25%; 10GM/100ML
 N19713 001
 SEP 09, 1988

AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER
 ABBOTT
 4.25%; 10GM/100ML
 N19713 001
 SEP 09, 1988

AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER
 ABBOTT
 4.25%; 20GM/100ML
 N19713 004
 SEP 09, 1988

AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER
 ABBOTT
 4.25%; 20GM/100ML
 N19713 004
 SEP 09, 1988

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER N19504 002
 4.25%; 25GM/100ML NOV 07, 1986
 ABBOTT
 4.25%; 25GM/100ML N19713 005
 SEP 09, 1988
 @ 4.25%; 25GM/100ML N19504 002
 NOV 07, 1986
 @ 4.25%; 25GM/100ML N19713 005
 SEP 09, 1988
 AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER N19713 003
 5%; 25GM/100ML SEP 09, 1988
 ABBOTT
 @ 5%; 25GM/100ML N19713 003
 SEP 09, 1988
 CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER N20734 002
 BAXTER HLTHCARE 2.75%; 10% SEP 29, 1997
 CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER N20734 005
 BAXTER HLTHCARE 2.75%; 25GM/100ML SEP 29, 1997
 CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER N20734 001
 BAXTER HLTHCARE 2.75%; 5GM/100ML SEP 29, 1997
 CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER N20734 008
 BAXTER HLTHCARE 4.25%; 10GM/100ML SEP 29, 1997
 CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER N20734 010
 BAXTER HLTHCARE 4.25%; 20GM/100ML SEP 29, 1997
 CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER N20734 011
 BAXTER HLTHCARE 4.25%; 25GM/100ML SEP 29, 1997
 CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER N20734 007
 BAXTER HLTHCARE 4.25%; 5GM/100ML SEP 29, 1997
 CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER N20734 014
 BAXTER HLTHCARE 5%; 10GM/100ML SEP 29, 1997

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER N20734 015
 BAXTER HLTHCARE 5%; 15GM/100ML SEP 29, 1997
 CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER N20734 016
 BAXTER HLTHCARE 5%; 20GM/100ML SEP 29, 1997
 CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER N20734 017
 BAXTER HLTHCARE 5%; 25GM/100ML SEP 29, 1997
 CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER N20734 018
 BAXTER HLTHCARE 5%; 35GM/100ML SEP 29, 1997

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE; DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER
 ABBOTT
 4.25%; 10GM/100ML; 51MG/100ML;
 176.5MG/100ML; 22.4MG/100ML;
 104.5MG/100ML; 205MG/100ML N19712 002
 SEP 08, 1988
 @ 4.25%; 10GM/100ML; 51MG/100ML;
 176.5MG/100ML; 22.4MG/100ML;
 104.5MG/100ML; 205MG/100ML N19712 002
 SEP 08, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE; DIBASIC

INJECTABLE; INJECTION

AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER
 ABBOTT
 3.5%; 5GM/100ML; 10MG/100ML;
 9.7MG/100ML; 120MG/100ML;
 49.3MG/100ML N19712 001
 SEP 08, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE; INJECTION

AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER
 @ ABBOTT
 3.5%; 5GM/100ML; 30MG/100ML;
 97MG/100ML; 120MG/100ML;
 49.3MG/100ML

N19712 001
 SEP 08, 1988

AMINOPHYLLINE

INJECTABLE; INJECTION

AMINOPHYLLIN

AP * SEARLE

25MG/ML
 25MG/ML

N87243 001
 MAY 24, 1982
 N87243 001
 MAY 24, 1982

AMINOPHYLLINE

ELKINS SINN

AP +

PHARMA SERVE NY

25MG/ML
 25MG/ML
 25MG/ML

N87239 001
 N87239 001
 N87387 001
 JUN 03, 1983
 N87387 001
 JUN 03, 1983

TABLET; ORAL

AMINOPHYLLINE

@ HALSEY

100MG
 100MG

N84674 001
 N84674 001

TABLET, EXTENDED RELEASE; ORAL
 PHYLLCONTIN

* PURDUE FREDERICK

225MG
 225MG

N86760 001
 N86760 001

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HCL

@ HALSEY

10MG
 50MG
 75MG

N85923 001
 N85925 001
 N85926 001
 MAY 20, 1983
 N85927 001
 MAY 20, 1983
 N85923 001

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HCL

@ HALSEY

50MG
 75MG

N85925 001
 N85926 001
 MAY 20, 1983
 N85927 001
 MAY 20, 1983

@

100MG

AMITRIPTYLINE HYDROCHLORIDE

VINTAGE PHARMS

10MG

25MG

50MG

75MG

100MG

150MG

> ADD >
 > ADD >

N40218 001
 SEP 11, 1997
 N40218 002
 SEP 11, 1997
 N40218 003
 SEP 11, 1997
 N40218 004
 SEP 11, 1997
 N40218 005
 SEP 11, 1997
 N40218 006
 SEP 11, 1997

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

LIMBITROL

ICN

ROCHE

AB + ICN
 AE * ROCHE

EQ 12.5MG BASE; 5MG
 EQ 12.5MG BASE; 5MG

N16949 001
 N16949 001

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

STRAFON-A

@ SCHERING

10MG; 4MG
 10MG; 4MG

N14713 002
 N14713 002

PERPHENAZINE AND AMITRIPTYLINE HCL

@ ZENITH GOLDLINE

10MG; 2MG
 10MG; 4MG

N70935 001
 SEP 11, 1986
 N70937 001
 SEP 11, 1986
 N70936 001
 SEP 11, 1986

25MG; 2MG

AZLOXILLIN SODIUM

INJECTABLE; INJECTION

AZLIN
* BAYER

EQ 2GM BASE/VIAL
EQ 3GM BASE/VIAL
EQ 4GM BASE/VIAL
EQ 2GM BASE/VIAL
EQ 3GM BASE/VIAL
EQ 4GM BASE/VIAL

N50562 001
SEP 03, 1982
N50562 002
SEP 03, 1982
N50562 003
SEP 03, 1982
N50562 001
SEP 03, 1982
N50562 002
SEP 03, 1982
N50562 003
SEP 03, 1982

> DLT >
> ADD >

N16818 006
N16818 006

BENZQUINAMIDE HYDROCHLORIDE

SUPPOSITORY; RECTAL

EMETE-CON
* ROERIG
@

EQ 100MG BASE
EQ 100MG BASE

BETAMETHASONE DIPROPIONATE

LOTION; TOPICAL

BETAMETHASONE DIPROPIONATE
@ ALPHARMA
EQ 0.05% BASE

EQ 0.05% BASE
EQ 0.05% BASE

N71085 001
FEB 03, 1987
N71085 001
FEB 03, 1987

BACITRACIN

INJECTABLE; INJECTION

BACIIM
PHARMA TEK

50,000 UNITS/VIAL

N64153 001
MAY 09, 1997

BACITRACIN

+ PHARMACIA AND UPJOHN 50,000 UNITS/VIAL

N60733 002

BETAMETHASONE VALERATE

CREAM; TOPICAL

BETAMETHASONE VALERATE
FOUGERA
EQ 0.1% BASE

EQ 0.1% BASE
EQ 0.1% BASE

N18861 001
AUG 31, 1983
N18861 001
AUG 31, 1983

BACITRACIN ZINC; HYDROCORTISONE, NEOMYCIN SULFATE; POLYMYXIN B SULFATE

ointment; TOPICAL

CORTISPORIN
* GLAXO WELLCOME

400 UNITS/GM; 1% EQ 3.5MG BASE/GM;
5,000 UNITS/GM
N50168 002
MAY 04, 1984
400 UNITS/GM; 1% EQ 3.5MG BASE/GM;
5,000 UNITS/GM
N50168 002
MAY 04, 1984

N16322 001
N16322 002
N16322 002
N16322 001

BETAMETHASONE VALERATE

LOTION; TOPICAL

BETAMETHASONE VALERATE
FOUGERA
EQ 0.1% BASE

EQ 0.1% BASE
EQ 0.1% BASE

N18866 001
AUG 31, 1983
N18866 001
AUG 31, 1983

VALISONE
* SCHERING
@

BETAMETHASONE VALERATE

ointment; TOPICAL

BETAMETHASONE VALERATE
FOUGERA
EQ 0.1% BASE

EQ 0.1% BASE
EQ 0.1% BASE

N18865 001
AUG 31, 1983
N18865 001
AUG 31, 1983
N16932 001
N16932 001

BECLMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED; NASAL

BECONASE AQ
GLAXO WELLCOME

EQ 0.042MG DIPROP/SPRAY
N19389 001
JUL 27, 1987
EQ 0.042MG DIPROP/SPRAY
N19389 001
JUL 27, 1987

N18865 001
AUG 31, 1983
N18865 001
AUG 31, 1983
N16740 001

> BN >
> BN >

BETAMETHASONE VALERATE

OINTMENT; TOPICAL
VALISONE
@ SCHERING

EQ 0.1% BASE

N16740 001

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC
ALPHAGAN
+ ALLERGAN

0.5%

N20490 001
MAR 13, 1997

BETAXOLOL HYDROCHLORIDE; Pilocarpine Hydrochloride

SUSPENSION/DROPS; OPHTHALMIC
BETOPTIC PILO
+ ALCON

EQ 0.25% BASE; 1.75%

N20619 001
APR 17, 1997

BROMFENAC SODIUM

CAPSULE; ORAL
DURACT
+ WYETH AVERST

EQ 25MG BASE

N20535 001
JUL 15, 1997

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE
@ ZENITH GOLDLINE
@ ZENITH LABS

25MG
25MG

N84689 001
N84689 001

TABLET; ORAL

BROMPHENIRAMINE MALEATE
@ ZENITH GOLDLINE
@ ZENITH LABS

4MG
4MG

N84351 001
N84351 001

> ADD >
> DLT >

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

BLENOXANE
AP + BRISTOL MYERS SQUIBB EQ 30 UNITS BASE/VIAL
BLEOMYCIN SULFATE
AP PHARMACIA AND UPJOHN EQ 30 UNITS BASE/VIAL
EQ 30 UNITS BASE/VIAL

N50443 002
SEP 07, 1995
N64084 002
JUN 01, 1996
N64084 002
JUN 01, 1996

BUDESONIDE

AEROSOL, METERED; NASAL
RHINOCORT
+ ASTRA

0.05MG/INH
0.032MG/INH

N20233 001
FEB 14, 1994
N20233 001
FEB 14, 1994

POWDER, METERED; INHALATION
PULMICORT
+ ASTRA

0.16MG/INH
0.32MG/INH

N20441 002
JUN 24, 1997
N20441 003
JUN 24, 1997

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER
AP * BAXTER HUTHCARE 200MG/100ML
AP * 400MG/100ML
@ 200MG/100ML
@ 400MG/100ML

N19837 002
APR 12, 1989
N19837 001
APR 12, 1989
N19837 002
APR 12, 1989
N19837 001
APR 12, 1989

BUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE
AP ABBOTT 0.25MG/ML
AP SANOFI WINTHROP 0.25MG/ML

N74332 001
OCT 31, 1994
N74332 001
OCT 31, 1994

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE; INJECTION
BUPRENORPHINE HCL

AP ABBOTT

EQ 0.3MG BASE/ML

AP SAMOFI WINTHROP

EQ 0.3MG BASE/ML

N74137 001
 JUN 03, 1996
 N74137 001
 JUN 03, 1996

AP BUTORPHANOL TARTRATE PRESERVATIVE FREE
 1MG/ML

AP ABBOTT

AP 1MG/ML

AP 2MG/ML

AP 2MG/ML

N74620 001
 JAN 22, 1997
 N74626 001
 JAN 23, 1997
 N74620 002
 JAN 22, 1997
 N74626 002
 JAN 23, 1997

EUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
 WELLBUTRIN

+ GLAXO WELLCOME

100MG

+ 150MG

ZYBAN

GLAXO WELLCOME

100MG

150MG

+ 100MG

+ 150MG

N20358 002
 OCT 04, 1996
 N20358 003
 OCT 04, 1996
 N20711 002
 MAY 14, 1997
 N20711 003
 MAY 14, 1997
 N20711 002
 MAY 14, 1997
 N20711 003
 MAY 14, 1997

CALCIPTRIENE

SOLUTION; TOPICAL

DOVONEX

+ BRISTOL MYERS SQUIBB 0.005%

N20611 001
 MAR 03, 1997

BUTABARBITAL SODIUM

TABLET; ORAL

SODIUM BUTABARBITAL

@ ZENITH GOLDLINE

@ ZENITH LABS

@ ZENITH LABS

15MG

30MG

15MG

30MG

N83484 001
 N84040 001
 N83484 001
 N84040 001

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

FEMSTAT ONE

+ SYNTEX

2%

N19881 001
 FEB 07, 1997

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 4% IN MODIFIED LACTATED RINGER'S IN PLASTIC CONTAINER

MCGAW

4MG/100ML; 4GM/100ML; 6MG/100ML;
 120MG/100ML; 62MG/100ML N19634 002
 FEB 24, 1988
 4MG/100ML; 4GM/100ML; 6MG/100ML;
 120MG/100ML; 62MG/100ML N19634 002
 FEB 24, 1988

DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER

MCGAW

20MG/100ML; 5GM/100ML; 30MG/100ML;
 60MG/100ML; 310MG/100ML N17510 001
 20MG/100ML; 5GM/100ML; 30MG/100ML;
 60MG/100ML; 310MG/100ML N17510 001

> ADD >
 > ADD >
 > DLT >
 > DLT >

CARBIDOPA, LEVODOPA

TABLET; ORAL

CARBIDOPA AND LEVODOPA
LEMMON

AB 10MG;100MG
AB 25MG;100MG
AB 25MG;250MG
AB 10MG;100MG
AB 25MG;100MG
AB 25MG;250MG

N73618 001
AUG 28, 1992
N73589 001
AUG 28, 1992
N73607 001
AUG 28, 1992
N73618 001
AUG 28, 1992
N73589 001
AUG 28, 1992
N73607 001
AUG 28, 1992

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL
AMIDE PHARM

AA 350MG
AA 350MG

N40188 001
MAR 07, 1997
N40245 001
SEP 08, 1997

>_ADD >
>_ADD >

CARVEDILOL

TABLET; ORAL
COREG

SMITHKLINE BEECHAM
3.125MG

N20297 004
MAY 29, 1997

CEFLACLOR

CAPSULE; ORAL
CEFLACLOR
RANBAXY

AB EQ 250MG BASE
AB EQ 500MG BASE

N64156 001
AUG 28, 1997
N64156 002
AUG 28, 1997

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM
LEMMON

AP EQ 250MG BASE/VIAL
AP EQ 500MG BASE/VIAL
AP EQ 1GM BASE/VIAL
AP EQ 5GM BASE/VIAL
AP EQ 10GM BASE/VIAL
AP EQ 250MG BASE/VIAL
AP EQ 500MG BASE/VIAL
AP EQ 1GM BASE/VIAL
AP EQ 5GM BASE/VIAL
AP EQ 10GM BASE/VIAL

N63016 001
MAR 14, 1989
N63016 002
MAR 14, 1989
N63016 003
MAR 14, 1989
N63018 001
MAR 05, 1990
N63018 002
MAR 05, 1990
N63016 001
MAR 14, 1989
N63016 002
MAR 14, 1989
N63016 003
MAR 14, 1989
N63018 001
MAR 05, 1990
N63018 002
MAR 05, 1990

TEVA

CEFUROXIME AXETIL

POWDER FOR RECONSTITUTION; ORAL

CEFTIN
* GLAXO WELLCOME

EQ 125MG BASE/5ML
EQ 125MG BASE/5ML
EQ 250MG BASE/5ML

N50672 001
JUN 30, 1994
N50672 001
JUN 30, 1994
N50672 002
APR 29, 1997

CEFUROXIME SODIUM

INJECTABLE; INJECTION

CEFUROXIME SODIUM
HANFORD GC

AB EQ 750MG BASE/VIAL
AP EQ 1.5GM BASE/VIAL
AP EQ 7.5GM BASE/VIAL

N64125 001
MAY 30, 1997
N64125 002
MAY 30, 1997
N64124 001
MAY 30, 1997

CEFUROXIME SODIUM

INJECTABLE; INJECTION

AB KEFUOX
LILLY

AB EQ 750MG BASE/VIAL N62591 001
JAN 10, 1986
AB EQ 750MG BASE/VIAL N62592 001
JAN 10, 1986
AP EQ 750MG BASE/VIAL N62591 001
JAN 10, 1986
AP EQ 750MG BASE/VIAL N62592 001
JAN 10, 1986

AB EQ 750MG BASE/VIAL N62591 001
JAN 10, 1986
AB EQ 750MG BASE/VIAL N62592 001
JAN 10, 1986
AP EQ 750MG BASE/VIAL N62591 001
JAN 10, 1986
AP EQ 750MG BASE/VIAL N62592 001
JAN 10, 1986

AB + ZINACEF
GLAXO WELLCOME

AP EQ 750MG BASE/VIAL N50558 002
OCT 19, 1983
AP EQ 750MG BASE/VIAL N50558 002
OCT 19, 1983

> ADD >
> ADD >
> ADD >
> ADD >
> DLT >
> DLT >
> DLT >

CEPHALEXIN

CAPSULE; ORAL
CEPHALEXIN
@ APOTHECON

AB EQ 250MG BASE N62973 001
NOV 08, 1988
AB EQ 500MG BASE N62974 001
NOV 23, 1988
EQ 250MG BASE N62973 001
NOV 08, 1988
EQ 500MG BASE N62974 001
NOV 23, 1988
EQ 250MG BASE N62809 001
APR 22, 1987
EQ 500MG BASE N62809 002
APR 22, 1987
EQ 250MG BASE N62809 001
APR 22, 1987
EQ 500MG BASE N62809 002
APR 22, 1987

N62973 001
NOV 08, 1988
N62974 001
NOV 23, 1988
N62973 001
NOV 08, 1988
N62974 001
NOV 23, 1988
N62809 001
APR 22, 1987
N62809 002
APR 22, 1987
N62809 001
APR 22, 1987
N62809 002
APR 22, 1987

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION

CEFADYL
@ APOTHECON

AB EQ 1GM BASE/VIAL N62724 001
DEC 23, 1986
AB EQ 2GM BASE/VIAL N62724 002
DEC 23, 1986

N62724 001
DEC 23, 1986
N62724 002
DEC 23, 1986

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION
CEFADYL
@ APOTHECON

EQ 1GM BASE/VIAL N62724 001
DEC 23, 1986
EQ 2GM BASE/VIAL N62724 002
DEC 23, 1986

N62724 001
DEC 23, 1986
N62724 002
DEC 23, 1986

CEPHRADINE

CAPSULE; ORAL
CEPHRADINE
@ ZENITH GOLDLINE

250MG N62762 001
MAR 06, 1987
500MG N62762 002
MAR 06, 1987
250MG N62762 001
MAR 06, 1987
500MG N62762 002
MAR 06, 1987

N62762 001
MAR 06, 1987
N62762 002
MAR 06, 1987
N62762 001
MAR 06, 1987
N62762 002
MAR 06, 1987

CERIVASTATIN SODIUM

TABLET; ORAL
BAYCOL
@ BAYER

0.05MG N20740 001
JUN 26, 1997
0.1MG N20740 002
JUN 26, 1997
0.2MG N20740 003
JUN 26, 1997
0.3MG N20740 004
JUN 26, 1997

N20740 001
JUN 26, 1997
N20740 002
JUN 26, 1997
N20740 003
JUN 26, 1997
N20740 004
JUN 26, 1997

CHLORAMPHENICOL, HYDROCORTISONE ACETATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
OPHTHOCORT
* PARKE DAVIS

10MG/GM; 5MG/GM; N50201 002
10,000 UNITS/GM;
10MG/GM; 5MG/GM;
10,000 UNITS/GM

N50201 002
N50201 002

CHLORAMPHENICOL PALMITATE

SUSPENSION; ORAL
 CHLOROMYCETIN PALMITATE
 PARKE DAVIS
 @
 EQ 150MG BASE/5ML
 EQ 150MG BASE/5ML

N62301 001
 N62301 001

N09435 004
 N09435 007
 MAY 02, 1996
 N09435 003
 N09435 004

CHLORDIAZEPOXIDE

TABLET; ORAL
 LIBRITABS
 ROCHE
 *
 +
 @
 @
 5MG
 10MG
 25MG
 5MG
 10MG
 25MG

N85482 001
 N85481 001
 N85488 001
 N85482 001
 N85481 001
 N85488 001

N87164 001
 N87164 001
 N80779 001
 N80779 001
 N83629 001
 N83629 001

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL
 CHLORDIAZEPOXIDE HCL
 @ ZENITH GOLDLINE
 @
 @
 @ ZENITH LABS
 5MG
 10MG
 25MG

N83741 001
 N83742 001
 N83570 001
 N83741 001
 N83742 001
 N83570 001

N87164 001
 N87164 001
 N80779 001
 N80779 001
 N83629 001
 N83629 001

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL
 CHLORHEXIDINE GLUCONATE
 LEMMON
 0.12%
 @
 TEVA
 0.12%

N74522 001
 DEC 15, 1995
 N74522 001
 DEC 15, 1995

N83549 001
 N83549 002
 N83549 003
 N83574 001
 N83575 001
 N83549 001
 N83549 002
 N83549 003
 N83574 001
 N83575 001

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
 NESACAIN-MPF
 * ASTRA
 +
 2%
 2%

N09435 003
 N09435 006
 MAY 02, 1996

N88840 001
 OCT 25, 1984
 N87353 001
 N88840 001
 OCT 25, 1984

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
 NESACAIN-MPF
 * ASTRA
 +
 @
 @
 3%
 3%
 2%
 3%

N09435 004
 N09435 007
 MAY 02, 1996
 N09435 003
 N09435 004

CHLORPHENIRAMINE MALEATE

TABLET; ORAL
 CHLORPHENIRAMINE MALEATE
 KV PHARM
 @
 @ ZENITH GOLDLINE
 @ ZENITH LABS
 KLOROMIN
 HALSEY
 @
 4MG
 4MG
 4MG
 4MG
 4MG

N87164 001
 N87164 001
 N80779 001
 N80779 001
 N83629 001
 N83629 001

CHLORPROMAZINE HYDROCHLORIDE

TABLET; ORAL
 CHLORPROMAZINE HCL
 @ ZENITH GOLDLINE
 @
 @
 @
 @
 @ ZENITH LABS
 10MG
 25MG
 50MG
 100MG
 200MG
 10MG
 25MG
 50MG
 100MG
 200MG

N83549 001
 N83549 002
 N83549 003
 N83574 001
 N83575 001
 N83549 001
 N83549 002
 N83549 003
 N83574 001
 N83575 001

CHLORPROPAMIDE

TABLET; ORAL
 CHLORPROPAMIDE
 @ ZENITH GOLDLINE
 @
 @ ZENITH LABS
 100MG
 250MG
 100MG

N88840 001
 OCT 25, 1984
 N87353 001
 N88840 001
 OCT 25, 1984

CIMETIDINE

TABLET; ORAL

CIMETIDINE

ENDO PHARMS

800MG

N74329 001

> DLT >

AA

SOLUTION; ORAL

CIMETIDINE HCL

ENDO LABS

EQ 300MG BASE/5ML

N74251 001

> ADD >

AB

ENDO PHARMS

200MG

MAY 17, 1994

> DLT

AA

ENDO PHARMS

EQ 300MG BASE/5ML

DEC 22, 1994

> ADD >

AB

LEMMON

300MG

FEB 28, 1995

> ADD >

AA

ENDO PHARMS

EQ 300MG BASE/5ML

DEC 22, 1994

> ADD >

AB

ENDO LABS

400MG

FEB 28, 1995

> ADD >

AA

PHARM ASSOC

EQ 300MG BASE/5ML

JAN 27, 1997

> ADD >

AB

ENDO PHARMS

800MG

FEB 28, 1995

> ADD >

AA

ROXANE

EQ 300MG BASE/5ML

JAN 27, 1997

> ADD >

AB

SIDMAK LABS NJ

200MG

FEB 28, 1995

> ADD >

AA

ROXANE

EQ 300MG BASE/5ML

AUG 05, 1997

> ADD >

AB

SIDMAK LABS NJ

300MG

FEB 27, 1997

> ADD >

AB

POWDER FOR RECONSTITUTION; ORAL

EQ 300MG BASE/5ML

SEP 26, 1997

> ADD >

AB

CIPRO

400MG

FEB 27, 1997

> ADD >

AB

BAYER

EQ 300MG BASE/5ML

SEP 26, 1997

> ADD >

AB

+

800MG

FEB 27, 1997

> ADD >

AB

500MG/5ML

EQ 300MG BASE/5ML

SEP 26, 1997

> ADD >

AB

TEVA

200MG

FEB 28, 1995

> ADD >

AB

CLEMASTINE FUMARATE

EQ 0.5MG BASE/5ML

JUN 30, 1994

> ADD >

AB

TEVA

300MG

FEB 28, 1995

> ADD >

AB

CLEMASTINE FUMARATE

EQ 0.5MG BASE/5ML

JUN 30, 1994

> ADD >

AB

TEVA

400MG

FEB 28, 1995

> ADD >

AB

LEMMON

EQ 0.5MG BASE/5ML

JUN 30, 1994

> ADD >

AB

TEVA

800MG

FEB 28, 1995

> ADD >

AB

TEVA

EQ 0.5MG BASE/5ML

JUN 30, 1994

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HCL

ABBOTT

EQ 300MG BASE/2ML

N74296 001

AB

TABLET; ORAL

CLEMASTINE FUMARATE

LEMMON

2.68MG

N73283 001

> DLT >

AP

ABBOTT

EQ 300MG BASE/2ML

MAR 28, 1997

AP

LEMMON

1.34MG

JAN 31, 1992

> DLT >

AP

ENDO LABS

EQ 300MG BASE/2ML

MAR 28, 1997

AP

LEMMON

2.68MG

JAN 31, 1992

> ADD >

AP

ENDO PHARMS

EQ 300MG BASE/2ML

AUG 31, 1994

AP

TEVA

1.34MG

JAN 31, 1992

> ADD >

AP

SANOFI

EQ 300MG BASE/2ML

MAR 28, 1997

AP

TEVA

1.34MG

JAN 31, 1992

> ADD >

AP

SANOFI

EQ 300MG BASE/2ML

MAR 28, 1997

AP

TEVA

1.34MG

JAN 31, 1992

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION
CLINDAMYCIN PHOSPHATE

AP QUAD PHARMS
 @
 EQ 150MG BASE/ML
 EQ 150MG BASE/ML

N62795 001
 DEC 21, 1987
 N62795 001
 DEC 21, 1987

SOLUTION; TOPICAL
CLINDAMYCIN PHOSPHATE

AT FOUGERA
AT LEMMON
AT MORTON GROVE
AT TEVA
 EQ 1% BASE
 EQ 1% BASE
 EQ 1% BASE
 EQ 1% BASE

N64159 001
 JUN 05, 1997
 N62330 001
 JUN 28, 1989
 N63304 001
 JUL 15, 1997
 N62930 001
 JUN 28, 1989

CLOBETASOL PROPIONATE

CREAM; TOPICAL
CORMAX

AB HEALTHPOINT
 0.05%

N74220 001
 MAY 16, 1997

CLOCORTOLONE PIVALATE

CREAM; TOPICAL
CLODERM

AB CHE LABS
 + EM INDS
 0.1%
 0.1%

N17765 001
 N17765 001

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL
CLOMIPRAMINE HCL

AB INVAMED 25MG
AB 50MG
AB 75MG
AB 25MG
AB LEMMON

N74953 001
 JUN 25, 1997
 N74953 002
 JUN 25, 1997
 N74953 003
 JUN 25, 1997
 N74958 001
 AUG 26, 1997

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL
CLOMIPRAMINE HCL

AB LEMMON 50MG
AB 75MG
AB NOVOPHARM 25MG
AB 50MG
AB 75MG

N74958 002
 AUG 26, 1997
 N74958 003
 AUG 26, 1997
 N74849 001
 APR 04, 1997
 N74849 002
 APR 04, 1997
 N74849 003
 APR 04, 1997

CLONAZEPAM

TABLET; ORAL
CLONAZEPAM

AB EON 0.5MG
AB 1MG
AB 2MG
AB 0.5MG
AB 1MG
AB 2MG
AB 0.5MG
AB 1MG
AB 2MG

N74979 001
 AUG 29, 1997
 N74979 002
 AUG 29, 1997
 N74979 003
 AUG 29, 1997
 N74925 001
 SEP 30, 1997
 N74925 002
 SEP 30, 1997
 N74925 003
 SEP 30, 1997

KLONOPIN
 + ROCHE

0.125MG
 0.25MG

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL
CLORAZEPATE DIPOTASSIUM

AB PUREPAC PHARM 7.5MG
AB 15MG
 @ 7.5MG

N71925 001
 APR 25, 1988
 N71925 001
 APR 25, 1988
 N71925 001
 APR 25, 1988

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL
CLORAZEPATE DIPOTASSIUM
 @ PUREPAC PHARM 15MG

TABLET; ORAL
CLORAZEPATE DIPOTASSIUM
 @ PUREPAC PHARM 3.75MG

AB N72330 001
 AUG 08, 1988
 AB N72331 001
 AUG 08, 1988
 AB N72332 001
 AUG 08, 1988
 @ N72330 001
 AUG 08, 1988
 @ N72331 001
 AUG 08, 1988
 @ N72332 001
 AUG 08, 1988

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PERAZINE W/ CODEINE
 @ HALSEY 10MG/5ML; 5.25MG/5ML
 @ 10MG/5ML; 6.25MG/5ML
 AA PROMETHAZINE HCL AND CODEINE PHOSPHATE
 HI TECH PHARMA 10MG/5ML; 6.25MG/5ML

CORTICOTROPIN

INJECTABLE; INJECTION
 ACTHAR
 @ * RHONE-POULENC RORER 40 UNITS/VIAL
 @ 25 UNITS/VIAL
 @ 40 UNITS/VIAL
 @ CORTICOTROPIN
 STERIS 40 UNITS/VIAL
 + 40 UNITS/VIAL

> DLT >
 > DLT >
 > ADD >
 > ADD >
 > DLT >
 > DLT >
 > ADD >
 > ADD >

CORTISONE ACETATE

TABLET; ORAL
CORTISONE ACETATE
 @ PUREPAC PHARM

BP N71926 001
 APR 25, 1988
 @ ZENITH GOLDLINE 25MG
 @ ZENITH LABS 25MG
 @ 25MG
 @ 25MG
 @ 25MG

N80493 001
 N80493 001
 N80630 001
 N83536 001
 N80630 001
 N83536 001

CROMOLYN SODIUM

AEROSOL, METERED; INHALATION
 INTAL
 * FISON'S 0.8MG/INH
 + RHONE-POULENC RORER 0.8MG/INH

N18887 001
 DEC 05, 1985
 N18887 001
 DEC 05, 1985

CAPSULE; INHALATION

INTAL
 * FISON'S 20MG
 + RHONE-POULENC RORER 20MG

N16990 001
 N16990 001

SOLUTION; INHALATION

AN * FISON'S 10MG/ML
 AN + RHONE-POULENC RORER 10MG/ML

N18596 001
 MAY 28, 1982
 N18596 001
 MAY 28, 1982

SOLUTION/DROPS; OPHTHALMIC

OPTICROM
 @ FISON'S 4%
 @ RHONE-POULENC RORER 4%

N18155 001
 OCT 03, 1984
 N18155 001
 OCT 03, 1984

SPRAY, METERED; NASAL

NASALCROM
 * FISON'S 5.2MG/SPRAY

N18306 001
 MAR 18, 1983

CYANOCOBALAMIN

INJECTABLE; INJECTION

COBAVITE
STERIS

AP	0.1MG/ML	N83013 001
AP	1MG/ML	N83064 001
	0.1MG/ML	N83013 001
	1MG/ML	N83064 001
AP	0.1MG/ML	N83120 001
	0.1MG/ML	N83120 001

CYANOCOBALAMIN
STERIS

CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; CYANOCOBALAMIN, CO-58

N/A; N/A
DICOPAC KIT
AMERSHAM
MEDI PHYSICS

N17406 001
N17406 001

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AK-PENTOLATE
AKORN

AT	1%	N85555 001
	1%	N85555 001

AKPENTOLATE
AKORN

N40164 001
JAN 13, 1997
N40165 001
JAN 13, 1997

CYCLOGYL
ALCON

N84108 001

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYCLOPHOSPHAMIDE

AP	100MG/VIAL	N88371 001
		JUL 03, 1986
AP	200MG/VIAL	N88372 001
		JUL 03, 1986
AP	500MG/VIAL	N88373 001
		JUL 03, 1986
AP	1GM/VIAL	N88374 001
		SEP 24, 1986

ASTA

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYCLOPHOSPHAMIDE
ELKINS SINN

AP	100MG/VIAL	N88371 001
		JUL 03, 1986
AP	200MG/VIAL	N88372 001
		JUL 03, 1986
AP	500MG/VIAL	N88373 001
		JUL 03, 1986
AP	1GM/VIAL	N88374 001
		SEP 24, 1986

CYTOXAN

* BRISTOL MYERS SQUIBB

AP	100MG/VIAL	N12142 001
AP	200MG/VIAL	N12142 002
AP	500MG/VIAL	N12142 003
AP	1GM/VIAL	N12142 004
AP	2GM/VIAL	N12142 005
		AUG 30, 1982
		AUG 30, 1982

@	100MG/VIAL	N12142 001
@	200MG/VIAL	N12142 002
@	500MG/VIAL	N12142 003
@	1GM/VIAL	N12142 004
@	2GM/VIAL	N12142 005
		AUG 30, 1982

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

CYPROHEPTADINE HCL
HALSEY

AA	4MG	N89057 001
		JUL 03, 1986
		N89057 001
		JUL 03, 1986

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

CERUBIDINE

@ RHONE POULENC RORER

AP	EQ 20MG BASE/VIAL	N61876 001
		N61876 001
AP	EQ 20MG BASE/VIAL	N50484 001
		N50484 001
AP	EQ 20MG BASE/VIAL	N64103 001
		FEB 03, 1995

* WYETH AYERST

@ DAUNORUBICIN HCL

BEDFORD

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
DAUNORUBICIN HCL
 + BEDFORD

EQ 20MG BASE/VIAL

N64103 001
 FEB 03, 1995

DELAVIRDINE MESYLATE

TABLET; ORAL
 RESCRIPTOR
 + PHARMACIA AND UPJOHN 100MG

N20705 001
 APR 04, 1997

DESERPIDINE

TABLET; ORAL
 HARMONYL
 + ABBOTT
 ©

0.25MG
 0.25MG

N10796 002
 N10796 002

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL
DESIPRAMINE HCL
 + SIDMAK LABS NJ

100MG

N71803 001
 MAY 29, 1997

150MG

N71804 001
 MAY 29, 1997

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL
 DDAVP
 + RHONE POULENC RORER
 ©

0.01MG/SPRAY

N17922 002
 FEB 06, 1989

0.01MG/SPRAY

N17922 002
 FEB 06, 1989

0.01MG/SPRAY

N17922 003
 AUG 07, 1996

DEXAMETHASONE

ELIXIR; ORAL
DEXAMETHASONE
 ALPHARMA

0.5MG/5ML

N8897 001
 OCT 10, 1986

0.5MG/5ML

N8897 001
 OCT 10, 1986

GEL; TOPICAL
 DECADERM

* MERCK SHARP DOHME
 ©

0.1%
 0.1%

N13538 001
 N13538 001

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
DEXASPORIN

BAUSCH AND LOMB

0.1%; EQ 3.5MG BASE/GM;
 10,000 UNITS/GM

N64063 001
 JUL 25, 1994

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

BAUSCH AND LOMB

0.1%; EQ 3.5MG BASE/GM;
 10,000 UNITS/GM

N64063 001
 JUL 25, 1994

DEXAMETHASONE SODIUM PHOSPHATE

CREAM; TOPICAL
 DECADRON

* MERCK SHARP DOHME
 ©

EQ 0.1% PHOSPHATE
 EQ 0.1% PHOSPHATE

N11983 002
 N11983 002

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

STERIS
 ©

EQ 4MG PHOSPHATE/ML
 EQ 4MG PHOSPHATE/ML

N84355 001
 N84355 001

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC
 CONTAINER
 MCGAW

5GM/100ML; 17MG/100ML

N19699 001
 SEP 29, 1989

DEXTROSE, POTASSIUM CHLORIDE, SODIUM CHLORIDE

> DLT >	INJECTABLE, INJECTION				
> DLT >	DEXTROSE 5% SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE				
> DLT >	0.15% IN PLASTIC CONTAINER	5GM/100ML; 150MG/100ML;	N18268 001		
> DLT >	MCGAW	450MG/100ML			
> ADD >	®	5GM/100ML; 150MG/100ML;			
> ADD >		450MG/100ML			
> DLT >	DEXTROSE 5% SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE				
> DLT >	0.22% IN PLASTIC CONTAINER	5GM/100ML; 220MG/100ML;			
> DLT >	MCGAW	450MG/100ML			
> DLT >	®	5GM/100ML; 220MG/100ML;			
> ADD >		450MG/100ML			
> ADD >		5GM/100ML; 200MG/100ML;			
> DLT >	DEXTROSE 5% SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE				
> DLT >	0.3% IN PLASTIC CONTAINER	5GM/100ML; 300MG/100ML;			
> DLT >	MCGAW	450MG/100ML			
> DLT >	®	5GM/100ML; 300MG/100ML;			
> ADD >		450MG/100ML			
> ADD >					

DEXTROSE, SODIUM CHLORIDE

> DLT >	INJECTABLE, INJECTION				
> DLT >	DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
> DLT >	MCGAW	10GM/100ML; 900MG/100ML	N18047 001		
> DLT >	®	10GM/100ML; 900MG/100ML			
> DLT >	DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
> DLT >	MCGAW	5GM/100ML; 900MG/100ML	N18026 001		
> DLT >	®	5GM/100ML; 900MG/100ML			

DEXTROTHYROXINE SODIUM

> DLT >	TABLET; ORAL				
> DLT >	CHOLOXIN				
> DLT >	KNOLL PHARM				
> DLT >	+	1MG	N12302 005		
> DLT >	®	2MG	N12302 002		
> DLT >	®	4MG	N12302 004		
> DLT >	®	1MG	N12302 005		
> DLT >	®	2MG	N12302 002		
> DLT >	®	4MG	N12302 004		

DIAZEPAM

> DLT >	GEL; RECTAL				
> DLT >	DIASTAT				
> DLT >	+ ATHENA	2.5MG/0.5ML			
> DLT >					N20648 001
> DLT >					JUL 29, 1997
> DLT >		5MG/ML			N20648 002
> DLT >					JUL 29, 1997
> DLT >		10MG/2ML			N20648 003
> DLT >					JUL 29, 1997
> DLT >		15MG/3ML			N20648 004
> DLT >					JUL 29, 1997
> DLT >		20MG/4ML			N20648 005
> DLT >					JUL 29, 1997
> DLT >	INJECTABLE; INJECTION				
> DLT >	DIAZEPAM				
> DLT >	ABBOTT	5MG/ML			N72079 001
> DLT >					DEC 20, 1988
> DLT >	AP	5MG/ML			N70912 001
> DLT >	STERIS				AUG 28, 1986
> DLT >	®	5MG/ML			N70912 001
> DLT >					AUG 28, 1986
> DLT >	AP	5MG/ML			N72079 001
> DLT >	STERLING WINTHROP				DEC 20, 1988

TABLET; ORAL

> DLT >	DIAZEPAM				
> DLT >	HALSEY				
> DLT >	AB	2MG			N70987 001
> DLT >					AUG 15, 1986
> DLT >	AB	5MG			N70996 001
> DLT >					AUG 15, 1986
> DLT >	AB	10MG			N70956 001
> DLT >					AUG 15, 1986
> DLT >	®	2MG			N70987 001
> DLT >					AUG 15, 1986
> DLT >	®	5MG			N70996 001
> DLT >					AUG 15, 1986
> DLT >	®	10MG			N70956 001
> DLT >					AUG 15, 1986
> DLT >	AB	10MG			N70362 001
> DLT >	ZENITH GOLDLINE				SEP 04, 1985
> DLT >					N70360 001
> DLT >	®	2MG			N70360 001
> DLT >					SEP 04, 1985
> DLT >	®	5MG			N70361 001
> DLT >					SEP 04, 1985
> DLT >	®	10MG			N70362 001
> DLT >					SEP 04, 1985

DIAZEPAM

> DLT >
> DLT >
> DLT >
> DLT >

TABLET; ORAL
DIAZEPAM
@ ZENITH LABS
2MG
5MG

N70360 001
SEP 04, 1985
N70361 001
SEP 04, 1985

N83004 001
N06194 001

DICLOFENAC SODIUM

TABLET, DELAYED RELEASE; ORAL
DICLOFENAC SODIUM
COPLEY PHARM
25MG
50MG
75MG

N74459 001
JUN 25, 1997
N74459 002
JUN 25, 1997
N74459 003
JUN 25, 1997

N74400 001
JUL 17, 1997
N74400 002
JUL 17, 1997

DICYCLOMINE HYDROCHLORIDE

AB CAPSULE; ORAL
DICYCLOMINE HCL
WEST WARD
10MG

AA SYRUP; ORAL
BENTYL
* HOECHST MARION RSSL
10MG/5ML
10MG/5ML

AA DICYCLOMINE HCL
ALPHARMA
10MG/5ML
10MG/5ML

N40204 001
FEB 28, 1997

N07961 002
OCT 15, 1984
N84479 001
N84479 001

N40093 001
MAY 16, 1996
N40093 001
MAY 16, 1996

N40092 001
APR 25, 1996
N40092 001
APR 25, 1996

DIETHYLSTILBESTROL

TABLET; ORAL
DIETHYLSTILBESTROL
LILLY
1MG
5MG
5MG
0.5MG

N04041 004
N04041 005
N04041 004
N04041 005

N83004 001

N20405 001
SEP 30, 1997
N20405 002
SEP 30, 1997
N20405 003
SEP 30, 1997
N20405 004
SEP 30, 1997
N20405 005
SEP 30, 1997
N20405 006
SEP 30, 1997

DIETHYLSTILBESTROL

TABLET; ORAL
STILBESTROL
@ TABLICAPS
STILBESTROL TAB
SMITH MILLER PATCH
0.5MG
25MG

DIFLUNISAL

TABLET; ORAL
DIFLUNISAL
DANBURY PHARMA
250MG
500MG

DIGOXIN

INJECTABLE; INJECTION
DIGOXIN
ABBOTT
0.25MG/ML
0.25MG/ML

AP DIGOXIN PEDIATRIC
ABBOTT
0.1MG/ML
0.1MG/ML

AP SANOFI WINTHROP
0.25MG/ML

N40093 001
MAY 16, 1996
N40093 001
MAY 16, 1996

N40092 001
APR 25, 1996
N40092 001
APR 25, 1996

TABLET; ORAL

> ADD >
> ADD >

LANOXIN
@ GLAXO WELLCOME
0.0625MG
0.125MG
0.1875MG
0.25MG
0.375MG
0.5MG

N20405 001
SEP 30, 1997
N20405 002
SEP 30, 1997
N20405 003
SEP 30, 1997
N20405 004
SEP 30, 1997
N20405 005
SEP 30, 1997
N20405 006
SEP 30, 1997

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILTIAZEM HCL

MYLAN

60MG

N74910 001

MAY 02, 1997

90MG

N74910 002

MAY 02, 1997

120MG

N74910 003

MAY 02, 1997

AP + HOECHST MARION RSSL 100MG/VIAL

SEP 05, 1997

DILTIAZEM HCL

GENSIA

5MG/ML

N74894 001

AUG 26, 1997

DIMENHYDRINATE

INJECTABLE; INJECTION

DIMENHYDRINATE

ELKINS SINN

50MG/ML

N84767 001

N84767 001

50MG/ML

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENHYDRAMINE HCL

EON

25MG

N80845 002

N80845 001

50MG

N80845 002

25MG

N80845 001

50MG

N80762 001

N80762 002

25MG

N80762 001

50MG

N80762 002

INJECTABLE; INJECTION

BENADRYL

PARKE DAVIS

10MG/ML

N86146 001

N89486 001

50MG/ML

N06146 001

10MG/ML

N09486 001

50MG/ML

N80586 002

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DIPHENHYDRAMINE HCL

INTL MEDICATION

STERIS

50MG/ML

N84094 001

N80873 001

10MG/ML

N83533 001

10MG/ML

N80873 001

10MG/ML

N83533 001

+ ® DIPHENHYDRAMINE HCL PRESERVATIVE FREE

FUJISAWA

50MG/ML

N80586 002

50MG/ML

N84094 001

50MG/ML

N80873 003

AP

INTL MEDICATION

STERIS

50MG/ML

N84094 001

N80873 001

N83533 001

N80873 001

N83533 001

N80586 002

N84094 001

N80873 003

N87160 001

JUN 07, 1996

N50678 001

N50678 001

JUN 19, 1995

N74292 001

FEB 16, 1995

N74292 001

FEB 16, 1995

N20624 001

SEP 11, 1997

> ADD >	<u>DOLASETRON MESYLATE MONOHYDRATE</u>						
> ADD >	TABLET; ORAL						
> ADD >	ANZEMET						
> ADD >	HOECHST MARION RSSL	EQ 50MG BASE	N20623 001				
> ADD >			SEP 11, 1997				
> ADD >	+	EQ 100MG BASE	N20623 002				
> ADD >			SEP 11, 1997				
> ADD >	<u>DOXAZOSIN MESYLATE</u>						
> ADD >	TABLET; ORAL						
> ADD >	CARDURA						
> ADD >	FEIZER	EQ 1MG BASE	N19668 001				
> ADD >	*	EQ 8MG BASE	NOV 02, 1990				
> ADD >			N19668 004				
> ADD >	+	EQ 1MG BASE	NOV 02, 1990				
> ADD >		EQ 8MG BASE	N19668 004				
> ADD >			NOV 02, 1990				
> ADD >	<u>DOXEPIH HYDROCHLORIDE</u>						
> ADD >	CAPSULE; ORAL						
> ADD >	DOXEPIH HCL						
> ADD >	FUREPAC PHARM	EQ 100MG BASE	N72110 001				
> ADD >	@	EQ 100MG BASE	SEP 08, 1988				
> ADD >			N72110 001				
> ADD >			SEP 08, 1988				
> ADD >	<u>DOXYCYCLINE HYCLATE</u>						
> ADD >	CAPSULE, COATED PELLETS; ORAL						
> ADD >	DORYX						
> ADD >	PARKE DAVIS	EQ 100MG BASE	N62653 001				
> ADD >	WARNER CHILCOTT	EQ 100MG BASE	OCT 30, 1985				
> ADD >			N62653 001				
> ADD >			OCT 30, 1985				
> ADD >	<u>DROPERIDOL</u>						
> ADD >	INJECTABLE; INJECTION						
> ADD >	DROPERIDOL						
> ADD >	ABBOTT	2.5MG/ML	N72272 001				
> ADD >			AUG 31, 1995				
> ADD >	<u>DROPERIDOL</u>						
> ADD >	INJECTABLE; INJECTION						
> ADD >	DROPERIDOL						
> ADD >	SANOFI WINTHROP	2.5MG/ML	N72272 001				
> ADD >			AUG 31, 1995				
> ADD >	<u>ECONAZOLE NITRATE</u>						
> ADD >	CREAM; TOPICAL						
> ADD >	SPECTAZOLE						
> ADD >	+ J AND J	1%	N18751 001				
> ADD >	* JOHNSON RW	1%	DEC 23, 1982				
> ADD >			N18751 001				
> ADD >			DEC 23, 1982				
> ADD >	<u>ERGOLOID MESYLATES</u>						
> ADD >	TABLET; SUBLINGUAL						
> ADD >	HYDROGENATED ERGOT ALKALOIDS						
> ADD >	@ ZENITH GOLDLINE	0.5MG	N87186 001				
> ADD >	@ ZENITH LABS	0.5MG	N87186 001				
> ADD >			SEP 30, 1997				
> ADD >	<u>ERYTHROMYCIN</u>						
> ADD >	GEL; TOPICAL						
> ADD >	ERYTHROMYCIN						
> ADD >	ALTANA	2%	N64184 001				
> ADD >			SEP 30, 1997				
> ADD >	SOLUTION; TOPICAL						
> ADD >	ERYTHROMYCIN						
> ADD >	ALTANA	2%	N64187 001				
> ADD >			SEP 30, 1997				
> ADD >	STIEFEL	2%	N64127 001				
> ADD >			FEB 14, 1997				
> ADD >	<u>ERYTHROMYCIN ESTOLATE</u>						
> ADD >	CAPSULE; ORAL						
> ADD >	ERYTHROMYCIN ESTOLATE						
> ADD >	@ ZENITH GOLDLINE	EQ 250MG BASE	N62237 001				
> ADD >	@ ZENITH LABS	EQ 250MG BASE	N62237 001				
> ADD >			SEP 30, 1997				

ESTAZOLAM

TABLET; ORAL
ESTAZOLAM
ROYCE LABS

<u>AB</u>	<u>1MG</u>	N74818 001	> ADD >	<u>AB</u>	<u>200MG</u>	N74942 001
		AUG 19, 1997	> ADD			SEP 30, 1997
<u>AB</u>	<u>2MG</u>	N74818 002	> ADD >	<u>AB</u>	<u>300MG</u>	N74942 002
		AUG 19, 1997	> ADD			SEP 30, 1997
<u>AB</u>	<u>1MG</u>	N74921 001	> ADD >	<u>AB</u>	<u>200MG</u>	N74932 001
		JUL 10, 1997				MAY 16, 1997
<u>AB</u>	<u>2MG</u>	N74921 002		<u>AB</u>	<u>300MG</u>	N74932 002
		JUL 10, 1997				MAY 16, 1997
<u>AB</u>	<u>1MG</u>	N74826 001		<u>AB</u>	<u>200MG</u>	N74899 001
		JUL 03, 1997				JUL 08, 1997
<u>AB</u>	<u>2MG</u>	N74826 002		<u>AB</u>	<u>300MG</u>	N74899 002
		JUL 03, 1997				JUL 08, 1997
<u>AB</u>	<u>1MG</u>	N19080 001		<u>AB</u>	<u>200MG</u>	N18922 002
		DEC 26, 1990				JAN 31, 1991
<u>AB</u>	<u>2MG</u>	N19080 002		<u>AB</u>	<u>300MG</u>	N18922 003
		DEC 26, 1990				JAN 31, 1991

PROSOM
ABBOTT

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21
ALESE
+ WYETH AYERST

	0.02MG;0.1MG	N20683 001		<u>AB</u>	<u>400MG</u>	N74841 001
		MAR 27, 1997				JUN 27, 1997

TABLET; ORAL-28
ALESE
WYETH AYERST

	0.02MG;0.1MG	N20683 002		<u>AB</u>	<u>400MG</u>	N74846 001
		MAR 27, 1997				FEB 28, 1997

ETODOLAC

CAPSULE; ORAL
ETODOLAC
ENDO PHARMS

<u>AB</u>	<u>200MG</u>	N74842 001		<u>AB</u>	<u>400MG</u>	N74819 001
		JUL 17, 1997				FEB 28, 1997
<u>AB</u>	<u>300MG</u>	N74842 002		<u>AB</u>	<u>400MG</u>	N74892 001
		JUL 17, 1997				APR 16, 1997
<u>AB</u>	<u>200MG</u>	N74840 001		<u>AB</u>	<u>400MG</u>	N74883 001
		AUG 29, 1997				FEB 28, 1997
<u>AB</u>	<u>300MG</u>	N74840 002		<u>AB</u>	<u>400MG</u>	N18922 004
		AUG 29, 1997				JUL 29, 1993

GENEVA PHARMS

ETODOLAC

CAPSULE; ORAL
ETODOLAC
INVAMED

<u>AB</u>	<u>200MG</u>	N74818 001		<u>AB</u>	<u>200MG</u>	N74942 001
		AUG 19, 1997				SEP 30, 1997
<u>AB</u>	<u>300MG</u>	N74818 002		<u>AB</u>	<u>300MG</u>	N74942 002
		AUG 19, 1997				SEP 30, 1997
<u>AB</u>	<u>200MG</u>	N74921 001		<u>AB</u>	<u>200MG</u>	N74932 001
		JUL 10, 1997				MAY 16, 1997
<u>AB</u>	<u>300MG</u>	N74921 002		<u>AB</u>	<u>300MG</u>	N74932 002
		JUL 10, 1997				MAY 16, 1997
<u>AB</u>	<u>200MG</u>	N74826 001		<u>AB</u>	<u>200MG</u>	N74899 001
		JUL 03, 1997				JUL 08, 1997
<u>AB</u>	<u>300MG</u>	N74826 002		<u>AB</u>	<u>300MG</u>	N74899 002
		JUL 03, 1997				JUL 08, 1997
<u>AB</u>	<u>200MG</u>	N19080 001		<u>AB</u>	<u>200MG</u>	N18922 002
		DEC 26, 1990				JAN 31, 1991
<u>AB</u>	<u>300MG</u>	N19080 002		<u>AB</u>	<u>300MG</u>	N18922 003
		DEC 26, 1990				JAN 31, 1991

LODINE
WYETH AYERST

TABLET; ORAL
ETODOLAC
ENDO PHARMS

<u>AB</u>	<u>400MG</u>	N74818 001		<u>AB</u>	<u>400MG</u>	N74841 001
		MAR 27, 1997				JUN 27, 1997
<u>AB</u>	<u>400MG</u>	N20683 001		<u>AB</u>	<u>400MG</u>	N74903 001
		MAR 27, 1997				APR 11, 1997
<u>AB</u>	<u>400MG</u>	N20683 002		<u>AB</u>	<u>400MG</u>	N74839 001
		MAR 27, 1997				JUL 11, 1997
<u>AB</u>	<u>400MG</u>	N20683 002		<u>AB</u>	<u>400MG</u>	N74846 001
		MAR 27, 1997				FEB 28, 1997
<u>AB</u>	<u>400MG</u>	N74842 001		<u>AB</u>	<u>400MG</u>	N74819 001
		JUL 17, 1997				FEB 28, 1997
<u>AB</u>	<u>400MG</u>	N74842 002		<u>AB</u>	<u>400MG</u>	N74892 001
		JUL 17, 1997				APR 16, 1997
<u>AB</u>	<u>400MG</u>	N74840 001		<u>AB</u>	<u>400MG</u>	N74883 001
		AUG 29, 1997				FEB 28, 1997
<u>AB</u>	<u>400MG</u>	N74840 002		<u>AB</u>	<u>400MG</u>	N18922 004
		AUG 29, 1997				JUL 29, 1993

ETOPOSIDE

INJECTABLE; INJECTION
ETOPOSIDE
IMMUNEX

<u>AB</u>	<u>20MG/ML</u>	N74513 001		<u>AB</u>	<u>20MG/ML</u>	N74513 001
		MAR 14, 1996				MAR 14, 1996

ETOPOSIDE

INJECTABLE; INJECTION
ETOPOSIDE

AP PIERRE FABRE 20MG/ML
AP SUPERGEN 20MG/ML

N74813 001
JUL 09, 1997
N74513 001
MAR 14, 1996

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION
CORLOPAM
+ NEUREX

EQ 10MG BASE/ML

N19922 001
SEP 23, 1997

FENTANYL CITRATE

INJECTABLE; INJECTION
FENTANYL CITRATE
ABBOTT

EQ 0.05MG BASE/ML
EQ 0.05MG BASE/ML

N72786 001
SEP 24, 1991
N72786 001
SEP 24, 1991

FLECAINIDE ACETATE

TABLET; ORAL
TAMOCOR
3M

50MG
100MG
150MG
50MG
100MG
150MG

N18830 004
AUG 23, 1988
N18830 001
OCT 31, 1985
N18830 003
JUN 03, 1988
N18830 004
AUG 23, 1988
N18830 001
OCT 31, 1985
N18830 003
JUN 03, 1988

FLUCONAZOLE

INJECTABLE; INJECTION
DIFLUCAN
PFIZER

200MG/100ML

N19950 001
JAN 29, 1990

DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER
+ PFIZER

200MG/100ML

N19950 003
SEP 29, 1992
N19950 005
JUL 08, 1994

@

2MG/ML

DIFLUCAN IN SODIUM CHLORIDE 0.9%

+ PFIZER 200MG/100ML

N19950 001
JAN 29, 1990

DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
+ PFIZER

200MG/100ML

N19950 002
JAN 29, 1990
N19950 004
JUL 08, 1994

@

2MG/ML

FLUCYTOSINE

CAPSULE; ORAL
ANCOBON

250MG
500MG
250MG
500MG

N17001 001
N17001 002
N17001 001
N17001 002

> ADD >
> ADD >
> DLT >
> DLT >

FLUNISOLIDE

SPRAY, METERED; NASAL

NASALIDE

0.025MG/SPRAY
0.025MG/SPRAY
0.025MG/SPRAY
0.025MG/SPRAY

N18148 001
N18148 001
N20409 001
MAR 08, 1995
N20409 001
MAR 08, 1995

BX + DURA
BX + SYNTEX
NASAREL
BX + DURA
BX + SYNTEX

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL
FLUCET
ALPHARMA

0.025%

N88360 001
JAN 16, 1984

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

AT FLUCET
NMC

0.025%

N88360 001
JAN 16, 1984

0.05%

N16908 003

AT FLUOCINOLONE ACETONIDE
@ ALPHARMA

0.01%

N88361 001
JAN 16, 1984
N88361 001
JAN 16, 1984

0.05%

N74935 001
JUL 29, 1997

AT SYNALAR
+ MEDICIS

0.01%

N12787 004

0.05%

N17373 001

AT + SYNTEX

0.025%

N12787 002

0.05%

N17373 001

AT + SYNTEX

0.01%

N12787 005

0.05%

N17373 001

AT + SYNTEX

0.025%

N12787 002

0.05%

N17373 001

AT + SYNTEX

0.025%

N12787 005

0.05%

N17373 001

ointment; TOPICAL

AT SYNALAR
+ MEDICIS

0.2%

N16161 002

0.05%

N74905 001

AT + SYNTEX

0.2%

N16161 002

0.05%

AUG 26, 1997

SOLUTION; TOPICAL

AT SYNALAR
+ MEDICIS

0.025%

N13960 001

0.05%

N18849 001

AT + SYNTEX

0.025%

N13960 001

0.05%

APR 06, 1984

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE

CREAM; TOPICAL

AT NEO-SYNALAR
+ MEDICIS

0.025%; EQ 3.5MG BASE/GM

N60700 001

0.025%

N12806 003

AT + SYNTEX

0.025%; EQ 3.5MG BASE/GM

N60700 001

0.025%

N12806 002

AT FLUOCINONIDE

CREAM; TOPICAL

AT LIDEX
+ MEDICIS

0.05%

N16908 002

0.05%

N13790 001

AT + SYNTEX

0.05%

N16908 002

0.05%

N12806 004

AT LIDEX-E
+ MEDICIS

0.05%

N16908 003

0.05%

N12806 004

FLUOCINONIDE

CREAM; TOPICAL

AB LIDEX-E
SYNTEX

0.05%

N16908 003

GEL; TOPICAL

AB FLUOCINONIDE
TARO

0.05%

N74935 001
JUL 29, 1997

AB + MEDICIS

0.05%

N17373 001

AB + SYNTEX

0.05%

N17373 001

ointment; TOPICAL

AB FLUOCINONIDE
ALTANA

0.05%

N74905 001

AB + MEDICIS

0.05%

N16909 002

AB + SYNTEX

0.05%

N16909 002

SOLUTION; TOPICAL

AT LIDEX
+ MEDICIS

0.05%

N18849 001

AT + SYNTEX

0.05%

APR 06, 1984

AT + SYNTEX

0.05%

APR 06, 1984

AB FLURANDRENOLIDE

CREAM; TOPICAL

AT CORDRAN SP
+ LIDEX

0.025%

N12806 003

AT + SYNTEX

0.05%

N12806 002

AT + SYNTEX

0.025%

N12806 003

AT + SYNTEX

0.05%

N12806 002

LOTION; TOPICAL

AT CORDRAN
+ LIDEX

0.05%

N13790 001

AT + SYNTEX

0.05%

N13790 001

ointment; TOPICAL

AB CORDRAN
+ LIDEX

0.025%

N12806 004

AB + SYNTEX

0.05%

N12806 001

AB + SYNTEX

0.025%

N12806 004

GLIPIZIDE

TABLET; ORAL
GLIPIZIDE
DURAMED

> ADD > AB 5MG
> ADD > AB 10MG
> ADD > AB 50MG
> DLT > AB 100MG
> DLT > AB 5MG
> DLT > AB 10MG
> DLT > AB 5MG
> ADD > AB 10MG
> ADD > AB 5MG
> ADD > AB 10MG

N74550 001
SEP 11, 1997
N74550 002
SEP 11, 1997
N74378 001
NOV 28, 1994
N74378 002
NOV 28, 1994
N74378 001
NOV 28, 1994
N74378 002
NOV 28, 1994
N74619 001
APR 04, 1997
N74619 002
APR 04, 1997

AB 5MG
AB 10MG
AB 50MG
AB 100MG
AB 5MG
AB 10MG
AB 5MG
AB 10MG
AB 5MG
AB 10MG

TABLET; ORAL
GRIFULVIN V
J AND J

AB 125MG
AB 250MG
AB 500MG
AB 125MG
AB 250MG
AB 500MG

N60618 001
N62279 001
N60618 002
N62279 002
N60618 003
N62279 003
N60618 001
N62279 001

ENDO PHARMS

ENDO PHARMS

SIDMAK LABS NJ

GUANFACINE HYDROCHLORIDE

TABLET; ORAL
GUANFACINE HCL
AMIDE PHARM

AB EQ 1MG BASE
AB EQ 2MG BASE
AB EQ 1MG BASE
AB EQ 2MG BASE
AB EQ 1MG BASE
AB EQ 2MG BASE

N74673 001
FEB 28, 1997
N74673 002
FEB 28, 1997
N74796 001
JAN 27, 1997
N74796 002
JAN 27, 1997
N74762 001
JUN 25, 1997
N74762 002
JUN 25, 1997

GLUTETHIMIDE

TABLET; ORAL
GLUTETHIMIDE
HALSEY

AA 500MG
AA 500MG

N89459 001
OCT 10, 1986
N89459 001
OCT 10, 1986

GRISEOFULVIN, MICROCRYSTALLINE

SUSPENSION; ORAL
GRIFULVIN V
+ J AND J

AB 125MG/5ML
AB 125MG/5ML
AB 125MG/5ML
AB 125MG/5ML

N50448 001
N62483 001
JAN 26, 1984
N50448 001
N62483 001
JAN 26, 1984

HALCINONIDE

CREAM; TOPICAL
HALOG
WESTWOOD SQUIBB
®

AB 0.025%
AB 0.025%

N17818 001
N17818 001

* JOHNSON RW

TABLET; ORAL
GRIFULVIN V
J AND J

AB 250MG
AB 250MG
AB 500MG
AB 500MG

N60618 002
N62279 002
N60618 003
N62279 003

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION
HALDOL
+ JOHNSON RW

AB EQ 50MG BASE/ML
AB EQ 100MG BASE/ML

N18701 001
JAN 14, 1986
N18701 002
JAN 31, 1997

HALOPERIDOL DECANOATE

INJECTABLE, INJECTION
 HALDOL DECANOATE 100
 * JOHNSON RW
 HALDOL DECANOATE 50
 * JOHNSON RW

EQ 100MG BASE/MG

EQ 50MG BASE/MG

N18701 002
 OCT 31, 1989

N18701 001
 JAN 14, 1986

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM
 ABBOTT

2,500 UNITS/ML

N88099 001
 APR 28, 1983

5,000 UNITS/ML

N88100 001
 APR 28, 1983

10,000 UNITS/ML

N40095 001
 JUL 26, 1996

20,000 UNITS/ML

N17029 004
 N40095 001

10,000 UNITS/ML

N17064 002
 JUL 26, 1996

1,000 UNITS/ML

N17064 002
 N88099 001

1,000 UNITS/ML

N88099 001
 APR 28, 1983

2,500 UNITS/ML

N88100 001
 APR 28, 1983

5,000 UNITS/ML

N88100 001
 APR 28, 1983

10,000 UNITS/ML

N19339 003
 MAR 27, 1985

10,000 UNITS/100ML

N19339 003
 MAR 27, 1985

5,000 UNITS/100ML

N19339 001
 MAR 27, 1985

5,000 UNITS/100ML

N19339 001
 MAR 27, 1985

10,000 UNITS/100ML

N19339 002
 MAR 27, 1985

10,000 UNITS/100ML

N19339 004
 MAR 27, 1985

10,000 UNITS/100ML

N19339 002
 MAR 27, 1985

10,000 UNITS/100ML

N19339 004
 MAR 27, 1985

10,000 UNITS/100ML

N19339 002
 MAR 27, 1985

10,000 UNITS/100ML

N19339 004
 MAR 27, 1985

10,000 UNITS/100ML

N19339 002
 MAR 27, 1985

10,000 UNITS/100ML

N19339 004
 MAR 27, 1985

10,000 UNITS/100ML

N19339 002
 MAR 27, 1985

10,000 UNITS/100ML

N19339 004
 MAR 27, 1985

10,000 UNITS/100ML

N19339 002
 MAR 27, 1985

10,000 UNITS/100ML

N19339 004
 MAR 27, 1985

10,000 UNITS/100ML

N19339 002
 MAR 27, 1985

10,000 UNITS/100ML

N19339 004
 MAR 27, 1985

10,000 UNITS/100ML

N19339 002
 MAR 27, 1985

10,000 UNITS/100ML

N19339 004
 MAR 27, 1985

10,000 UNITS/100ML

N19339 002
 MAR 27, 1985

10,000 UNITS/100ML

N19339 004
 MAR 27, 1985

10,000 UNITS/100ML

HEPARIN SODIUM

INJECTABLE, INJECTION

HEP FLUSH KIT IN PLASTIC CONTAINER
 FUJISAWA

10 UNITS/ML

N17029 017
 DEC 05, 1985

100 UNITS/ML

N17029 018
 DEC 05, 1985

10 UNITS/ML

N17029 017
 DEC 05, 1985

100 UNITS/ML

N17029 018
 DEC 05, 1985

10 UNITS/ML

N17029 018
 DEC 05, 1985

100 UNITS/ML

N40082 001
 FEB 28, 1995

10 UNITS/ML

N88097 001
 APR 28, 1983

10 UNITS/ML

N88346 001
 MAY 18, 1983

100 UNITS/ML

N40082 002
 FEB 28, 1995

100 UNITS/ML

N88097 001
 APR 28, 1983

100 UNITS/ML

N88346 001
 MAY 18, 1983

100 UNITS/ML

N88098 001
 APR 28, 1983

100 UNITS/ML

N88347 001
 MAY 18, 1983

100 UNITS/ML

HEPARIN LOCK FLUSH
 ABBOTT

INJECTABLE, INJECTION

HEP FLUSH KIT IN PLASTIC CONTAINER
 FUJISAWA

10 UNITS/ML

N17029 017
 DEC 05, 1985

100 UNITS/ML

N17029 018
 DEC 05, 1985

10 UNITS/ML

N17029 017
 DEC 05, 1985

100 UNITS/ML

N17029 018
 DEC 05, 1985

10 UNITS/ML

N17029 018
 DEC 05, 1985

100 UNITS/ML

N40082 001
 FEB 28, 1995

10 UNITS/ML

N88097 001
 APR 28, 1983

10 UNITS/ML

N88346 001
 MAY 18, 1983

100 UNITS/ML

N40082 002
 FEB 28, 1995

100 UNITS/ML

N88097 001
 APR 28, 1983

100 UNITS/ML

N88346 001
 MAY 18, 1983

100 UNITS/ML

N88098 001
 APR 28, 1983

100 UNITS/ML

N88347 001
 MAY 18, 1983

100 UNITS/ML

HEPARIN SODIUM PRESERVATIVE FREE
 ABBOTT

INJECTABLE, INJECTION

HEP FLUSH KIT IN PLASTIC CONTAINER
 FUJISAWA

10 UNITS/ML

N17029 017
 DEC 05, 1985

100 UNITS/ML

N17029 018
 DEC 05, 1985

10 UNITS/ML

N17029 017
 DEC 05, 1985

100 UNITS/ML

N17029 018
 DEC 05, 1985

10 UNITS/ML

N17029 018
 DEC 05, 1985

100 UNITS/ML

N40082 001
 FEB 28, 1995

10 UNITS/ML

N88097 001
 APR 28, 1983

10 UNITS/ML

N88346 001
 MAY 18, 1983

100 UNITS/ML

N40082 002
 FEB 28, 1995

100 UNITS/ML

N88097 001
 APR 28, 1983

100 UNITS/ML

N88346 001
 MAY 18, 1983

100 UNITS/ML

N88098 001
 APR 28, 1983

100 UNITS/ML

N88347 001
 MAY 18, 1983

100 UNITS/ML

HEPARIN SODIUM PRESERVATIVE FREE
 ABBOTT

INJECTABLE, INJECTION

HEP FLUSH KIT IN PLASTIC CONTAINER
 FUJISAWA

10 UNITS/ML

N17029 017
 DEC 05, 1985

100 UNITS/ML

N17029 018
 DEC 05, 1985

10 UNITS/ML

N17029 017
 DEC 05, 1985

100 UNITS/ML

N17029 018
 DEC 05, 1985

10 UNITS/ML

N17029 018
 DEC 05, 1985

100 UNITS/ML

N40082 001
 FEB 28, 1995

10 UNITS/ML

N88097 001
 APR 28, 1983

10 UNITS/ML

N88346 001
 MAY 18, 1983

100 UNITS/ML

N40082 002
 FEB 28, 1995

100 UNITS/ML

N88097 001
 APR 28, 1983

100 UNITS/ML

N88346 001
 MAY 18, 1983

100 UNITS/ML

N88098 001
 APR 28, 1983

100 UNITS/ML

N88347 001
 MAY 18, 1983

100 UNITS/ML

HEPARIN SODIUM PRESERVATIVE FREE
 ABBOTT

INJECTABLE, INJECTION

HEP FLUSH KIT IN PLASTIC CONTAINER
 FUJISAWA

10 UNITS/ML

N17029 017
 DEC 05, 1985

100 UNITS/ML

N17029 018
 DEC 05, 1985

10 UNITS/ML

N17029 017
 DEC 05, 1985

100 UNITS/ML

N17029 018
 DEC 05, 1985

10 UNITS/ML

N17029 018
 DEC 05, 1985

100 UNITS/ML

N40082 001
 FEB 28, 1995

10 UNITS/ML

N88097 001
 APR 28, 1983

10 UNITS/ML

N88346 001
 MAY 18, 1983

100 UNITS/ML

N40082 002
 FEB 28, 1995

100 UNITS/ML

N88097 001
 APR 28, 1983

100 UNITS/ML

N88346 001
 MAY 18, 1983

100 UNITS/ML

N88098 001
 APR 28, 1983

100 UNITS/ML

N88347 001
 MAY 18, 1983

100 UNITS/ML

HEPARIN SODIUM PRESERVATIVE FREE
 ABBOTT

INJECTABLE, INJECTION

HEP FLUSH KIT IN PLASTIC CONTAINER
 FUJISAWA

10 UNITS/ML

OMATROPINE METHYLBROMIDE, HYDROCODONE BITARTRATE

SYRUP; ORAL
HYCODAN
 AA * DUPONT MERCK
 1.5MG/5ML; 5MG/5ML
 N05213 002
 JUL 26, 1988
 AA + ENDO PHARMS
 1.5MG/5ML; 5MG/5ML
 N05213 002
 JUL 26, 1988
HYDROPAINE
 HALSEY
 AA
 1.5MG/5ML; 5MG/5ML
 N88066 001
 JUN 28, 1985
 @
 1.5MG/5ML; 5MG/5ML
 N88066 001
 JUN 28, 1985

TABLET; ORAL

HYCODAN
 AA * DUPONT MERCK
 1.5MG; 5MG
 N05213 001
 JUL 26, 1988
 AA + ENDO PHARMS
 1.5MG; 5MG
 N05213 001
 JUL 26, 1988

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDRALAZINE HCL
 AP LUITPOLD
 20MG/ML
 N40136 001
 JUN 30, 1997

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL
HYDRALAZINE HCL
 ZENITH LABS
 50MG
 100MG
 N84469 002
 N84581 001
 APR 10, 1984
 APR 10, 1984

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL
 HYDRALAZINE HCL W/
 @ ZENITH GOLDLINE
 100MG; 50MG
 180MG; 50MG
 N88358 001
 APR 10, 1984
 @ ZENITH LABS
 180MG; 50MG
 N88358 001
 APR 10, 1984
HYDRALAZINE HCL W/
 @ ZENITH GOLDLINE
 25MG; 25MG
 N88356 001
 APR 10, 1984
HYDRALAZINE HCL W/
 @ ZENITH GOLDLINE
 50MG; 50MG
 N88357 001
 APR 10, 1984
HYDRALAZINE HCL W/
 @ ZENITH LABS
 50MG; 50MG
 N88357 001
 APR 10, 1984

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL
HYDRALAZINE HCL, HYDROCHLOROTHIAZIDE AND RESERPINE
 @ ZENITH GOLDLINE
 25MG; 15MG; 0.1MG
 25MG; 15MG; 0.1MG
 N84291 001
 N84291 001
 @ ZENITH LABS
 25MG; 15MG; 0.1MG
 N83877 001
 N83877 001
 @ ZENITH GOLDLINE
 25MG; 15MG; 0.1MG
 25MG; 15MG; 0.1MG
 N86298 001
 N86298 001
 @ UNIPRES
 25MG; 15MG; 0.1MG
 25MG; 15MG; 0.1MG
 @ SOLVAY
 25MG; 15MG; 0.1MG
 25MG; 15MG; 0.1MG
 N86298 001
 N86298 001

HYDROCHLOROTHIAZIDE

TABLET; ORAL
HYDROCHLOROTHIAZIDE
 @ ZENITH GOLDLINE
 50MG
 50MG
 N84658 001
 N84658 001
 @ ZENITH LABS
 50MG
 50MG

> DLT >
 > DLT >
 > ADD >
 > ADD >

> ADD >
 > ADD >
 > ADD >
 > ADD >
 > DLT >
 > DLT >

HYDROCHLOROTHIAZIDE, IRBESARTAN

> ADD >
 > ADD >

TABLET; ORAL
 IRBESARTAN - HYDROCHLOROTHIAZIDE
 @ SANOFI 12.5MG; 75MG
 + 12.5MG; 150MG

N20758 001
 SEP 30, 1997
 N20758 002
 SEP 30, 1997

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL
 UNIRETIC
 + SCHWARZ PHARMA 25MG; 15MG

N20729 002
 JUN 27, 1997

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL
 METHYLDOPA AND HYDROCHLOROTHIAZIDE
 @ PUREPAC PHARM 15MG; 250MG
 @ 25MG; 250MG
 @ 30MG; 500MG
 @ 15MG; 250MG
 @ 25MG; 250MG
 @ 30MG; 500MG
 @ 15MG; 250MG
 @ 25MG; 250MG
 @ 30MG; 500MG
 @ 15MG; 250MG
 @ 25MG; 250MG
 @ 30MG; 500MG
 @ 50MG; 500MG
 @ 15MG; 250MG
 @ 25MG; 250MG
 @ 30MG; 500MG
 @ 50MG; 500MG

N70853 001
 OCT 08, 1986
 N70688 001
 APR 24, 1986
 N70854 001
 OCT 08, 1986
 N70853 001
 OCT 08, 1986
 N70688 001
 APR 24, 1986
 N70854 001
 OCT 08, 1986
 N71458 001
 MAR 08, 1988
 N71459 001
 MAR 08, 1988
 N71460 001
 MAR 08, 1988
 N71461 001
 MAR 08, 1988
 N71458 001
 MAR 08, 1988
 N71459 001
 MAR 08, 1988
 N71460 001
 MAR 08, 1988
 N71461 001
 MAR 08, 1988

TABLET; ORAL
 PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE
 @ ZENITH GOLDLINE 25MG; 40MG
 @ 25MG; 80MG
 @ ZENITH LABS 25MG; 40MG
 @ 25MG; 80MG

N71552 001
 DEC 01, 1988
 N71553 001
 DEC 01, 1988
 N71552 001
 DEC 01, 1988
 N71553 001
 DEC 01, 1988

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL
 HYDROCHLOROTHIAZIDE W/
 @ ZENITH GOLDLINE 25MG; 0.1MG
 @ 25MG; 0.125MG
 @ 50MG; 0.1MG
 @ 50MG; 0.125MG
 @ ZENITH LABS 25MG; 0.125MG
 @ 50MG; 0.125MG
 @ 25MG; 0.1MG
 @ 50MG; 0.1MG

N83572 001
 N83571 001
 N83568 001
 N83573 001
 N83571 001
 N83573 001
 N83572 001
 N83568 001

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL
 SPIRONOLACTONE W/
 @ ZENITH GOLDLINE 25MG; 25MG
 @ ZENITH LABS 25MG; 25MG

N87004 002
 MAY 24, 1982
 N87004 002
 MAY 24, 1982

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL
 UNIRETIC
 SCHWARZ PHARMA 12.5MG; 7.5MG

N20729 001
 JUN 27, 1997

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL
TRIAMTERENE AND HYDROCHLOROTHIAZIDE
 GENEVA PHARMS 25MG; 37.5MG

AB > ADD > N74821 001
 > ADD > JUN 05, 1997
 AB > ADD > N74857 001
 > ADD > SEP 09, 1997

B* > DLT > N72337 001
 > DLT > MAY 11, 1988

TABLET; ORAL
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE
 PAR PHARM 50MG; 75MG

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL
 VICOPROFEN 7.5MG; 200MG
 + KNOLL PHARM

> ADD >
 > ADD >
 > ADD >
 > ADD >

N20716 001
 SEP 23, 1997

HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP; ORAL
 HYCOMINE
 * DUPONT MERCK 5MG/5ML; 25MG/5ML
 + ENDO PHARMS 5MG/5ML; 25MG/5ML
 HYCOMINE PEDIATRIC
 DUPONT MERCK 2.5MG/5ML; 12.5MG/5ML
 ENDO PHARMS 2.5MG/5ML; 12.5MG/5ML

> DLT > N19410 001
 > DLT > AUG 17, 1990
 > ADD > N19410 001
 > ADD > AUG 17, 1990

> DLT > N19411 001
 > DLT > AUG 17, 1990
 > ADD > N19411 001
 > ADD > AUG 17, 1990

HYDROCORTISONE

CREAM; TOPICAL
 DERMACORT
 MONARCH PHARMS 1%
 SOLVAY 1%
 HYDROCORTISONE 2.5%
 @ ALPHARMA 2.5%

AT > ADD > N83011 002
 AT > ADD > N83011 002

AT > ADD > N89754 001
 > ADD > FEB 01, 1989
 > ADD > N89754 001
 > ADD > FEB 01, 1989

HYDROCORTISONE

CREAM; TOPICAL
 PROTOCORT
 MONARCH PHARMS 1%
 SOLVAY 1%
 SYNACORT 1%
 MEDICIS 2.5%
 @ SYNTEX 0.5%
 @ 2.5%
 @ 0.5%

AT > ADD > N83011 001
 AT > ADD > N83011 001

AT > ADD > N87458 001
 AT > ADD > N87457 001
 AT > ADD > N87459 001
 AT > ADD > N87458 001
 AT > ADD > N87457 001
 AT > ADD > N87459 001

TABLET; ORAL

HYDROCORTISONE
 PUREPAC PHARM 10MG

BP > ADD > N84247 003
 > ADD > AUG 31, 1982
 BP > ADD > N84247 002
 > ADD > N84247 003
 > ADD > AUG 31, 1982
 > ADD > N84247 002

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; AURICULAR (OTIC)
 CORTISPORIN
 + MONARCH PHARMS 1%; EQ 3.5MG BASE/ML;
 10,000 UNITS/ML
 OTOCORT 1%; EQ 3.5MG BASE/ML;
 @ STERIS 10,000 UNITS/ML

AT > ADD > N50479 001
 > ADD >

AT > ADD > N60730 002
 > ADD >

SOLUTION/DROPS; OTIC

CORTISPORIN
 @ GLAXO WELLCOME 1%; EQ 3.5MG BASE/ML;
 10,000 UNITS/ML

AT > ADD > N50479 001
 > ADD >

AT > ADD > N60730 002
 > ADD >

SUSPENSION/DROPS; AURICULAR (OTIC)

OTOCORT
 @ STERIS 1%; EQ 3.5MG BASE/ML;
 10,000 UNITS/ML

AT > ADD > N62521 001
 > ADD > JUL 11, 1985

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; AURICULAR (OTIC)

PEDIOTIC

AT MONARCH PHARMS 1% EQ 3.5MG BASE/ML;
10,000 UNITS/ML

N62822 001
SEP 29, 1987

HYDROCORTISONE ACETATE

INJECTABLE; INJECTION
HYDROCORTONE

BP * MERCK SHARP DOHME 50MG/ML
+ 50MG/ML

N08228 004
N08228 004

SUSPENSION/DROPS; OTIC

OTOCORT

* STERIS

1% EQ 3.5MG BASE/ML;
10,000 UNITS/ML

N62521 001
JUL 11, 1985

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM; TOPICAL

CORTISPORIN

* GLAXO WELLCOME

0.5% EQ 3.5MG BASE/GM;
10,000 UNITS/GM

N50218 001
AUG 09, 1985

PEDIOTIC

* GLAXO WELLCOME

1% EQ 3.5MG BASE/ML;
10,000 UNITS/ML

N62822 001
SEP 29, 1987

0.5% EQ 3.5MG BASE/GM;
10,000 UNITS/GM

N50218 001
AUG 09, 1985

HYDROCORTISONE; UREA

CREAM; TOPICAL

ALPHADERM

* BIOGLAN

* VIVAN

1% 10%

1% 10%

N86008 001

N86008 001

0.1%

N20453 001

FEB 28, 1997

HYDROCORTISONE ACETATE

CREAM; TOPICAL

HEMISOL-HC

* ABLE

1%

1%

N81274 001
JUN 19, 1992

N81274 001
JUN 19, 1992

> ADD >

> ADD >

0.1%

N20769 001
SEP 08, 1997

HYDROCORTISONE ACETATE

* PUREPAC PHARM

1%

1%

N86052 001

N86052 001

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

HYDROCORTISONE SODIUM SUCCINATE

* ELKINS SINN

* EQ 1GM BASE/VIAL

@ EQ 1GM BASE/VIAL

N87569 001
N87569 001

INJECTABLE; INJECTION

HYDROCORTISONE ACETATE

* AKORN

25MG/ML

50MG/ML

25MG/ML

50MG/ML

25MG/ML

50MG/ML

25MG/ML

50MG/ML

N09637 001

N09637 002

N09637 001

N09637 002

N83759 001

N83759 002

N83759 001

N83759 002

TABLET; ORAL

RESERPINE AND HYDROFLUMETHIAZIDE

@ ZENITH GOLDLINE 50MG;0.125MG

N88932 001
JAN 11, 1985

> ADD >

> ADD >

HYDROFLUMETHIAZIDE; RESERPINE

TABLET; ORAL
RESERPINE AND HYDROFLUMETHIAZIDE
BP ZENITH LABS 50MG;0.125MG

> DLT > N88932 001
> DLT > JAN 11, 1985

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDROMORPHONE HCL

AP ABBOTT 10MG/ML
AP SANOFI 10MG/ML

N74598 001
JUN 19, 1997
N74598 001
JUN 19, 1997

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDROXYZINE HCL

AP ABBOTT 25MG/ML
AP STERLING WINTHROP 50MG/ML
AP 50MG/ML

N87416 001
N87546 001
N87416 001
N87546 001

TABLET; ORAL
HYDROXYZINE HCL

AB HALSEY 25MG
25MG

N89117 001
MAY 02, 1988
N89117 001

AB KV PHARM 10MG

MAY 02, 1988
N87819 001

AB 25MG

JUN 23, 1982
N87820 001

AB 50MG

JUN 23, 1982
N87821 001

AB 100MG

JUN 23, 1982
N87822 001

10MG

JUN 23, 1982
N87819 001

25MG

JUN 23, 1982
N87820 001

50MG

JUN 23, 1982
N87821 001

100MG

JUN 23, 1982
N87822 001

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL
HYDROXYZINE HCL
PUREPAC PHARM

> DLT > AB 10MG
> DLT > AB 25MG
> DLT > AB 50MG
> DLT > AB 10MG
> ADD > 10MG
> ADD > 25MG
> ADD > 50MG
> ADD > 10MG
> ADD > 25MG
> ADD > 50MG
> ADD > 10MG
> ADD > 25MG
> ADD > 50MG
> DLT > AB 10MG
> DLT > AB 25MG
> DLT > AB 50MG

N88120 001
SEP 25, 1984
N88121 001
SEP 25, 1984
N88122 001
SEP 25, 1984
N88120 001
SEP 25, 1984
N88121 001
SEP 25, 1984
N88122 001
SEP 25, 1984
N87216 001
N87410 001
N87411 001
N87216 001
N87410 001
N87411 001

HYDROXYZINE PAMOATE

CAPSULE; ORAL
HY-PAM
EON

AB EON EQ 25MG HCL
AB EON EQ 25MG HCL

N87479 001
N87479 001

IBUPROFEN

SUSPENSION; ORAL
IBU
KNOLL PHARM

EX 100MG/5ML
100MG/5ML

N19784 001
DEC 18, 1989
N19784 001
DEC 18, 1989

TABLET; ORAL

IBUPROFEN
PUREPAC PHARM

AB 300MG
AB 400MG

N71123 001
SEP 19, 1986
N71124 001
SEP 19, 1986

IBUPROFEN

TABLET; ORAL

IBUPROFEN
PURBAC PHARM

> DLT >
> DLT >

> ADD >
> ADD >
> ADD >
> ADD >
> ADD >
> ADD >

> ADD >
> ADD >
> ADD >
> ADD >

AB 600MG
AB 800MG

300MG
400MG
600MG
800MG

N71125 001
SEP 19, 1986
N71964 001
FEB 01, 1988
N71123 001
SEP 19, 1986
N71124 001
SEP 19, 1986
N71125 001
SEP 19, 1986
N71964 001
FEB 01, 1988

IFOSFAMIDE, MESNA
INJECTABLE; INJECTION
IFEX/MESNEX KIT
+ BRISTOL MYERS SQUIBB 1GM/VIAL; 100MG/ML
+ 3GM/VIAL; 100MG/ML

N19763 003
OCT 10, 1992
N19763 004
OCT 10, 1992

AB 300MG

AB 400MG

AB 600MG

AB 800MG

AB 300MG

AB 400MG

AB 600MG

AB 800MG

MOTRIN
MCNEIL

AB 300MG
AB 400MG
AB 600MG
AB 800MG

N17463 003
N17463 002
N17463 004
N17463 005
MAY 22, 1985
N17463 003
N17463 002
N17463 004
N17463 005
MAY 22, 1985

INDAPAMIDE

TABLET; ORAL
INDAPAMIDE

AB 1.25MG
AB 1.25MG
AB 2.5MG

N74461 002
MAR 26, 1997
N74665 001
APR 04, 1997
N74665 002
APR 04, 1997

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
IDAMYCIN PFS

+ PHARMACIA AND UPJOHN 1MG/ML

N50734 001
FEB 17, 1997

INDIUM IN-111 OXYQUINOLINE

INJECTABLE; INJECTION
INDIUM IN-111 OXYQUINOLINE
AMERSHAM
MEDI PHYSICS 1mCi/ML

N19044 001
DEC 23, 1985
N19044 001
DEC 23, 1985

IFOSFAMIDE

INJECTABLE; INJECTION
IFEX

* BRISTOL MYERS SQUIBB 1GM/VIAL

N19763 001
DEC 30, 1988
N19763 002
DEC 30, 1988
N19763 001
DEC 30, 1988
N19763 002
DEC 30, 1988

* 3GM/VIAL

@ 1GM/VIAL

@ 3GM/VIAL

INDOCYANINE GREEN

INJECTABLE; INJECTION
CARDIO-GREEN
+ AKORN 25MG/VIAL
+ * 50MG/VIAL
+ * BECTON DICKINSON 25MG/VIAL
+ * 50MG/VIAL

N11525 001
N11525 002
N11525 001
N11525 002

IODIXANOL

INJECTABLE; INJECTION
VISIPAQUE 270
NYCOMED 55%
VISIPAQUE 320
NYCOMED 65.2%

N20808 001
AUG 29, 1997
N20808 002
AUG 29, 1997

IPODATE CALCIUM

GRANULE; ORAL
ORGRAFIN CALCIUM
BRACCO
3GM/PACKET
3GM/PACKET

N12968 001
N12968 001

IODOHIPPURATE SODIUM, I-131

INJECTABLE; INJECTION
HIPPTOPE
BRACCO
1-2mCi/VIAL
1-2mCi/VIAL
IODOHIPPURATE SODIUM I 131
0.2mCi/ML
SORIN 0.2mCi/ML

N15419 002
N15419 002
N17313 001
N17313 001

SOLUTION; INHALATION

ATROVENT
AN + BOEHRINGER INGELHEIM 0.02%
IPRATROPIUM BROMIDE
DEY 0.02%

N20228 001
SEP 29, 1993
N74755 001
JAN 10, 1997

IOPAMIDOL

INJECTABLE; INJECTION
IOPAMIDOL-250
FUJISAWA 51%
IOPAMIDOL-300
ABBOTT 61%
FUJISAWA 61%
IOPAMIDOL-300 IN PLASTIC CONTAINER
ABBOTT 61%
FUJISAWA 76%
ISOVUE-250
BRACCO 51%
+
+ 51%

N20757 001
SEP 30, 1997
N20757 002
SEP 30, 1997
N20757 003
SEP 30, 1997

IOPAMIDOL-370

FUJISAWA 76%
+ BRACCO 51%

N87101 001
N87101 001

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION
ISOETHARINE HCL
ALPHARMA 1%
1%
ISOFLUROPHATE
OINTMENT; OPHTHALMIC
FLOROPRYL
* MERCK SHARP DOHME
0.025%
0.025%

N10656 001
N10656 001

ISONIAZID

SYRUP; ORAL
ISONIAZID
AA + CAROLINA MEDCL

50MG/5ML

N88235 001
NOV 10, 1983
N88235 001
NOV 10, 1983
N81118 001
JUL 21, 1997

AP

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
KETAMINE HCL
ABBOTT

EQ 50MG BASE/ML

N74549 001
JUN 27, 1996
N74549 002
JUN 27, 1996
N74549 001
JUN 27, 1996
N74549 002
JUN 27, 1996

AA MIKART

50MG/5ML

N81118 001
JUL 21, 1997

AP SANOFI WINTHROP

EQ 50MG BASE/ML

AA LANIAZID
LANNETT

50MG/5ML

N89243 001
FEB 03, 1986
N89243 001
FEB 03, 1986

AP
KETOROLAC TROMETHAMINE

TABLET; ORAL
ISONIAZID
AA MIKART

100MG

N40090 001
JUN 26, 1997

AP
KETOROLAC TROMETHAMINE

15MG/ML

N74801 001
JUN 05, 1997
N74802 001
JUN 05, 1997
N74801 002
JUN 05, 1997
N74802 002
JUN 05, 1997

AA

300MG

N40090 002
JUN 26, 1997

AP

> ADD >
> ADD >
> DLT >
> DLT >

ZENITH GOLDLINE
ZENITH LABS
ZENITH LABS

100MG
300MG
100MG
300MG
300MG

N80270 001
N83610 001
N80270 001
N83610 001

AP
30MG/ML

ISOPROTERENOL HYDROCHLORIDE

AEROSOL, METERED; INHALATION
ISOPROTERENOL HCL

BN + 3M
BN + ALPHARMA
INJECTABLE; INJECTION

N10375 004
N10375 004
N85904 001
N85904 001

10MG
10MG
10MG
10MG

N74955 001
SEP 19, 1997
N74761 001
MAY 16, 1997
N74790 001
JUN 26, 1997
N74754 001
MAY 16, 1997

ISUPREL
AP + ABBOTT
AP + SANOFI WINTHROP

0.2MG/ML
0.2MG/ML

N10515 001
N10515 001

AP + SYNTEX

N19645 001
DEC 20, 1991

ITRACONAZOLE

SOLUTION; ORAL
SPORANOX
+ JANSSEN

10MG/ML

N20657 001
FEB 21, 1997

150MG; 300MG

N20857 001
SEP 26, 1997

> ADD >
> ADD >
> ADD >
> ADD >

TABLET; ORAL
COMBIVIR
+ GLAXO WELLCOME

LANSOPRAZOLE

CAPSULE, DELAYED REL GRANULES, ORAL
PREVACID
TAP HOLDINGS

15MG
30MG
N20406 001
MAY 10, 1995
N20406 002
MAY 10, 1995

N74544 002
AUG 28, 1997
N73099 001
MAR 28, 1997
N73101 001
MAR 28, 1997

EQ 25MG BASE
EQ 5MG BASE
EQ 25MG BASE

CAPSULE, DELAYED REL PELLETS; ORAL
PREVACID
TAP HOLDINGS

15MG
30MG
N20406 001
MAY 10, 1995
N20406 002
MAY 10, 1995

LEUPROLIDE ACETATE

INJECTABLE; INJECTION
LUPRON DEPOT-3
+ TAP HOLDINGS

N20708 001
MAR 07, 1997
N20517 002
MAY 30, 1997

11.25MG/VIAL
30MG/VIAL

LETROZOLE

TABLET; ORAL
FEMARA
+ NOVARTIS

2.5MG
N20726 001
JUL 25, 1997

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION
LEUCOVORIN CALCIUM

AP + ABBOTT
AP + BEDFORD
+
AP GENSIA
AP + IMMUNEX
AP PHARMACHEMIE
AP
EQ 10MG BASE/ML
EQ 200MG BASE/VIAL
EQ 200MG BASE/VIAL
EQ 350MG BASE/VIAL
EQ 350MG BASE/VIAL
EQ 50MG BASE/VIAL
EQ 100MG BASE/VIAL

N40147 001
JUN 25, 1997
N40056 001
MAY 23, 1995
N40055 001
MAY 23, 1995
N40174 001
JUN 12, 1997
N08107 005
APR 05, 1989
N89628 001
APR 17, 1997
N89915 001
APR 17, 1997

AP
AP
AP
AP
1%
2%
1%
2%

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
LIDOCAINE HCL
ABBOTT

N40013 001
JUN 23, 1995
N40078 001
JUN 23, 1995
N40013 001
JUN 23, 1995
N40078 001
JUN 23, 1995

LIOTHYRONINE SODIUM

TABLET; ORAL
CYTOMEL
JONES MEDCL INDS

> ADD >
> ADD >
> ADD >
> DLT >
> DLT >
> DLT >
> DLT >
EQ 0.005MG BASE
EQ 0.025MG BASE
EQ 0.05MG BASE
EQ 0.005MG BASE
EQ 0.025MG BASE
EQ 0.05MG BASE

N10379 001
N10379 002
N10379 003
N10379 001
N10379 002
N10379 003

TABLET; ORAL
LEUCOVORIN CALCIUM
PAR PHARM

N74544 001
AUG 28, 1997

EQ 5MG BASE

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE; ORAL
LITHOBID
SOLVAY
+
360MG
300MG

N18027 001
N18027 001

MAGNESIUM SULFATE

INJECTABLE; INJECTION
MAGNESIUM SULFATE IN PLASTIC CONTAINER
ABBOTT

N20309 002
JUN 24, 1994
N20309 001
JUN 24, 1994
N20309 002
JUN 24, 1994

4GM/100ML
80MG/ML

LORAZEPAM

INJECTABLE; INJECTION
LORAZEPAM
ABBOTT

N74243 001
APR 12, 1994
N74300 001
APR 12, 1994
N74243 002
APR 12, 1994
N74300 003
MAR 19, 1997
N74243 001
APR 12, 1994
N74300 001
APR 12, 1994
N74243 002
APR 12, 1994

2MG/ML
2MG/ML
4MG/ML
4MG/ML
2MG/ML
2MG/ML
4MG/ML

MECLIZINE HYDROCHLORIDE

TABLET; ORAL
MECLIZINE HCL
KY PHARM

N85524 001
N85523 001
N85524 001
N85523 001
N40179 001
JAN 30, 1997
N40179 002
JAN 30, 1997
N84975 001
N84657 001
N83784 001
N83784 001
N84975 001
N84657 001

12.5MG
25MG
12.5MG
25MG
12.5MG
25MG
12.5MG
25MG
12.5MG
25MG

AA
AA

> ADD >
> ADD >
> ADD >
> DLT >
> DLT >
> DLT >

SOLUTION; ORAL

LORAZEPAM
+ ROXANE

N74648 001
MAR 18, 1997

0.5MG/5ML

MECLIZINE HCL

@ ZENITH GOLDLINE
ZENITH LABS

N84976 001
N84976 001

25MG
25MG

AA
AA

> ADD >
> DLT >

MAGNESIUM SULFATE

INJECTABLE; INJECTION
MAGNESIUM SULFATE
FUJISAWA

N19316 001
SEP 08, 1986
N19316 001
SEP 08, 1986

500MG/ML
500MG/ML

AA
AA

> ADD >
> DLT >

+
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER
ABBOTT

N20328 001
SEP 01, 1994
N20328 001
SEP 01, 1994
N20328 002
SEP 01, 1994
N20328 002
SEP 01, 1994

75 IU/VIAL; 75 IU/VIAL
75 IU/VIAL; 75 IU/VIAL
150 IU/VIAL; 150 IU/VIAL
150 IU/VIAL; 150 IU/VIAL

MENOTROPINS (FSH; LH)

INJECTABLE; INJECTION
HUMEGON
* ORGAMON

N20328 001
SEP 01, 1994
N20328 001
SEP 01, 1994
N20328 002
SEP 01, 1994
N20328 002
SEP 01, 1994

75 IU/VIAL; 75 IU/VIAL
75 IU/VIAL; 75 IU/VIAL
150 IU/VIAL; 150 IU/VIAL
150 IU/VIAL; 150 IU/VIAL

AB
AB
AB
AB

> ADD >
> DLT >

+
MAGNESIUM SULFATE IN PLASTIC CONTAINER
ABBOTT

N20309 001
JUN 24, 1994

4GM/100ML

AB

> ADD >
> DLT >

MENOTROPINS (FSH, LH)

INJECTABLE; INJECTION
REPRONAL
FERRING

AB 75 IU/VIAL; 75 IU/VIAL N73598 001
JAN 30, 1997
AB 75 IU/VIAL; 75 IU/VIAL N73598 001
JAN 30, 1997
AB 150 IU/VIAL; 150 IU/VIAL N73599 001
JAN 30, 1997
AB 150 IU/VIAL; 150 IU/VIAL N73599 001
JAN 30, 1997

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
MEPERIDINE HCL
MALLINCKRODT

AP 10MG/ML N40163 001
MAY 12, 1997
AA 50MG N40110 001
MAR 12, 1997
AA 100MG N40110 002
MAR 12, 1997
AA 50MG N40186 001
JUN 30, 1997
AA 100MG N40186 002
JUN 30, 1997

MEPROBAMATE

TABLET; ORAL
MEPROBAMATE
PUREPAC PHARM

AA 200MG N84804 001
AA 400MG N84804 002
200MG
400MG
400MG
600MG
AA 600MG N84181 001
AA 600MG N84181 001

> ADD >
> DLT >

METAPROTERENOL SULFATE

SYRUP; ORAL

AA METAPROTERENOL SULFATE 10MG/5ML
JVL
AA MORTON GROVE 10MG/5ML
AA 10MG/5ML N74702 001
MAR 24, 1997
AA 10MG/5ML N71656 001
OCT 13, 1987
AA 10MG/5ML N74702 001
MAR 24, 1997
AA 10MG/5ML N71656 001
OCT 13, 1987

METFORMIN HYDROCHLORIDE

TABLET; ORAL
GLUCOPHAGE
BRISTOL MYERS SQUIBB

* 500MG 850MG 500MG 850MG
+ 500MG 850MG
N20357 001
DEC 29, 1994
N20357 002
DEC 29, 1994
N20357 001
MAR 03, 1995
N20357 002
MAR 03, 1995

METHACHOLINE CHLORIDE

POWDER FOR RECONSTITUTION; INHALATION
PROVOCHOLINE
METHAPHARM

ROCHE 100MG/VIAL 100MG/VIAL
N19193 001
OCT 31, 1986
N19193 001
OCT 31, 1986

METHAZOLAMIDE

TABLET; ORAL
METHAZOLAMIDE
APPLIED ANAL

AB 25MG N40011 001
JUL 17, 1997
AB 50MG N40011 002
JUL 17, 1997

METHOCARBAMOL

TABLET; ORAL
METHOCARBAMOL
PUREPAC PHARM
 @
 @ ZENITH GOLDLINE
 @ ZENITH LABS

AA
 AA
 @
 @
 @
 @
 AA
 AA

500MG
 750MG
 500MG
 750MG
 500MG
 500MG
 500MG
 750MG

N71751 001
 MAR 28, 1988
 N71752 001
 MAR 28, 1988
 N71751 001
 MAR 28, 1988
 N71752 001
 MAR 28, 1988
 N70749 001
 FEB 07, 1986
 N70750 001
 FEB 07, 1986
 N70452 001
 FEB 07, 1986
 N70749 001
 FEB 07, 1986
 N70750 001
 FEB 07, 1986
 N70452 001
 FEB 07, 1986

METHOTREXATE SODIUM

INJECTABLE; INJECTION
MEXATE-AQ PRESERVED
BRISTOL MYERS
 @ BRISTOL MYERS SQUIBB

AP
 @

EQ 25MG BASE/ML
 EQ 25MG BASE/ML

EQ 25MG BASE/ML
 EQ 25MG BASE/ML

METHOXSALEN

CAPSULE; ORAL
 OXSORALEN-ULTRA
 + ICN
 CAPSULE, LIQUID FILLED; ORAL
 OXSORALEN-ULTRA
 * ICN

N19600 001
 OCT 30, 1986
 N19600 001
 OCT 30, 1986

10MG
 10MG
 10MG

N40220 001
 AUG 29, 1997
 N40220 002
 AUG 29, 1997
 N40220 003
 AUG 29, 1997

METHYCLOTHIAZIDE

TABLET; ORAL
METHYCLOTHIAZIDE
ZENITH GOLDLINE
 @
ZENITH LABS

AB
 @
 AB
 AB

2.5MG
 5MG
 2.5MG
 5MG

N74147 001
 AUG 02, 1996
 N71990 001
 JAN 18, 1989
 N71990 001
 JAN 18, 1989

METHYLDOPA

TABLET; ORAL
METHYLDOPA
HAISEX
 @
 @
PUREPAC PHARM

AB
 AB

125MG
 250MG

125MG
 250MG

METHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL
METHYLPHENIDATE HCL
DANBURY PHARMA
 @
 @
 @

AB
 AB
 AB

125MG
 250MG
 500MG
 125MG
 250MG
 500MG

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
METOCLOPRAMIDE HCL
 ABBOTT
 PAULDING
 @

AP
 AP

EQ 5MG BASE/ML
 EQ 5MG BASE/ML

EQ 5MG BASE/ML
 EQ 5MG BASE/ML

<u>METOCLOPRAMIDE HYDROCHLORIDE</u>									
INJECTABLE; INJECTION									
<u>METOCLOPRAMIDE HCL</u>									
<u>AP</u> SANOPI WINTHROP	<u>EQ 5MG BASE/ML</u>	N74147 001							N70042 001
		AUG 02, 1996							DEC 20, 1984
TABLET; ORAL									
<u>METOCLOPRAMIDE HCL</u>	<u>EQ 5MG BASE</u>	N71536 002							
<u>AB</u> MUTUAL PHARM		JAN 16, 1997							
<u>METOLAZONE</u>									
TABLET; ORAL									
MYKROX	0.5MG	N19532 001							
MEDEVA	0.5MG	OCT 30, 1987							
+		N19532 001							
		OCT 30, 1987							
<u>METOPROLOL TARTRATE</u>									
INJECTABLE; INJECTION									
<u>METOPROLOL TARTRATE</u>	<u>1MG/ML</u>	N74133 001							
<u>AP</u> ABBOTT		DEC 21, 1993							
<u>AP</u> STERLING WINTHROP	<u>1MG/ML</u>	N74133 001							
		DEC 21, 1993							
<u>METRONIDAZOLE</u>									
CREAM; TOPICAL									
NORITATE	1%	N20743 001							
+ DERMIK LABS		SEP 26, 1997							
<u>METRONIDAZOLE</u>									
GEL; VAGINAL									
METROGEL-VAGINAL	0.75%	N20208 001							
+ 3M		AUG 17, 1992							
* CURATEK	0.75%	N20208 001							
		AUG 17, 1992							
INJECTABLE; INJECTION									
<u>METRONIDAZOLE</u>	<u>500MG/100ML</u>	N70042 001							
<u>AP</u> STERIS		DEC 20, 1984							
<u>METRONIDAZOLE</u>									
INJECTABLE; INJECTION									
<u>METRONIDAZOLE</u>									
@ STERIS	500MG/100ML	N70042 001							
		DEC 20, 1984							
<u>METRONIDAZOLE</u>									
INJECTABLE; INJECTION									
<u>METRONIDAZOLE</u>									
@ STERIS	500MG/100ML	N70042 001							
		DEC 20, 1984							
<u>MEXILETINE HYDROCHLORIDE</u>									
CAPSULE; ORAL									
<u>MEXILETINE HCL</u>									
<u>AB</u> WATSON LABS	<u>150MG</u>	N74711 001							
		FEB 26, 1997							
<u>AB</u>	<u>200MG</u>	N74711 002							
		FEB 26, 1997							
<u>AB</u>	<u>250MG</u>	N74711 003							
		FEB 26, 1997							
<u>MIBEFRADIL DIHYDROCHLORIDE</u>									
TABLET; ORAL									
POSICOR									
ROCHE	EQ 50MG BASE	N20689 001							
+		JUN 20, 1997							
		N20689 002							
		JUN 20, 1997							
<u>MICONAZOLE</u>									
INJECTABLE; INJECTION									
<u>MONISTAT</u>									
* JANSSEN	10MG/ML	N18040 001							
@	10MG/ML	N18040 001							
<u>MICONAZOLE NITRATE</u>									
CREAM; TOPICAL									
<u>MONISTAT-DERM</u>									
+ J AND J	2%	N17494 001							
* JOHNSON RW	2%	N17494 001							
LOTION; TOPICAL									
<u>MONISTAT-DERM</u>									
@ J AND J	2%	N17739 001							
@ JOHNSON RW	2%	N17739 001							

> ADD >
> ADD >
> ADD >

MINOCYCLINE HYDROCHLORIDE

TABLET, ORAL
MINOCYCLINE HCL
LEDERLE

EQ 50MG BASE
EQ 100MG BASE
EQ 50MG BASE
EQ 100MG BASE

N50451 003
AUG 10, 1982
N50451 002
AUG 10, 1982
N50451 003
AUG 10, 1982
N50451 002
AUG 10, 1982

> ADD >
> ADD >
> ADD >
> ADD >
> ADD >

MOLINDONE HYDROCHLORIDE

TABLET, ORAL
MOBAN

ENDO PHARMS
5MG
10MG
25MG
50MG
100MG

N17111 004
N17111 005
N17111 006
N17111 007
N17111 008

MYCOPHENOLATE MOFETIL

TABLET, ORAL
CELLCEPT
+ SYNTEX

500MG

N50723 001
JUN 19, 1997

MIRTAZAPINE

TABLET, ORAL
REMERON
+ ORGANON

30MG
30MG
45MG

N20415 002
JUN 14, 1996
N20415 002
JUN 14, 1996
N20415 003
MAR 17, 1997

> DLT >
> DLT >
> DLT >
> ADD >
> ADD >

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

MUBAIN
* DUPONT MERCK
* *

10MG/ML
20MG/ML
10MG/ML
20MG/ML

N18024 001
N18024 002
MAY 27, 1982
N18024 001
N18024 002
MAY 27, 1982

MOLINDONE HYDROCHLORIDE

CAPSULE; ORAL

MOBAN
* DUPONT MERCK
* *
* ENDO PHARMS
* *
* *

5MG
10MG
25MG
5MG
10MG
25MG

N17111 001
N17111 002
N17111 003
N17111 001
N17111 002
N17111 003

> DLT >
> DLT >
> DLT >
> ADD >
> ADD >

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE HCL
ABBOTT

0.02MG/ML
0.4MG/ML
0.02MG/ML
0.4MG/ML

N70171 001
SEP 24, 1986
N70172 001
SEP 24, 1986
N70171 001
SEP 24, 1986
N70172 001
SEP 24, 1986

CONCENTRATE; ORAL

MOBAN
* DUPONT MERCK
+ ENDO PHARMS

20MG/ML
20MG/ML

N17938 001
N17938 001

> DLT >
> ADD >

TABLET; ORAL

MOBAN
DUPONT MERCK

5MG
10MG
25MG
50MG
100MG

N17111 004
N17111 005
N17111 006
N17111 007
N17111 008

> DLT >
> DLT >
> DLT >
> DLT >
> ADD >

NARCAN
* DUPONT MERCK
* *

0.02MG/ML
0.4MG/ML
1MG/ML
0.02MG/ML

N16636 002
N16636 001
N16636 003
JUN 14, 1982
N16636 002

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

AP + AP

+ ENDO PHARMS

0.4MG/ML
1MG/ML

N16636 001
N16636 003
JUN 14, 1982

TABLET; ORAL
SERZONE
@ BRISTOL MYERS SQUIBB 50MG

+ 50MG

N20152 001
DEC 22, 1994
N20152 001
DEC 22, 1994

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

AB PENTAZOCINE AND NALOXONE HYDROCHLORIDES

ROYCE LABS

EQ 0.5MG BASE;
EQ 50MG BASE

N74736 001
JAN 21, 1997

POWDER FOR RECONSTITUTION; ORAL

VIRACEPT

+ AGOURON

EQ 50MG BASE/SCOOPFUL

N20778 001
MAR 14, 1997

AB + SANOFI

EQ 0.5MG BASE;
EQ 50MG BASE

N18733 001
DEC 16, 1982

TABLET; ORAL

VIRACEPT

+ AGOURON

EQ 250MG BASE

N20779 001
MAR 14, 1997

NANDROLONE DECANOATE

INJECTABLE; INJECTION

AO NANDROLONE DECANOATE

STERIS

50MG/ML

N87598 001
OCT 06, 1983

100MG/ML

N87599 001
OCT 06, 1983

50MG/ML

N87598 001
OCT 06, 1983

100MG/ML

N87599 001
OCT 06, 1983

AA NEOMYCIN SULFATE

NEO-RX

PHARMA TEK

100%
100%

N61579 001
N61579 001

AA NEOMYCIN SULFATE

PADDOCK

100%

N62385 001
JUN 01, 1982

NIACIN

NEDOCROMIL SODIUM

AEROSOL, METERED; INHALATION

TILADE

* FISON'S

1.75MG/INH

N19660 001
DEC 30, 1992

1.75MG/INH

N19660 001
DEC 30, 1992

TABLET; ORAL

AA NIACIN

HALSEY

500MG

500MG

500MG

500MG

500MG

500MG

500MG

500MG

N83453 001
N83453 001
N83271 001
N83271 001
N83180 001
N83180 001
N83180 001

TABLET, EXTENDED RELEASE; ORAL

NIASPAN

+ KOS

375MG

N20381 001
JUL 28, 1997

> ADD >
> ADD >
> ADD >

> ADD >
> DLT >

NIACIN

TABLET, EXTENDED RELEASE; ORAL

NIASPAN
+ KOS 500MG N20381 002
JUL 28, 1997
+ 750MG N20381 003
JUL 28, 1997
+ 1GM N20381 004
JUL 28, 1997
NIASPAN TITRATION STARTER PACK
+ KOS 375MG; 500MG; 750MG N20381 005
JUL 28, 1997

NICOTINE

INHALANT; INHALATION
NICOTROL
+ PHARMACIA AND UPJOHN 4MG/CARTRIDGE N20714 001
MAY 02, 1997

NITROFURANTOIN

TABLET; ORAL
NITROFURANTOIN
@ ZENITH GOLDLINE 50MG N80078 002
@ 100MG N80078 001
@ ZENITH LABS 50MG N80078 002
@ 100MG N80078 001

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL
NITROFURANTION 100MG N74967 002
JUL 09, 1997
NITROFURANTOIN 50MG N74967 001
JUL 09, 1997

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION
LEVOPHED
+ ABBOTT EQ 1MG BASE/ML N07513 001

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION
LEVOPHED EQ 1MG BASE/ML N07513 001
* SANOPI WINTHROP

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL
NORTRIPTYLINE HCL
INVAMED EQ 10MG BASE N74835 001
JUN 30, 1997
EQ 25MG BASE N74835 002
JUN 30, 1997
EQ 50MG BASE N74835 003
JUN 30, 1997
EQ 75MG BASE N74835 004
JUN 30, 1997

NYSTATIN

CREAM; TOPICAL
MYKINAC 100,000 UNITS/GM N62387 001
@ ALPHARMA JUL 29, 1982
AT 100,000 UNITS/GM N62387 001
NMC JUL 29, 1982

OINTMENT; TOPICAL

MYCOSTATIN
* SQUIBB 100,000 UNITS/GM N60571 001
@ WESTWOOD SQUIBB 100,000 UNITS/GM N60571 001
MYKINAC 100,000 UNITS/GM N62731 001
@ ALPHARMA SEP 22, 1986
NMC 100,000 UNITS/GM N62731 001
SEP 22, 1986
NILSTAT 100,000 UNITS/GM N61444 001
LEDERLE 100,000 UNITS/GM N61444 001
AT +

SUSPENSION; ORAL

NYSTATIN 100,000 UNITS/ML N62571 001
ALPHARMA OCT 29, 1985
@ 100,000 UNITS/ML N62571 001
OCT 29, 1985

> ADD >
> ADD >
> DLT >
> DLT >

ONDANSETRON HYDROCHLORIDE

SOLUTION; ORAL
 ZOFRAN
 + GLAXO WELLCOME
 EQ 4MG BASE/5ML

N20605 001
 JAN 24, 1997

N20553 002
 DEC 12, 1995
 N20553 003
 DEC 12, 1995
 N20553 004
 JAN 06, 1997

OXACILLIN SODIUM

CAPSULE; ORAL
BACTOCILL
 SMITHKLINE BEECHAM
 +
OXACILLIN SODIUM
 APOTHECON
 *
 @
 @
 EQ 250MG BASE
 EQ 250MG BASE
 EQ 500MG BASE
 EQ 250MG BASE
 EQ 500MG BASE

N61336 001
 N61336 001
 N61450 002
 N61450 001
 N61450 002
 N61450 001

OXTRIPHYLLINE

TABLET, EXTENDED RELEASE; ORAL
 CHOLEDFYL SA
 * PARKE DAVIS
 + WARNER CHILCOTT
 600MG
 600MG

> DLT >
 > DLT >
 > ADD >
 > ADD >

N86742 001
 N86742 001

N16848 001
 N16848 001

OXYBUTYRIN CHLORIDE

SYRUP; ORAL
OXYBUTYRIN CHLORIDE
 MORTON GROVE
 5MG/5ML

> DLT >
 > ADD >

N74868 001
 FEB 12, 1997

N11707 002
 N11707 001
 N11707 002
 N11707 001

N11738 004
 N11738 004

OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
 OXYCONTIN
 * PURDUE FREDERICK
 10MG
 20MG
 40MG
 + PURDUE PHARMA
 10MG

N20553 001
 DEC 12, 1995
 N20553 002
 DEC 12, 1995
 N20553 003
 DEC 12, 1995
 N20553 001
 DEC 12, 1995

40 USP UNITS/ML
 40 USP UNITS/ML

N12285 001
 N12285 001

PAROMOMYCIN SULFATE

CAPSULE; ORAL
HUMATIN
 + PARKE DAVIS
 EQ 250MG BASE
 EQ 250MG BASE

N60521 001
 N62310 001

OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
 OXYCONTIN
 + PURDUE PHARMA
 20MG
 +
 40MG
 +
 80MG

OXYMETHOLONE

TABLET; ORAL
 ANADROL-50
 * SYNTEX
 + UNIMED
 50MG
 50MG

OXYMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION
 NUMORPHAN
 * DUPONT MERCK
 + ENDO PHARMS
 1MG/ML
 1.5MG/ML
 1MG/ML
 1.5MG/ML
 SUPPOSITORY; RECTAL
 NUMORPHAN
 * DUPONT MERCK
 + ENDO PHARMS
 5MG
 5MG

OXYTOCIN

SOLUTION; NASAL
 SYNTOCINON
 * NOVARTIS
 @

N12285 001
 N12285 001

EQ 250MG BASE
 EQ 250MG BASE

RX DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 9 / JAN' 97 - SEP' 97

PAROMOMYCIN SULFATE

AB CAPSULE; ORAL
PAROMOMYCIN SULFATE
CARACO

EQ 250MG BASE

N64171 001
JUN 30, 1997

> ADD >
> ADD >
> DLT >
> DLT >

PENTOBARBITAL SODIUM

CAPSULE; ORAL
SODIUM PENTOBARBITAL
@ ZENITH GOLDLINE
@ ZENITH LABS

50MG
100MG
50MG
100MG

N83461 001
N83461 002
N83461 001
N83461 002

PAROXETINE HYDROCHLORIDE

SUSPENSION; ORAL
PAXIL
+ SMITHKLINE BEECHAM

EQ 10MG BASE/5ML

N20710 001
JUN 25, 1997

AB TABLET, EXTENDED RELEASE; ORAL
PENTOXIFYLLINE
ESI LEDERLE

400MG

N74877 001
JUL 08, 1997
N74425 001
JUL 08, 1997
N74878 001
JUL 09, 1997
N18631 001
AUG 30, 1984

PENICILLIN G POTASSIUM

TABLET; ORAL
PENICILLIN G POTASSIUM
@ ZENITH GOLDLINE
@ ZENITH LABS

400,000 UNITS
400,000 UNITS

N60073 004
N60073 004

> ADD >
> DLT >

PENICILLIN V POTASSIUM

TABLET; ORAL
PENICILLIN V POTASSIUM
@ ZENITH GOLDLINE
@ ZENITH LABS

EQ 125MG BASE
EQ 250MG BASE
EQ 500MG BASE
EQ 125MG BASE
EQ 250MG BASE
EQ 500MG BASE
EQ 125MG BASE
EQ 125MG BASE

N60518 001
N60518 002
N60518 003
N60518 001
N60518 002
N60518 003
N60003 001
N60003 001

> ADD >
> ADD >
> ADD >
> DLT >
> ADD >

PERINDOPRIL ERBUMINE

TABLET; ORAL
ACEON
RHONE POULENC RORER

2MG
4MG
8MG
2MG
4MG
8MG

N20184 001
DEC 30, 1993
N20184 002
DEC 30, 1993
N20184 003
DEC 30, 1993
N20184 001
DEC 30, 1993
N20184 002
DEC 30, 1993
N20184 003
DEC 30, 1993

PENTAZOCINE LACTATE

INJECTABLE; INJECTION
TALWIN
+ ABBOTT
+ SANOFI WINTHROP

EQ 30MG BASE/ML
EQ 30MG BASE/ML

N16194 001
N16194 001

PHENDIMETRAZINE TARTRATE
CAPSULE, EXTENDED RELEASE; ORAL
BONTRIL
MALLINCKRODT

105MG

N88021 001
SEP 21, 1982

PHENDIMETRAZINE TARTRATE

BC CAPSULE, EXTENDED RELEASE; ORAL
PHENDIMETRAZINE TARTRATE
GRAHAM DM 105MG

BC 105MG
BC 105MG
BC 105MG
BC 105MG
BC 105MG
BC 105MG
BC 105MG

> DLT >
> DLT >

N87214 001
MAY 26, 1982
N88020 001
AUG 16, 1982
N88021 001
SEP 21, 1982
N88028 001
AUG 16, 1982
N88062 001
SEP 13, 1982
N88063 001
SEP 10, 1982
N88111 001
OCT 18, 1982
N87214 001
MAY 26, 1982
N88020 001
AUG 16, 1982
N88028 001
AUG 16, 1982
N88062 001
SEP 13, 1982
N88111 001
OCT 18, 1982

PHENDIMETRAZINE TARTRATE

TABLET; ORAL

PHENDIMETRAZINE TARTRATE
ZENITH LABS 35MG
35MG

> DLT >
> DLT >

N85611 001
N85612 001

PHENTERMINE HYDROCHLORIDE

AA CAPSULE; ORAL
PHENTERMINE HCL
AMIDE PHARM 30MG

AA 30MG
AA 37.5MG
AA 30MG
AA 30MG
AA 30MG

> ADD >
> DLT >

N40227 001
JUN 18, 1997
N40228 001
JUN 19, 1997
N40083 001
MAR 07, 1997
N86329 001
N86329 001

TABLET; ORAL

PHENTERMINE HCL
AMIDE PHARM 37.5MG

AA 37.5MG

> DLT >
> ADD >
> ADD >
> DLT >

N40190 001
MAY 30, 1997
N85689 001
N85689 001
N85553 001
N85553 001

TABLET; ORAL

PHENDIMETRAZINE TARTRATE
INWOOD LABS 35MG

AA 35MG
AA 35MG
AA 35MG
AA 35MG
AA 35MG
AA 35MG
AA 35MG

> DLT >
> ADD >

AA 35MG
AA 35MG
AA 35MG
AA 35MG
AA 35MG
AA 35MG
AA 35MG

N84740 001
N84741 001
N84742 001
N84743 001
N84740 001
N84741 001
N84742 001
N84743 001
N84138 001
N85525 001
N84138 001
N85525 001
N83682 001
N85611 001
N85612 001
N83682 001

PHENYLBUTAZONE

CAAPSULE; ORAL
PHENYLBUTAZONE
ZENITH GOLDLINE 100MG

> ADD >
> ADD >
> DLT >
> DLT >

N88218 001
JUN 24, 1983
N88218 001
JUN 24, 1983

PHENYTOIN SODIUM

INJECTABLE; INJECTION
PHENYTOIN SODIUM
ABBOTT 50MG/ML

AP 50MG/ML
AP 50MG/ML

N89744 001
DEC 18, 1987
N89744 001
DEC 18, 1987

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE; ORAL
 POTASSIUM CITRATE 10MEQ
 + MISSION PHARMA
 UNIV TX
 *
 10MEQ

> ADD >
 > ADD >
 > DLT >
 > DLT >
 > DLT >
 > DLT >

N19071 002
 AUG 31, 1992
 N19071 001
 AUG 30, 1985
 N19071 002
 AUG 31, 1992

EQ 5MG BASE/5ML
 EQ 5MG BASE/5ML

N19157 001
 MAY 28, 1986
 N19157 001
 MAY 28, 1986

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL
 PEDIAPRED
 * FISOXS
 + MEDEVA

PREDNISONE

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL
 MIRAPEX
 + PHARMACIA AND UPJOHN 0.125MG
 0.25MG
 1MG
 1.25MG
 @
 1.5MG
 +

N20667 001
 JUL 01, 1997
 N20667 002
 JUL 01, 1997
 N20667 003
 JUL 01, 1997
 N20667 004
 JUL 01, 1997
 N20667 005
 JUL 01, 1997

TABLET; ORAL
PREDNISONE
 HALSEY
 @ ZENITH GOLDLINE
 @
 @
 @
 BX ZENITH LABS
 BX
 @

5MG
 5MG
 5MG
 10MG
 20MG
 5MG
 10MG
 20MG
 5MG
 10MG
 20MG

PREDNISOLONE

TABLET; ORAL
 PREDNISOLONE
 PUREPAC PHARM
 @ ZENITH GOLDLINE
 @ ZENITH LABS
 5MG
 5MG
 5MG
 5MG

> ADD >
 > DLT >

N80325 001
 N80325 001
 N80378 001
 N80378 001

INJECTABLE; INJECTION
PROCAINAMIDE HCL

AP ABBOTT
 AP WINTHROP
 500MG/ML
 500MG/ML

N89537 001
 AUG 25, 1987
 N89537 001
 AUG 25, 1987

PREDNISOLONE ACETATE

INJECTABLE; INJECTION
 PREDNISOLONE ACETATE
 STERIS
 @
 25MG/ML
 25MG/ML

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
 NOVOCAIN
 + ABBOTT
 +
 +
 AP * STERLING WINTHROP

N83654 001
 N83654 001

1%
 2%
 10%
 1%

TABLET, EXTENDED RELEASE; ORAL
PROCAINAMIDE HCL
 INWOOD LABS
 @
 500MG
 500MG

N89840 001
 MAR 06, 1989
 N89840 001
 MAR 06, 1989

N85362 003
 N85362 004
 N86797 001
 N85362 003

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

AP * NOVOCAIN 2%
 * STERLING WINTHROP 10%

AP * PROCAINE HCL 1%
 * STERIS 2%
 @ 1%
 @ 2%

N85362 004
 N86797 001

N83535 001
 N83535 002
 N83535 001
 N83535 002

GEL; VAGINAL
 CRINONE

4%

8%

8%

N20701 001
 JUL 31, 1997
 N20701 002
 JUL 31, 1997
 N20756 001
 MAY 13, 1997

PROCAINE HYDROCHLORIDE; TETRACYCLINE HYDROCHLORIDE

INJECTABLE; INJECTION

AP TETRACYN 40MG/VIAL; 250MG/VIAL
 * PFIZER 40MG/VIAL; 250MG/VIAL
 @

N60285 003
 N60285 003

50MG/ML
 25MG/ML
 50MG/ML
 25MG/ML
 50MG/ML
 50MG/ML

N83838 002
 N83532 001
 N83532 002
 N83532 001
 N83532 002
 N83838 002

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

AP PROCHLORPERAZINE EDISYLATE EQ 5MG BASE/ML

AP STERIS EQ 5MG BASE/ML

@ EQ 5MG BASE/ML

AP STERLING WINTHROP EQ 5MG BASE/ML

N89703 001 > ADD >
 APR 07, 1988 > ADD >
 N89605 001 > ADD >
 JUL 08, 1987 > DLT >
 N89605 001 > DLT >
 JUL 08, 1987 > DLT >
 N89703 001 > DLT >
 APR 07, 1988

12.5MG
 25MG
 50MG
 12.5MG
 25MG
 50MG

N83604 001
 N83603 001
 N83613 001
 N83604 001
 N83603 001
 N83613 001

PROCHLORPERAZINE MALEATE

TABLET; ORAL

AP PROCHLORPERAZINE MALEATE EQ 5MG BASE

DURAMED EQ 5MG BASE

AP EQ 10MG BASE

N40207 001
 MAY 01, 1997
 N40207 002
 MAY 01, 1997

15MG

15MG

N88377 001
 DEC 08, 1983
 N88377 001
 DEC 08, 1983

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

AA PROPOXYPHENE HCL

AA ROXANE

32MG

65MG

N83089 001
 N83089 002

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL
PROPOXYPHENE HCL
 @ ROXANE
 @ ZENITH GOLDLINE
 @ ZENITH LABS

> ADD >
 > DLT >

32MG
 65MG
 32MG
32MG

N83089 001
 N83089 002
 N83597 001
N83597 001

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL
 @ ROXANE

> ADD >
 > DLT >

10MG
 20MG
 40MG
 60MG
 80MG
 90MG

N70516 001
 JUL 07, 1986
 N70517 001
 JUL 07, 1986
 N70518 001
 JUL 07, 1986
 N70519 001
 SEP 24, 1986
 N70520 001
 JUL 07, 1986
 N70521 001
 SEP 24, 1986
 N70516 001
 JUL 07, 1986
 N70517 001
 JUL 07, 1986
 N70518 001
 JUL 07, 1986
 N70519 001
 SEP 24, 1986
 N70520 001
 JUL 07, 1986
 N70521 001
 SEP 24, 1986

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL
 @ ZENITH LABS

> DLT >
 > DLT >

10MG
 20MG
 40MG
 80MG
 60MG

N72063 001
 JUL 29, 1988
 N72066 001
 JUL 29, 1988
 N72067 001
 JUL 29, 1988
 N72069 001
 JUL 29, 1988
 N72068 001
 JUL 29, 1988

PROPYLTHIOURACIL

TABLET; ORAL
 PROPYLTHIOURACIL
 @ ZENITH GOLDLINE
 @ ZENITH LABS

> ADD >
 > DLT >

50MG
 50MG

N80215 001
 N80215 001

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TABLET; ORAL
TRIPROLIDINE HCL AND PSEUDOEPHEDRINE HCL
 @ ZENITH GOLDLINE

> ADD >
 > ADD >
 > DLT >
 > DLT >

60MG; 2.5MG
 60MG; 2.5MG

N85273 001
 DEC 12, 1984
 N85273 001
 DEC 12, 1984

PYRIDOSTIGMINE BROMIDE

INJECTABLE; INJECTION

AP
 AP
 AP
 AP

+ ICN
 * ROCHE

5MG/ML
 5MG/ML

N09830 001
 N09830 001

SYRUP; ORAL

MESTINON
 + ICN
 * ROCHE

60MG/5ML
 60MG/5ML

N15193 001
 N15193 001

TABLET; ORAL

MESTINON
 + ICN

60MG

N09829 002

PYRIDOSTIGMINE BROMIDE

TABLET; ORAL

MESTINON
* ROCHE

60MG

TABLET, EXTENDED RELEASE; ORAL

MESTINON

+ ICN

* ROCHE

180MG

180MG

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION

PYRIDOXINE HCL

* STERRIS

@

100MG/ML

100MG/ML

QUETIAPINE FUMARATE

TABLET; ORAL

SEROQUEL

ZENECA

EQ 25MG BASE

EQ 100MG BASE

EQ 200MG BASE

+

EQ 200MG BASE

> ADD >
> ADD >

QUINIDINE SULFATE

CAPSULE; ORAL

CIN-QUIN

SOLVAY

*

@

@

200MG

300MG

200MG

300MG

> DLT >
> DLT >
> DLT >
> DLT >
> ADD >
> ADD >

TABLET; ORAL

CIN-QUIN

SOLVAY

@

@

@

@

@

100MG

200MG

300MG

100MG

200MG

300MG

> DLT >
> DLT >
> DLT >
> ADD >
> ADD >
> ADD >

QUINIDINE SULFATE

TABLET; ORAL

QUINIDINE SULFATE

@ ZENITH GOLDLINE

ZENITH LABS

200MG

200MG

N89829 002

N89829 002

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HCL

BOEHRINGER INGELHEIM

EQ 150MG BASE

EQ 300MG BASE

N11665 001

N11665 001

N83760 001

N83760 001

N20639 001

SEP 26, 1997

N20639 002

SEP 26, 1997

N20639 003

SEP 26, 1997

> ADD >
> ADD >

ZANTAC 150

GLAXO WELLCOME

EQ 150MG BASE

ZANTAC 300

+ GLAXO WELLCOME

EQ 300MG BASE

EQ 150MG BASE

EQ 300MG BASE

EQ 150MG BASE

EQ 300MG BASE

EQ 150MG BASE

EQ 300MG BASE

N18703 001
JUN 09, 1983
N18703 002
DEC 09, 1985

RAUWOLFIA SERPENTINA

TABLET; ORAL

RAUVAL

* FAL PAK

+

RAUWOLFIA SERPENTINA

GLOBAL PHARM

100MG

100MG

50MG

100MG

N85299 001

N84932 001

N85298 001

N85299 001

N84932 001

N85298 001

> DLT >
> DLT >
> DLT >
> ADD >
> ADD >
> ADD >

N84549 001
N84549 001

N74662 001
AUG 29, 1997
N74662 002
AUG 29, 1997
N74467 001
AUG 29, 1997
N74467 002
AUG 29, 1997
N74023 001
AUG 22, 1997
N74023 002
AUG 22, 1997
N74488 001
JUL 31, 1997
N74488 002
JUL 31, 1997
N74680 001
SEP 12, 1997
N74680 002
SEP 12, 1997

N18703 001
JUN 09, 1983
N18703 002
DEC 09, 1985

N09108 004
N09108 004
N09273 001
N09273 002

SELEGILINE HYDROCHLORIDE

TABLET; ORAL

SELEGILINE HCL

APOTHECON

5MG

N74672 001

SODIUM IODIDE, I-131

CAPSULE; ORAL

IODOTOPE

BRACCO

8-100 uCi

N10929 001

ENDO LABS

5MG

N74565 001

1-50mCi

N10929 003

ENDO PHARMS

5MG

N74565 001

8-100 uCi

N10929 001

TEVA

5MG

N74744 001

1-130mCi

N10929 003

SELMORELIN ACETATE

INJECTABLE; INJECTION

GEREF

+ SERONO

EQ 0.5MG BASE/VIAL

N20443 001

50MG/VIAL

N71555 001

INJECTABLE; INJECTION

NORDITROPIN

+ NOVO NORDISK

EQ 1MG BASE/VIAL

N20443 002

4MG/VIAL

N71555 001

SODIUM CHLORIDE

INJECTABLE; INJECTION

SEROSTIM

SERONO

9MG/ML

N19465 002

4MG/VIAL

N19721 001

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

ABBOTT

9MG/ML

JUL 15, 1985

4MG/VIAL

MAY 08, 1995

SODIUM IODIDE, I-123

CAPSULE; ORAL

GOLDEN PHARMS

100 uCi

N18671 001

25MG

N87108 001

GOLDEN PHARMS

200 uCi

N18671 002

25MG

N87108 001

SYNCOR PHARMS

400 uCi

N18671 003

25MG

N87108 001

SYNCOR PHARMS

100 uCi

N18671 001

500MG/5ML

N13664 002

SYNCOR PHARMS

200 uCi

N18671 002

500MG/5ML

N13664 002

ROCHE

400 uCi

N18671 003

500MG/5ML

N13664 002

<u>SULFAMETHOXAZOLE, TRIMETHOPRIM</u>									
	INJECTABLE; INJECTION								
	<u>SULFAMETHOXAZOLE AND TRIMETHOPRIM</u>								
AP	ABBOTT	80MG/ML; 16MG/ML							
			N73199 001						
			SEP 11, 1992						
AP	STERLING WINthrop	80MG/ML; 16MG/ML							
			N73199 001						
			SEP 11, 1992						
<u>SULFINPYRAZONE</u>									
	CAPSULE; ORAL								
	<u>SULFINPYRAZONE</u>								
	ZENITH GOLDLINE	200MG							
> ADD >			N87770 001						
> ADD >			NOV 19, 1982						
> DLT >			N87770 001						
> DLT >			NOV 19, 1982						
<u>SULFINPYRAZONE</u>									
	CAPSULE; ORAL								
	<u>SULFINPYRAZONE</u>								
	ZENITH GOLDLINE	100MG							
> ADD >			N87769 001						
> ADD >			JUN 01, 1982						
> DLT >			N87769 001						
> DLT >			JUN 01, 1982						
<u>SULFISOXAZOLE</u>									
	TABLET; ORAL								
	<u>SULFISOXAZOLE</u>								
	PUREPAC PHARM	500MG							
AB		500MG							
> ADD >			N80087 001						
> DLT >			N80087 001						
	ZENITH GOLDLINE	500MG							
AB		500MG							
> ADD >			N80142 001						
> DLT >			N80142 001						
	ZENITH LABS	500MG							
AB		500MG							
> ADD >			N80087 001						
> DLT >			N80087 001						
<u>SULFISOXAZOLE DIOLAMINE</u>									
	SOLUTION/DROPS; OPHTHALMIC								
	<u>GANTRISIN</u>								
	ROCHE	EQ 4% BASE							
> DLT >			N07757 002						
> DLT >			N07757 002						
> DLT >			N07757 002						
> ADD >			N07757 002						
<u>SUMATRIPTAN</u>									
	SPRAY; NASAL								
	<u>IMITREX</u>								
	GLAXO WELLCOME	5MG/SPRAY							
> ADD >			N20626 001						
> ADD >			AUG 26, 1997						
> DLT >			N20626 002						
> DLT >			AUG 26, 1997						
	GLAXO WELLCOME	10MG/SPRAY							
> ADD >			N20626 003						
> ADD >			AUG 26, 1997						
	GLAXO WELLCOME	20MG/SPRAY							
> ADD >			N20626 003						
> ADD >			AUG 26, 1997						
<u>TAMOXIFEN CITRATE</u>									
	TABLET; ORAL								
	<u>NOLVADEX</u>								
	ZENECA	EQ 10MG BASE							
> ADD >			N17970 001						
> ADD >			N17970 001						
> DLT >			N17970 001						
> DLT >			N17970 001						
<u>TAMSULOSIN HYDROCHLORIDE</u>									
	CAPSULE; ORAL								
	<u>FLOMAX</u>								
	BOEHRINGER INGELHEIM	0.4MG							
> ADD >			N20579 001						
> ADD >			APR 15, 1997						
> DLT >			N20579 001						
> DLT >			APR 15, 1997						
<u>TAZAROTENE</u>									
	GEL; TOPICAL								
	<u>TAZORAC</u>								
	ALLERGAN	0.05%							
> ADD >			N20600 001						
> DLT >			JUN 13, 1997						
	ALLERGAN	0.1%							
> ADD >			N20600 002						
> DLT >			N20600 002						
	ALLERGAN	0.1%							
> ADD >			N20600 002						
> DLT >			JUN 13, 1997						
<u>TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT</u>									
	INJECTABLE; INJECTION								
	<u>AW-MBA</u>								
	CIS	N/A							
> DLT >			N17792 001						
> DLT >			N17792 001						
> DLT >			N17792 001						
> ADD >			N17792 001						

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION

AP MDP-BRACCO N/A
 BRACCO
 AP MDP-SQUIBB N/A
 BRACCO

N18107 001
 N18107 001

AB 125MG/5ML
 @ ALPHARMA
 AB 125MG/5ML
 @ PUREPAC PHARM
 @ 125MG/5ML
 TETRACYN
 PFIPHARMECS
 @ 125MG/5ML
 @ 125MG/5ML
 TETRAMED
 @ ZENITH GOLDLINE
 @ ZENITH LABS
 AB 125MG/5ML

N60633 001
 N60633 001
 N60291 001
 N60291 001
 N60095 001
 N60095 001

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION

MIRALUMA N/A
 DUPONT

N19785 003
 MAY 23, 1997

> ADD >
 > DLT >
 AB

N61468 001
 N61468 001

TERFENADINE

TABLET; ORAL

AB SELDANE 60MG
 + HOECHST MARION RSSL
 AB TERFENADINE 60MG
 BAKER NORTON

N18949 001
 MAY 08, 1985
 N74475 001
 JAN 03, 1997

AP 1mCi/ML
 AP 1mCi/ML
 AP 1mCi/ML
 AP 1mCi/ML
 AP 1mCi/ML
 AP 1mCi/ML

N17806 001
 N17806 001
 N18150 001
 N18150 001
 N18110 002
 FEB 27, 1996
 N18110 002
 FEB 27, 1996

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

AB TETRACYCLINE HCL 250MG
 WARNER CHILCOTT
 AB 500MG
 250MG
 500MG

N62300 001
 N62300 002
 N62300 001
 N62300 002

BP 100MG
 BP 200MG
 @ 100MG
 @ 200MG
 THEOPHYLLINE
 KY PHARM
 BP 100MG
 BP 200MG
 @ 100MG
 @ 200MG

N85264 001
 N85264 002
 N85264 001
 N85264 002

INJECTABLE; INJECTION

AP ACHROMYCIN 250MG/VIAL
 + LEDERLE
 AP 500MG/VIAL
 + 250MG/VIAL
 500MG/VIAL

N50273 002
 N50273 003
 N50273 002
 N50273 003

BP 100MG
 BP 200MG
 @ 100MG
 @ 200MG
 CAPSULE, EXTENDED RELEASE; ORAL
 SOMOPHYLLIN-CRT
 GRAHAM DM
 BC 50MG
 BC 100MG

N85263 001
 N85263 002
 N85263 001
 N85263 002

TETRACYN

PFIZER

AP 250MG/VIAL
 AB 500MG/VIAL
 250MG/VIAL
 500MG/VIAL

N60096 001
 N60096 002
 N60096 001
 N60096 002

N87763 001
 FEB 27, 1985
 N877194 001

TIMOLOL

SOLUTION/DROPS; OPHTHALMIC
 BETIMOL
 + OY STAR

EQ 0.5% BASE

N20439 002
 MAR 31, 1995

> DLT >
 > DLT >

TIOPRONIN

TABLET; ORAL
 TIOPRONIN
 * UNIV TX

100MG

N19569 001
 AUG 11, 1988

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC
TIMOLOL MALEATE
 ADV REMEDIES

EQ 0.25% BASE

EQ 0.5% BASE

N74465 001
 MAR 25, 1997
 N74466 001
 MAR 25, 1997
 N74515 001
 MAR 25, 1997
 N74516 001
 MAR 25, 1997
 N74778 001
 MAR 25, 1997
 N74776 001
 MAR 25, 1997
 N74667 001
 MAR 25, 1997
 N74668 001
 MAR 25, 1997
 N74746 001
 MAR 25, 1997
 N74747 001
 MAR 25, 1997

TOLBUTAMIDE

TABLET; ORAL
TOLBUTAMIDE
 PUREPAC PHARM

500MG

500MG

N88950 001
 JUN 17, 1985
 N88950 001
 JUN 17, 1985

TOLMETIN SODIUM

TABLET; ORAL
TOLMETIN SODIUM
 BAKER NORTON

EQ 600MG BASE

EQ 600MG BASE

EQ 600MG BASE

EQ 600MG BASE

N74399 001
 MAR 28, 1996
 N74729 001
 FEB 27, 1997
 N74729 001
 FEB 27, 1997
 N74399 001
 MAR 28, 1996

@ TEVA
 ZENITH GOLDLINE

TOPIRAMATE

TABLET; ORAL
 TOPAMAX
 @ JOHNSON RW

400MG

N20505 006
 DEC 24, 1996

TOREMIFENE CITRATE

TABLET; ORAL
 FARESTON
 + ORION

EQ 60MG BASE

N20497 001
 MAY 29, 1997

TIOCONAZOLE

OINTMENT; VAGINAL
 VAGISTAT-1
 * BRISTOL MYERS

6.5%

N19355 001
 DEC 30, 1986

TIOPRONIN

TABLET; ORAL
 TIOPRONIN
 + MISSION PHARMA

100MG

N19569 001
 AUG 11, 1988

> ADD >
 > ADD >

TRAZODONE HYDROCHLORIDE

TABLET; ORAL
TRAZODONE HCL
 TEVA

150MG

N74357 001
 APR 30, 1997

N85529 001
 N85529 001

TRETINOIN

CREAM; TOPICAL
AVITA
 PENEUDERM

0.025%

N20404 003
 JAN 14, 1997

N40209 001
 JUL 07, 1997

RETIN-A
 + J AND J

0.025%

N19049 001
 SEP 16, 1988

N40209 002
 JUL 07, 1997

GEL; TOPICAL
 RETIN-A MICRO
 + ADV POLYMER

0.1%

N20475 001
 FEB 07, 1997

N40209 004
 JUL 07, 1997

TRIAMCINOLONE

TABLET; ORAL
TRIAMCINOLONE
 FUREPAC PHARM

2MG

N84020 002

4MG

N84020 003

2MG

N84020 002

4MG

N84020 003

4MG

N83750 001

4MG

N83750 001

> - ADD >
 > - DLT >

N12947 001
 N12947 001

TRIAMCINOLONE ACETONIDE

LOTION; TOPICAL
TRIAMCINOLONE ACETONIDE
 ALPHARMA

0.1%

N87192 001

0.1%

SEP 08, 1982

N87192 001

SEP 08, 1982

N88804 001
 APR 03, 1987
 N88804 001
 APR 03, 1987

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION
TRIAMCINOLONE DIACETATE
 STERIS

40MG/ML
 40MG/ML

N85529 001
 N85529 001

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL
TRIFLUOPERAZINE HCL
 MYLAN

EQ 1MG BASE

N40209 001

EQ 2MG BASE

N40209 002

EQ 5MG BASE

N40209 003

EQ 10MG BASE

N40209 004

TRIHENXYPHENIDYL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
ARTANE
 * LEDERLE

5MG

N12947 001

5MG

N12947 001

ELIXIR; ORAL

TRIHENXYPHENIDYL HCL
 PHARM ASSOC

2MG/5ML

N40177 001

APR 17, 1997

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
TRIMETHOBENZAMIDE HCL
 ABBOTT

100MG/ML

N88804 001

100MG/ML

N88804 001

STERLING WINTHROP

N88804 001

APR 03, 1987

TRIMETHOPRIM

TABLET; ORAL

AB PROLOPRIM
GLAXO WELLCOME

200MG

N17943 003
JUL 14, 1982

INJECTABLE; INJECTION
VANCOCIN HCL IN PLASTIC CONTAINER
+ BAXTER HLTHCARE EQ 500MG BASE/100ML

N50671 001
APR 29, 1993
N50671 001
APR 29, 1993

AB +

200MG

N17943 003
JUL 14, 1982

* LILLY
EQ 500MG BASE/100ML

AB * TRIMPEX 200
ROCHE

200MG

N17953 002
NOV 09, 1982

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION
VERAPAMIL HCL

N70577 001
FEB 02, 1987
N70577 001
FEB 02, 1987

200MG

N17952 002
NOV 09, 1982

VERAPAMIL HCL

2.5MG/ML

AP ABBOTT
AB * STERLING WINTHROP

2.5MG/ML

TROGLITAZONE

TABLET; ORAL
PRELAY

AB SANKYO

200MG

N20719 001
JAN 29, 1997

TABLET, EXTENDED RELEASE; ORAL
ISOPTIN SR

300MG

N20719 003
AUG 04, 1997

+ KNOLL PHARM
120MG

400MG

N20719 002
JAN 29, 1997

VERAPAMIL HCL
BAKER NORTON

> DLT >

180MG

> DLT >

120MG

200MG

N20720 001
JAN 29, 1997

MYLAN

300MG

N20720 003
AUG 04, 1997

180MG

400MG

N20720 002
JAN 29, 1997

ZENITH GOLDLINE

> ADD >

180MG

> ADD >

180MG

> ADD >

180MG

UREA, C-14

CAPSULE; ORAL
PYTEST

1 uCi

N20617 001
MAY 09, 1997

INJECTABLE; INJECTION
VINCOREX

5MG/VIAL

N70867 001
JUL 12, 1988

1 uCi

N20617 002
MAY 09, 1997

BRISTOL MYERS

N70867 001
JUL 12, 1988

1 uCi

N20617 002
MAY 09, 1997

@ BRISTOL MYERS SQUIBB

N71561 001
APR 11, 1988

1 uCi

N20617 002
MAY 09, 1997

5MG/VIAL

N71561 001
APR 11, 1988

1 uCi

N20617 002
MAY 09, 1997

5MG/VIAL

N71561 001
APR 11, 1988

1 uCi

N20617 002
MAY 09, 1997

5MG/VIAL

N71561 001
APR 11, 1988

1 uCi

N20617 002
MAY 09, 1997

5MG/VIAL

N71561 001
APR 11, 1988

1 uCi

N20617 002
MAY 09, 1997

5MG/VIAL

N71561 001
APR 11, 1988

1 uCi

N20617 002
MAY 09, 1997

5MG/VIAL

N71561 001
APR 11, 1988

1 uCi

N20617 002
MAY 09, 1997

5MG/VIAL

N71561 001
APR 11, 1988

1 uCi

N20617 002
MAY 09, 1997

5MG/VIAL

N71561 001
APR 11, 1988

1 uCi

N20617 002
MAY 09, 1997

5MG/VIAL

N71561 001
APR 11, 1988

1 uCi

N20617 002
MAY 09, 1997

5MG/VIAL

N71561 001
APR 11, 1988

1 uCi

N20617 002
MAY 09, 1997

5MG/VIAL

N71561 001
APR 11, 1988

1 uCi

N20617 002
MAY 09, 1997

5MG/VIAL

N71561 001
APR 11, 1988

1 uCi

N20617 002
MAY 09, 1997

5MG/VIAL

N71561 001
APR 11, 1988

1 uCi

N20617 002
MAY 09, 1997

5MG/VIAL

N71561 001
APR 11, 1988

1 uCi

N20617 002
MAY 09, 1997

5MG/VIAL

N71561 001
APR 11, 1988

1 uCi

N20617 002
MAY 09, 1997

5MG/VIAL

N71561 001
APR 11, 1988

1 uCi

N20617 002
MAY 09, 1997

5MG/VIAL

N71561 001
APR 11, 1988

1 uCi

N20617 002
MAY 09, 1997

5MG/VIAL

N71561 001
APR 11, 1988

1 uCi

N20617 002
MAY 09, 1997

5MG/VIAL

N71561 001
APR 11, 1988

1 uCi

N20617 002
MAY 09, 1997

5MG/VIAL

N71561 001
APR 11, 1988

1 uCi

N20617 002
MAY 09, 1997

5MG/VIAL

N71561 001
APR 11, 1988

VITAMIN A PALMITATE

CAPSULE; ORAL

VITAMIN A

@ ZENITH GOLDLINE

@ ZENITH LABS

@

EQ 50,000 UNITS BASE
EQ 50,000 UNITS BASE
EQ 50,000 UNITS BASE
EQ 50,000 UNITS BASE

N83035 001
N83190 001
N83035 001
N83190 001

> ADD >
> ADD >
> DLT >
> DLT >

7.5MG
10MG

N40196 006
SEP 30, 1997
N40196 007
SEP 30, 1997

WARFARIN SODIUM

TABLET; ORAL

WARFARIN SODIUM

INVAMED

AB

> ADD >

> ADD >

> ADD >

> ADD >

WARFARIN SODIUM

TABLET; ORAL

COUMADIN

DUPONT MERCK

AB

+

1MG

N09218 022

MAR 01, 1990

N09218 013

N09218 018

N09218 023

AUG 24, 1993

N09218 007

N09218 016

N09218 005

2MG

2.5MG

4MG

5MG

7.5MG

10MG

1MG

N40145 001

MAR 26, 1997

N40145 002

MAR 26, 1997

N40145 003

MAR 26, 1997

N40145 004

MAR 26, 1997

N40145 005

MAR 26, 1997

N40145 006

MAR 26, 1997

N40145 007

MAR 26, 1997

N40196 001

SEP 30, 1997

N40196 002

SEP 30, 1997

N40196 003

SEP 30, 1997

N40196 004

SEP 30, 1997

N40196 005

SEP 30, 1997

EQ 25MG ZINC

EQ 50MG ZINC

N20458 001
JAN 28, 1997
N20458 002
JAN 28, 1997

ZINC ACETATE

CAPSULE; ORAL

GALZIN

TEVA

+

WARFARIN SODIUM

BARR

AB

INVAMED

> ADD >

CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL
DYNA-HEX
XTTRIUM

0.75%
N20111 001
SEP 11, 1997

>_ADD >
>_ADD >
>_ADD >

CHLORPHENIRAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL
CHLORPHENIRAMINE MALEATE
GENEVA PHARMS

12MG
12MG
N70797 001
AUG 12, 1988

>_DLT >
>_DLT >
>_ADD >
>_ADD >

TELDRIN

* SMITHKLINE
@

12MG
12MG
N17369 002
N17369 002
AUG 12, 1988

>_DLT >
>_ADD >
>_ADD >

CHLORPHENIRAMINE MALEATE, PHENYLPROPANOLAMINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
COLD CAPSULE IV
* GRAHAM DM

12MG;75MG
12MG;75MG
N18793 001
APR 25, 1985
N18793 001
APR 25, 1985

>_DLT >
>_DLT >
>_ADD >
>_ADD >

COLD CAPSULE V

GRAHAM DM
@

8MG;75MG
8MG;75MG
N18794 001
APR 23, 1985
N18794 001
APR 23, 1985

>_DLT >
>_ADD >

TABLET, EXTENDED RELEASE; ORAL

CONTAC
NOVARTIS

12MG;75MG
N19613 001
JUN 13, 1986

>_DLT >
>_ADD >

PHENYLPROPANOLAMINE HCL/CHLORPHENIRAMINE SANDOZ

12MG;75MG
N19613 001

12MG;75MG

>_DLT >
>_ADD >

CHLORPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
CODINAL-I.A. 12
* CENT PHARMS

12MG;120MG
N18935 001
APR 15, 1985

>_DLT >
>_ADD >

CHLORPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
CODINAL-I.A. 12
@ SCHWARZ PHARMA

12MG;120MG
N18935 001
APR 15, 1985

PSEUDOEPHEDRINE HCL AND CHLORPHENIRAMINE MALEATE KV PHARM

12MG;120MG
12MG;120MG
@

N71455 001
MAR 01, 1989
N71455 001
MAR 01, 1989

CIMETIDINE

TABLET; ORAL
TAGAMET HB
SMITHKLINE BEECHAM

100MG
100MG
N20238 001
JUN 19, 1995
N20238 001
JUN 19, 1995

CLEMASTINE FUMARATE

TABLET; ORAL
CLEMASTINE FUMARATE
LEWMON

1.34MG
1.34MG
N73282 002
DEC 03, 1992
N73282 002
DEC 03, 1992

TEVA

1.34MG
N73282 002
DEC 03, 1992

CLOTRIMAZOLE

CREAM; TOPICAL
LOTRIMIN AF
* SCHERING PLOUGH

1%
1%
N17619 002
OCT 27, 1989
N20888 001
OCT 27, 1989

CREAM, SUPPOSITORY, TOPICAL, VAGINAL

GYNE-LOTRIMIN 3 COMBINATION PACK
* SCHERING PLOUGH
GYNE-LOTRIMIN COMBINATION PACK
* SCHERING PLOUGH

1%,200MG
1%,100MG
N20526 002
JUL 29, 1996
N20289 002
APR 26, 1993

IBUPROFEN

TABLET; ORAL
NUPRIN
* PHARMACIA AND UPJOHN 200MG

N13012 003
JUL 29, 1987

MICONAZOLE NITRATE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL
M-ZOLE 7 DUAL PACK
ALPHARMA

N74586 001
JUL 17, 1997

INSULIN SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION
VELOSULIN BR HUMAN
+ NOVO NORDISK

N19450 001
MAY 30, 1986

100MG

N74414 001
APR 30, 1997
N74395 001
MAR 20, 1997

VELOSULIN HUMAN
* NOVO NORDISK

N19450 001
MAY 30, 1986

100MG

MINOXIDIL

SOLUTION; TOPICAL
MINOXIDIL (FOR MEN)
MORTON GROVE

N74767 001
FEB 28, 1997

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL
LOPERAMIDE HCL
MORTON GROVE

N74730 001
AUG 28, 1997

1MG/5ML

TABLET, CHEWABLE; ORAL
IMODIUM A-D
+ MCNEIL

N20448 001
JUL 24, 1997

2MG

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET, CHEWABLE; ORAL
IMODIUM ADVANCED
+ MCNEIL

N20606 001
JUN 26, 1996

2MG; 125MG

MICONAZOLE NITRATE

CREAM; VAGINAL
MICONAZOLE NITRATE
PERRIGO

N74760 001
MAY 15, 1997

2%

TARO

N74444 001
JAN 13, 1997

2%

PERMETHRIN

LOTION; TOPICAL

NIX

+ WARNER LAMBERT

1%

* WARNER WELLCOME

1%

N19918 001
MAY 02, 1990
N19918 001
MAY 02, 1990

EQ 200MG BASE

N74635 001
JAN 13, 1997

EQ 200MG BASE

N74646 001
JAN 13, 1997

EQ 200MG BASE

N74635 001
JAN 13, 1997

EQ 200MG BASE

N74661 001
JAN 13, 1997

EQ 200MG BASE

N74789 001
FEB 27, 1997

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES
KV PHARM
120MG;5MG
N71798 001
MAR 16, 1989
120MG;5MG
N71798 001
MAR 16, 1989

@

SODIUM FLUORIDE; TRICLOSAN

PASTE; DENTAL
COLGATE TOTAL
+ COLGATE PALMOLIVE 0.24%;0.3%
N20231 001
JUL 11, 1997

TIOCONAZOLE

OINTMENT; VAGINAL
VAGISTAT-1
+ BRISTOL MYERS SQUIBB 6.5%
N20676 001
FEB 11, 1997

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST
CUMULATIVE SUPPLEMENT NUMBER 9/ SEPTEMBER '97

NO SEPTEMBER 1997 APPROVALS

This data is provided to the Division of Data Management and Services from the Office of Orphan Products Development and it is not edited prior to publication.

Orphan Product Designations and Approvals List
January 1997 through September 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
15AU81 TN=	Treatment of primary pulmonary hypertension.	Lung Rx, Inc. 2 Davis Drive P.O. Box 13169 Research Triangle Park, NC 27709 DD=06/04/1997
8 Cyclopentyl 1,3-dipropylxant hine TN=	Treatment of cystic fibrosis.	SciClone Pharmaceuticals, Inc. 901 Mariner's Island Boulevard Suite 315 San Mateo, CA 94404 DD=03/24/1997
9-cis-retinoic acid TN=	Prevention of retinal detachment due to proliferative vitreoretinopathy.	Allergan, Inc. 2525 Dupont Drive P.O. Box 19534 Irvine, CA 92623 DD=01/02/1997
Allogeneic peripheral blood mononuclear cells sensitized against patient alloantigens by mixed lymphocyte culture TN= CYTOIMPLANT	Treatment of pancreatic cancer.	Applied Immunotherapeutics, LLC 14132 E. Firestone Boulevard Santa Fe Springs, CA 90670 DD=06/13/1997
Alpha-melanocyte stimulating hormone TN=	Prevention and treatment of intrinsic acute renal failure due to ischemia.	Star, Robert A., M.D. UT-Southwestern Medical School 5323 Harry Hines Dallas, TX 75235 DD=08/19/1997

Orphan Product Designations and Approvals List January 1997 through September 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Anagrelide TN= Agrylin	Treatment of essential thrombocythemia.	Roberts Pharmaceutical Corp. Meridian Center III 6 Industrial Way West Eatontown, NJ 07724 DD=01/27/1988 MA=03/14/1997
B2036-PEG TN= Trovert	Treatment of acromegaly.	Sensus Corporation Suite 430, 98 San Jacinto Boulevard Austin, TX 78701 DD=06/24/1997
Beta alethine TN= Betathine	Treatment of multiple myeloma.	Dovetail Technologies, Inc. 337 Paint Branch Drive College Park, MD 20742 DD=03/24/1997
Beta alethine TN= Betathine	Treatment of metastatic melanoma.	Dovetail Technologies, Inc. 10615 Mantz Road Silver Spring, MD 20903 DD=03/24/1997
Busulfan TN=	Treatment of primary brain malignancies.	Sparta Pharmaceuticals, Inc. 111 Rock Road Horsham, PA 19044 DD=07/07/1997
CY-1503 TN= Cylexin	Treatment of neonates and infants undergoing cardiopulmonary bypass during surgical repair of congenital heart lesions.	Cytel Corporation 3525 John Hopkins Court San Diego, CA 92121 DD=07/18/1997

Orphan Product Designations and Approvals List January 1997 through September 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Coagulation Factor IX (recombinant) TN= BeneFix	Treatment of hemophilia B.	Genetics Institute, Inc. 87 Cambridge Park Drive Cambridge, MA 02140 DD=10/03/1994 MA=02/11/1997
Cysteamine hydrochloride TN=	Treatment of corneal cystine crystal accumulation in cystinosis patients.	Sigma-Tau Pharmaceuticals, Inc. 800 South Frederick Avenue Gaithersburg, MD 20877 DD=08/19/1997
Dehydroepiandrosterone sulfate sodium TN=	To accelerate the re-epithelialization of donor sites in those hospitalized burn patients who must undergo autologous skin grafting.	Pharmadigm, Inc. 2401 Foothill Drive Salt Lake City, UT 84109 DD=01/28/1997
Dehydroepiandrosterone sulfate sodium TN=	Treatment of serious burns requiring hospitalization.	Pharmadigm, Inc. 2401 Foothill Drive Salt Lake City, UT 84109 DD=01/29/1997
Diazepam viscous solution for rectal administration TN=	For the management of selected, refractory, patients with epilepsy, on stable regimens of antiepileptic drugs (AEDs), who require intermittent use of diazepam to control bouts of increased seizure activity.	Athena Neurosciences, Inc. 800f Gateway Boulevard South San Francisco, CA 94080 DD=02/25/1992 MA=07/29/1997
Dimethylsulfoxide TN=	Topical treatment for the prevention of soft tissue injury following extravastion of cytotoxic drugs.	Cancer Technologies, Inc. 7301 East 22nd Street Suite 10E Tucson, AZ 85710 DD=04/15/1997

Orphan Product Designations and Approvals List January 1997 through September 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Enadoline hydrochloride TN=	Treatment of severe head injury.	Warner-Lambert Company Parke-Davis Pharmaceutical Research Division 2800 Plymouth Road Ann Arbor, MI 48105 DD=01/28/1997
Fampridine TN=	Treatment of chronic, incomplete spinal cord injury.	Acorda Therapeutics, Inc. 145 West 58th Sreet Suite 8J New York, NY 10019 DD=06/02/1997
Gp100 adenoviral gene therapy TN=	Treatment of metastatic melanoma.	Genzyme Corporation P.O. Box 9322 One Mountain Road Framingham, MA 01701 DD=03/25/1997
Human retinal pigmented epithelial cells on collagen microcarriers TN= Spheramine	Treatment of Hoehn and Yahr stage 3 and 4 Parkinson's disease.	Theracell, Inc. 50 Division Street, Suite 503 Somerville, NJ 08876 DD=07/18/1997
Icodextrin 7.5% with Electrolytes Peritoneal Dialysis Solution TN= Extraneal (with 7.5% Icodextrin) Peritoneal Dialysis Solution	Treatment of those patients having end stage renal disease and requiring peritoneal dialysis treatment.	Baxter Healthcare Corporation Renal Division 1620 Waukegan Road Waukegan, IL 60085 DD=07/18/1997

Orphan Product Designations and Approvals List January 1997 through September 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Lepirudin TN= Refluden	Treatment of heparin-associated thrombocytopenia Type II.	Behringwerke AG P.O. Box 1140 D-35001 Marburg Germany, DD=02/13/1997
Levocarnitine TN= Carnitor	Treatment of zidovudine-induced mitochondrial myopathy.	Sigma-Tau Pharmaceuticals, Inc. 800 S. Frederick Avenue, Suite 300 Gaithersburg, MD 20877 DD=04/07/1997
MART-1 adenoviral gene therapy for malignant melanoma TN=	Treatment of metastatic melanoma.	Genzyme Corporation One Kendall Square Cambridge, MA 02139 DD=03/28/1997
Oxandrolone TN= Oxandrin	Treatment of patients with Duchenne's muscular dystrophy and Becker's muscular dystrophy.	Bio-Technology General Corporation 70 Wood Avenue South Iselin, NJ 08830 DD=04/22/1997
Paclitaxel TN= Taxol	Treatment of AIDS-related Kaposi's sarcoma.	Bristol-Myers Squibb Pharmaceutical Research Institute 5 Research Parkway P.O. Box 5100 Wallingford, CT 06492 DD=03/25/1997 MA=08/04/1997
Paclitaxel TN= Paxene	Treatment of AIDS-related Kaposi's sarcoma.	Baker Norton Pharmaceuticals, Inc. 4400 Biscayne Boulevard Miami, FL 33137 DD=04/15/1997

**Orphan Product Designations and Approvals List
January 1997 through September 1997**

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Patul-end TN=	Treatment of patulous eustachian tube.	Ear Foundation 24209 Castillo Street, Suite 100 Santa Barbara, CA 93105 DD=02/18/1997
Poloxamer 188 TN=	Treatment of vasospasm in subarachnoid hemorrhage patients following surgical repair of a ruptured cerebral aneurysm.	CytRx Corporation 154 Technology Parkway Norcross, GA 30092 DD=08/05/1997
Poly-ICLC TN=	Treatment of primary brain tumors.	Salazar, Andres M. M.D. and Levy, Hilton B. Ph.D. 3202 Cleveland Avenue N.W. Washington, DC 20008 DD=03/17/1997
Porcine Sertoli cells aseptically prepared for intracerebral co-implantation with fetal neural tissue TN= N-Graft	Treatment of Hoehn and Yahr stage four and five Parkinson's disease.	Theracell, Inc. 50 Division Street Suite 503 Somerville, NJ 08876 DD=06/24/1997
Porfiromycin TN= Promycin	Treatment of cervical cancer.	Vion Pharmaceuticals, Inc. Four Science Park New Haven, CT 06511 DD=03/13/1997

Orphan Product Designations and Approvals List January 1997 through September 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Purified extract of <i>Pseudomonas</i> <i>aeruginosa</i> TN= ImmuDyn	Treatment of immune thrombocytopenia purpura where it is required to increase platelet counts.	DynaGen, Inc. 99 Erie Street Cambridge, MA 02139 DD=09/22/1997
Recombinant human acid alpha-glucosidas e TN=	Treatment of glycogen storage disease type II.	Chen, Y.T., M.D., Ph.D. Department of Pediatrics Duke University Medical Center Durham, NC 27710 DD=08/19/1997
Recombinant human alpha-L-iduronid ase TN=	Treatment of patients with mucopolysaccharidosis-I.	BioMarin Pharmaceuticals, Inc. 11 Pimental Court Novato, CA 94949 DD=09/24/1997
Recombinant human thrombopoietin TN=	For use in accelerating platelet recovery in patients undergoing hematopoietic stem cell transplantation.	Genentech, Inc. 1 DNA Way South San Francisco, CA 94080 DD=09/29/1997
Retroviral vector, R-GC and GC gene 1750 TN=	Treatment of Gaucher disease.	Genzyme Corporation One Kendall Square Cambridge, MA 02139 DD=05/06/1997
Sermorelin acetate TN= Geref	Treatment of idiopathic or organic growth hormone deficiency in children with growth failure.	Serono Laboratories, Inc. 100 Longwater Circle Norwell, MA 02061 DD=09/14/1988 MA=09/26/1997

Orphan Product Designations and Approvals List January 1997 through September 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Short chain fatty acid enema TN= Colomed	Treatment of chronic radiation proctitis.	Orphan Medical, Inc. 13911 Ridgedale Drive, Suite 475 Minnetonka, MN 55305 DD=08/19/1997
Suramin TN=	Treatment of metastatic hormone-refractory prostate cancer.	Warner-Lambert Company Parke-Davis Pharmaceutical Research Division 2800 Plymouth Road Ann Arbor, MI 48105 DD=05/06/1997
Testosterone TN= TheraDerm Testosterone Transdermal System	For use as physiologic testosterone replacement in androgen deficient HIV+ patients with an associated weight loss.	TheraTech, Inc. 417 Wakara Way Salt Lake City, UT 84108 DD=09/22/1997
Toremifene TN= Fareston	Hormonal therapy of metastatic carcinoma of the breast.	Orion Corporation P.O. Box 65 02101 ESPOO Finland, DD=09/19/1991 MA=05/29/1997
Zinc acetate TN= Galzin	Treatment of Wilson's disease.	Lemmon Company 1510 Delp Drive Kulpsville, PA 19443 DD=11/06/1985 MA=01/28/1997

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY
IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO SEPTEMBER 1997 ADDITIONS

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 17TH EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

REFERENCES

NEW DOSING SCHEDULE

- D-33 ONCE DAILY DOSING FOR PLAQUE PSORIASIS
D-34 EVERY FOUR MONTHS DOSAGE REGIMEN

NEW INDICATION

- I-177 TREATMENT OF MODERATE ACNE VULGARIS IN FEMALES, GREATER OR EQUAL TO 15 YEARS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, DESIRE CONTRACEPTION, HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS
- I-178 TREATMENT OF ONCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN
- I-179 NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE
- I-180 TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE)
- I-181 TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION
- I-182 TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME
- I-183 MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11
- I-184 TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2 MG/DAY (MAXIMUM OF 4MG)
- I-185 PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
- I-186 TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE)
- I-187 PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
- I-188 TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS
- I-189 TREATMENT OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS
- I-190 PLANAR IMAGING AS SECOND LINE DIAGNOSTIC DRUG AFTER MAMMOGRAPHY TO ASSIST IN THE EVALUATION OF BREAST LESIONS IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE BREAST MASS
- I-191 ENDOMETRIAL THNNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR DYSFUNCTIONAL UTERINE BLEEDING
- I-192 THE PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS AND A NEW DOSAGE REGIMEN, 40MG ONCE DAILY, FOR THIS INDICATION
- I-193 TREATMENT OF PANIC DISORDER IN A RECOMMENDED DOSE RANGE OF 50 TO 200MG/DAY
- I-194 CONGESTIVE HEART FAILURE
- I-195 USE OF LANSOPRAZOLE IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HSTORY OF DUODENAL ULCER

PATENT AND EXCLUSIVITY TERMS
NEW INDICATION

I-196 ACUTE TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
 I-197 MAINTENANCE OF HEALING OF DUODENAL ULCER
 I-198 USE OF LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE ERADICATION OF
 HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OF A
 ONE-YEAR HISTORY OF A DUODENAL ULCER
 I-199 MONOTHERAPY AND COMBINATION THERAPY WITH SULFONYLUREAS IN THE TREATMENT OF
 TYPE II DIABETES
 I-200 TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR
 I-201 EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS
 I-202 SECOND-LINE TREATMENT OF AIDS-RELATED KAPOSI'S SARCOMA
 I-203 MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS
 I-204 USE IN PEDIATRIC PATIENTS BETWEEN THE AGES OF 6 AND 11 FOR THE TREATMENT OF
 THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS
 I-205 INITIAL ANTICONVULSANT TREATMENT OF STATUS EPILEPTICUS
 I-206 TREATMENT OF EDEMA ASSOCIATED WITH CHRONIC RENAL FAILURE
 I-207 FOR THE SUPPRESSION OF RECURRENT EPISODES OF GENITAL HERPES IN IMMUNOCOMPETENT
 ADULTS

PATENT USE CODE

U-161 METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT
 U-162 METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM
 HYPERCHOLESTEROLEMIA
 U-163 METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR
 DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS
 U-164 METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-
 DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS
 U-165 TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
 U-166 TREATMENT OF H. PYLORI ASSOCIATED DUODENAL ULCER
 U-167 METHOD FOR TREATING HIV-1 INFECTION
 U-168 METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF
 ACTION IN THE TREATMENT OF ASTHMA
 U-169 METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC
 RESONANCE IMAGING
 U-170 METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST
 AGENT
 U-171 METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC
 RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT
 U-172 TREATMENT OF GENITAL WARTS
 U-173 ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES
 U-174 USE AS AN ANTIHISTAMINE AGENT
 U-175 METHOD OF TREATING MALIGNANT TUMORS
 U-176 METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING
 SPECIFIC PSYCHOSIS
 U-177 FUNGICIDE
 U-178 FACILITATED ADHERENCE OF AGENTS TO SKIN
 U-179 ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE
 AGENT
 U-180 TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER SIX MONTHS OF AGE) WITH ADVANCED
 HIV INFECTION
 U-181 PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST
 U-182 USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION
 U-183 TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION
 U-184 TREATING ALLERGIC EYE DISEASES IN HUMANS
 U-185 METHOD OF TREATING HYPERTENSION

PATENT AND EXCLUSIVITY TERMS
PATENT USE CODE

- U-186 METHOD FOR TREATING GI DISORDERS CAUSED BY H. PYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT
- U-187 THERAPEUTIC TREATMENT OF CALCIFIC TUMORS
- U-188 TREATMENT OF H. PYLORI ASSOCIATED DUODENAL ULCER
- U-189 ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE
- U-190 USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR
- U-191 METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN
- U-192 USE IN TREATING ALLERGIC REACTIONS
- U-193 PSORIASIS
- U-194 TREATING AGINA PECTORIS AND HIGH BLOOD PRESSURE
- U-195 METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOAC OR NITROGEN LABELED CARBON
- U-196 TREATMENT OF METASTIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS
- U-197 USE IN COMBINATION WITH CERTAIN LHRH ANALOGUES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER
- U-198 TREATMENT METASTIC CARCINOMA OF OVARY AFTER FIRST-LINE FAILURE OR SUBSEQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND SECOND-LINE TREATMENT OF AIDS-RELATED KAPOSI'S SARCOMA
- U-199 METHOD OF TREATING INFECTIOUS UPPER GI TRACT DISORDERS CAUSED BY CAMPYLOBACTER PYLORDIS INFECTION COMPRISING ADMINISTRATION OF A BISMUTH AGENT AND AN ANTIMICROBIAL AGENT
- U-200 METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF A BISMUTH-CONTAINING AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT
- U-201 METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF CAMPYLOBACTER-INHIBITING ANTIMICROBIAL AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT
- U-202 METHOD OF TREATING PEPTIC ULCER DISEASE CAUSED BY CAMPYLOBACTER PYLORDIS COMPRISING ORAL ADMINISTRATION OF 50 TO 5,000MG BISMUTH DAILY FOR 3-56 DAYS
- U-203 TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY
- U-204 USE OF TAXOL IN COMBINATION WITH G-CSF FOR TREATMENT OF PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA
- U-205 METHOD FOR TREATING HEARTBURN
- U-206 METHOD OF USING FSH ALONE, WITHOUT THE PRESENCE OF EXOGENOUS LH, IN IN VITRO FERTILIZATION

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020059 001	ADENOSINE; ADENOSCAN	5070877	MAY 18, 2009	U-116	NC	OCT 24, 1999
020291 001	ALBUTEROL SULFATE; COMBIVENT	5603918	JUN 09, 2015		NP	AUG 15, 1999
020503 001	ALBUTEROL SULFATE; PROVENTIL-HFA	5225183	JUL 06, 2010			
		5439670	JUL 06, 2010			
		5605674	FEB 25, 2014			
020560 001	ALENDRONATE SODIUM; FOSAMAX				I-185	APR 25, 2000
020560 002	ALENDRONATE SODIUM; FOSAMAX				I-187	APR 25, 2000
020560 003	ALENDRONATE SODIUM; FOSAMAX	5358941	DEC 02, 2012	U-114	I-185	APR 25, 2000
		4621077	NOV 04, 2003		I-187	APR 25, 2000
					NCE	SEP 29, 2000
>ADD>	ALPROSTADIL; EDEX				NP	JUL 06, 1998
>ADD>	ALPROSTADIL; EDEX				NP	JUL 06, 1988
>ADD>	ALPROSTADIL; EDEX				NP	JUL 06, 1998
>ADD>	ALPROSTADIL; EDEX				NP	JUL 06, 1998
020221 001	AMIFOSTINE; ETHYOL	5424471	JUL 31, 2012		NP	JUL 06, 1998
		5591731	JUL 31, 2012			
020333 001	ANAGRELIDE HYDROCHLORIDE; AGRYLIN				ODE	MAR 14, 2004
020333 002	ANAGRELIDE HYDROCHLORIDE; AGRYLIN				NCE	MAR 14, 2002
					ODE	MAR 14, 2004
					NCE	MAR 14, 2002
>ADD>	ARBUTAMINE HYDROCHLORIDE; GENESA				NCE	SEP 12, 2002
020420 001	ARDEPARIN SODIUM; NORMIFLO	4681893	MAY 30, 2006	U-161	NCE	MAY 23, 2002
020227 002	ATORVASTATIN CALCIUM; LIPITOR	5273995	DEC 28, 2010	U-162	NCE	DEC 17, 2001
020702 001	ATORVASTATIN CALCIUM; LIPITOR	5385929	MAY 04, 2014	U-59		
020702 002	ATORVASTATIN CALCIUM; LIPITOR	4681893	MAY 30, 2006	U-161	NCE	DEC 17, 2001
020702 003	ATORVASTATIN CALCIUM; LIPITOR	5273995	DEC 28, 2010	U-162	NCE	DEC 17, 2001
		5385929	MAY 04, 2014	U-59		
020486 001	BECLMETHASONE DIPROPIONATE; VANCERIL DOUBLE STRENGTH	4397839	JUL 01, 2005		NP	DEC 24, 1999
020032 001	BERACTANT; SURVANTA	5635172	JUN 03, 2014		NC	APR 17, 2000
020619 001	BETAXOLOL HYDROCHLORIDE; BETOPTIC PILO	4636505	OCT 01, 2008	U-191		
020498 001	BICALUTAMIDE; CASODEX	4636505	JAN 13, 2004			
>ADD>	BICALUTAMIDE; CASODEX	4472382	SEP 18, 2001	U-197		
>DLT>	BICALUTAMIDE; CASODEX	5389613	SEP 18, 2001	U-197		
>ADD>	BRIMONIDINE TARTRATE; ALPHAGAN				NP	MAR 13, 2000
020490 001	BRIMONIDINE TARTRATE; ALPHAGAN				NCE	SEP 06, 2001
020535 002	BROMFENAC SODIUM; DURACT	4907583	MAR 13, 2007		NCE	JUL 15, 2002
020441 002	BUDESONIDE; PULMICORT	4907583	MAR 13, 2007			
>ADD>	BUDESONIDE; PULMICORT	4524769	JUN 25, 2002			
>DLT>	BUDESONIDE; PULMICORT	4668218	APR 11, 2006			
020441 003	BUDESONIDE; PULMICORT	4907583	MAR 13, 2007			
>ADD>	BUDESONIDE; PULMICORT	4524769	JUN 25, 2002			
>DLT>	BUDESONIDE; PULMICORT	4668218	APR 11, 2006			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>						
018644 001	BUPROPION HYDROCHLORIDE; WELLBUTRIN	5358970	AUG 12, 2013			
018644 002	BUPROPION HYDROCHLORIDE; WELLBUTRIN	5358970	AUG 12, 2013			
018644 003	BUPROPION HYDROCHLORIDE; WELLBUTRIN	5358970	AUG 12, 2013		NP	MAY 14, 2000
020711 002	BUPROPION HYDROCHLORIDE; ZYBAN	5427798	AUG 12, 2013			
		RE33994	AUG 18, 2004			
020711 003	BUPROPION HYDROCHLORIDE; ZYBAN	5358970	AUG 12, 2013		NP	MAY 14, 2000
		5427798	AUG 12, 2013			
		RE33994	AUG 18, 2004			
		5021458	JUN 04, 2008	U-177		
020524 001	BUTENAFINE HYDROCHLORIDE; MENTAX	4078071	MAR 07, 1997			
019881 001	BUTOCONAZOLE NITRATE; FEMSTAT ONE	4526892	JUL 02, 2002		NP	FEB 07, 2000
020664 001	CABERGOLINE; DOSTINEX	4866048	DEC 29, 2007		NCE	DEC 23, 2001
020273 001	CALCIPOTRIENE; DOVONEX	4866048	DEC 29, 2007		D-33	MAR 20, 2000
020554 001	CALCIPOTRIENE; DOVONEX	4866048	DEC 29, 2007		NCE	DEC 29, 1998
020611 001	CALCIPOTRIENE; DOVONEX	4866048	SEP 12, 2006		NDF	DEC 29, 1998
						MAR 03, 2000
019880 001	CARBOPLATIN; PARAPLATIN	4657927	APR 14, 2004	U-175		
019880 002	CARBOPLATIN; PARAPLATIN	4657927	APR 14, 2004	U-175		
019880 003	CARBOPLATIN; PARAPLATIN	4657927	APR 14, 2004	U-175		
020297 001	CARVEDILOL; COREG					
020297 002	CARVEDILOL; COREG					
020297 003	CARVEDILOL; COREG					
020297 004	CARVEDILOL; COREG					
>ADD>						
>ADD>						
>ADD>						
>ADD>						
>ADD>						
>ADD>						
>ADD>						
>ADD>						
020740 001	CERIVASTATIN SODIUM; BAYCOL	5006530	JAN 17, 2009			
		5177080	NOV 26, 2011			
020740 002	CERIVASTATIN SODIUM; BAYCOL	5006530	JAN 17, 2009			
		5177080	NOV 26, 2011			
020740 003	CERIVASTATIN SODIUM; BAYCOL	5006530	JAN 17, 2009			
		5177080	NOV 26, 2011			
020740 004	CERIVASTATIN SODIUM; BAYCOL	5006530	JAN 17, 2009			
		5177080	NOV 26, 2011			
019835 001	CETIRIZINE HYDROCHLORIDE; ZYRTEC	4525358	JUN 25, 2007			
019835 002	CETIRIZINE HYDROCHLORIDE; ZYRTEC	4525358	JUN 25, 2007			
020346 001	CETIRIZINE HYDROCHLORIDE; ZYRTEC	4525358	JUN 25, 2007			
020519 001	CICLOPIROX; LOPROX	4525358	JUN 25, 2007			
019537 001	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	5286754	FEB 15, 2011			
		4670444	DEC 09, 2003	U-36		
019537 002	CIPROFLOXACIN HYDROCHLORIDE; CIPRO					
019537 003	CIPROFLOXACIN HYDROCHLORIDE; CIPRO					
019537 004	CIPROFLOXACIN HYDROCHLORIDE; CIPRO					
019847 001	CIPROFLOXACIN; CIPRO	4705789	NOV 10, 2004			
019857 001	CIPROFLOXACIN; CIPRO IN DEXTROSE 5%	4808583	FEB 28, 2006			
019858 001	CIPROFLOXACIN; CIPRO IN SODIUM CHLORIDE 0.9%	4705789	NOV 10, 2004			
017533 001	CLONAZEPAM; KLONOPIN					
017533 002	CLONAZEPAM; KLONOPIN					

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
017533 003	CLONAZEPAM; KLOMOPIN	5164377	OCT 03, 2010		I-184	APR 09, 2000
017533 005	CLONAZEPAM; KLOMOPIN	5563142	OCT 08, 2013		I-184	APR 09, 2000
017533 006	CLONAZEPAM; KLOMOPIN	5674850	DEC 23, 2013		I-184	APR 09, 2000
020463 001	CROMOLYN SODIUM; NASALCROM	5498598	JUN 29, 2013		NP	JAN 03, 2000
020430 001	DANAPAROID SODIUM; ORGARAN	5500413	JUN 29, 2013			
020705 001	DELAVIRIDINE MESYLATE; RESCRIPTOR	5482931	JUN 29, 2013			
017922 001	DESMOPRESSIN ACETATE; DDAVP	5674850	DEC 23, 2013		NCE	APR 04, 2002
017922 002	DESMOPRESSIN ACETATE; DDAVP	5498598	JUN 29, 2013			
017922 003	DESMOPRESSIN ACETATE; DDAVP	5500413	JUN 29, 2013			
018938 001	DESMOPRESSIN ACETATE; DDAVP	5674850	DEC 23, 2013			
018938 002	DESMOPRESSIN ACETATE; DDAVP	5482931	JUN 29, 2013			
019955 001	DESMOPRESSIN ACETATE; DDAVP	5674850	DEC 23, 2013			
019955 002	DESMOPRESSIN ACETATE; DDAVP	5500413	JUN 29, 2013			
020648 001	DIAZEPAM; DIASTAT	5462740	OCT 31, 2012		NDF	JUL 29, 2000
020648 002	DIAZEPAM; DIASTAT	5462740	OCT 31, 2012		ODE	JUL 29, 2004
020648 003	DIAZEPAM; DIASTAT	5462740	OCT 31, 2012		NDF	JUL 29, 2000
020648 004	DIAZEPAM; DIASTAT	5462740	OCT 31, 2012		ODE	JUL 29, 2004
020648 005	DIAZEPAM; DIASTAT	5462740	OCT 31, 2012		NDF	JUL 29, 2000
020037 001	DICLOFENAC SODIUM; VOLTAREN	4960799	OCT 03, 2007		ODE	JUL 29, 2004
020154 002	DIDANOSINE; VIDEX	4829088	APR 14, 2007		NDF	JUL 29, 2000
020154 003	DIDANOSINE; VIDEX	5616566	AUG 29, 2006	U-180		
020154 004	DIDANOSINE; VIDEX	5616566	AUG 29, 2006	U-180		
020154 005	DIDANOSINE; VIDEX	5616566	AUG 29, 2000	U-180		
020155 003	DIDANOSINE; VIDEX	5616566	AUG 29, 2006	U-180		
020155 004	DIDANOSINE; VIDEX	5616566	AUG 29, 2006	U-180		
020155 005	DIDANOSINE; VIDEX	5616566	AUG 29, 2000	U-180		
020156 001	DIDANOSINE; VIDEX	5616566	AUG 29, 2000	U-180		
018723 001	DIVALPROEX SODIUM; DEPAKOTE		AUG 29, 2006	U-180		
018723 002	DIVALPROEX SODIUM; DEPAKOTE					
018723 003	DIVALPROEX SODIUM; DEPAKOTE					
019680 001	DOLASETRON MESYLATE; DEPAKOTE					
020623 001	DOLASETRON MESYLATE MONOHYDRATE; ANZEMET	4988731	JAN 29, 2008		I-181	JUN 20, 1999
020623 002	DOLASETRON MESYLATE MONOHYDRATE; ANZEMET				I-181	JUN 20, 1999
020624 001	DOLASETRON MESYLATE MONOHYDRATE; ANZEMET				I-181	JUN 20, 1999
>ADD>					NCE	SEP 11, 2002
>ADD>					NCE	SEP 11, 2002

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>						
020624 002	DOLASETRON MESYLATE MONOHYDRATE; ANZEMET	4472380	SEP 18, 2001		NCE	SEP 11, 2002
020668 001	ENALAPRIL MALEATE; LEXXEL	4374829	DEC 30, 2001	U-3		
		4703038	OCT 07, 2005	U-3		
020164 001	ENOXAPARIN SODIUM; LOVENOX	4335139	JUN 15, 1999			
020444 001	EPOPROSTENOL SODIUM; FLOLAN	4539333	SEP 03, 2002	U-185		MAY 06, 2000
		4883812	MAY 12, 2006			
		4338325	JUL 06, 1999			
		4539333	SEP 03, 2002			
		4338325	JUL 06, 1999			
020444 002	EPOPROSTENOL SODIUM; FLOLAN	4883812	MAY 12, 2006	U-185		
		4335139	JUN 15, 1999			
		4906463	MAR 06, 2007			
		5006342	APR 09, 2008			
020417 001	ESTRADIOL; FEMPATCH				NP	DEC 03, 1999
020683 001	ETHINYL ESTRADIOL; ALESSE				NP	MAR 27, 2000
020683 002	ETHINYL ESTRADIOL; ALESSE	4544554	SEP 26, 2003	U-66	NP	MAR 27, 2000
019697 001	ETHINYL ESTRADIOL; ORTHO TRI-CYCLEN	4544554	SEP 26, 2003	U-66	I-177	DEC 31, 1999
019697 002	ETHINYL ESTRADIOL; ORTHO TRI-CYCLEN				I-177	DEC 31, 1999
018922 005	ETOOLAC; LODINE				I-24	JUN 28, 1999
020457 001	ETOPOSIDE PHOSPHATE; ETOPOPHOS	RE35524	AUG 04, 2007			
020363 001	FAMCICLOVIR; FAMVIR				I-207	SEP 16, 2000
020363 002	FAMCICLOVIR; FAMVIR				I-207	SEP 16, 2000
020363 003	FAMCICLOVIR; FAMVIR				I-207	SEP 16, 2000
020325 001	FAMOTIDINE; PEPCID AC					
>ADD>						
>ADD>						
>ADD>						
>ADD>						
019922 001	FENOLDOPAM MESYLATE; CORLOPAM	4283408	OCT 15, 2000	U-205	NCE	SEP 23, 2002
020410 001	FERUMOXSI1; GASTROMARK	5667794	MAY 02, 2015	U-171	NCE	DEC 06, 2001
		5069216	MAY 09, 2006			
		5219554	JUN 15, 2010			
		4827945	MAY 09, 2006	U-170		
		4951675	SEP 13, 2005	U-169		
		5055288	OCT 08, 2008			
		4695392	SEP 22, 2004			
		4695393	SEP 22, 2004			
		4770183	SEP 13, 2005	U-169		
020625 001	FEKOFENADINE HYDROCHLORIDE; ALLEGRA	5578610	NOV 26, 2013	U-192		
020038 001	FLUDARABINE PHOSPHATE; FLUDARA	4357324	FEB 24, 2003			
020582 001	FOLLITROPIN ALFA/BETA; FOLLISTIM	5270057	MAR 20, 2011	U-206	NP	SEP 29, 2000
>ADD>		4589402	JUL 26, 2004			
>ADD>		5270057	MAR 20, 2011	U-206	NP	SEP 29, 2000
>ADD>		4589402	JUL 26, 2004			
020582 002	FOLLITROPIN ALFA/BETA; FOLLISTIM					
020378 001	FOLLITROPIN ALFA/BETA; GONAL - F					
020378 002	FOLLITROPIN ALFA/BETA; GONAL - F	4087544	JAN 16, 2000	U-86	NP	SEP 29, 2000
020235 001	GABAPENTIN; NEURONTIN	4087544	JAN 16, 2000	U-86	NP	SEP 29, 2000
020235 002	GABAPENTIN; NEURONTIN	4894476	MAY 02, 2008			
020235 003	GABAPENTIN; NEURONTIN	4087544	JAN 16, 2000	U-86		
020622 001	GLATIRAMER ACETATE; COPAXONE					
020329 001	GLIPIZIDE; GLUCOTROL XL	5591454	JAN 07, 2014	U-150	ODE	DEC 20, 2003

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020329 002	GLIPIZIDE; GLUCOTROL XL	5591454	JAN 07, 2014	U-150		
019726 001	GOSERELIN ACETATE; ZOLADEX	5270317	MAR 20, 2011		I-191	JUN 27, 2000
>ADD>		5270317	MAR 20, 2011		NCE	SEP 30, 2002
>ADD>		5270317	MAR 20, 2011		NCE	SEP 30, 2002
020758 001	HYDROCHLOROTHIAZIDE; IRBESARTAN-HYDROCHLOROTHIAZID	4344949	OCT 03, 2000		NS	DEC 27, 1999
020758 002	HYDROCHLOROTHIAZIDE; IRBESARTAN-HYDROCHLOROTHIAZID	4743450	FEB 24, 2007		NC	JUN 27, 2000
020504 001	HYDROCHLOROTHIAZIDE; MICROZIDE	4344949	FEB 24, 2007		NC	JUN 27, 2000
020729 001	HYDROCHLOROTHIAZIDE; UNIRETIC	4743450	OCT 03, 2000		NC	JUN 27, 2000
020729 002	HYDROCHLOROTHIAZIDE; UNIRETIC	4743450	FEB 24, 2007		NC	JUN 27, 2000
020716 001	HYDROCODONE BITARTRATE; VICOPROFEN	4689338	AUG 25, 2004		NC	SEP 23, 2000
020267 002	IBUPROFEN; JUNIOR STRENGTH ADVIL	5238944	AUG 24, 2010		NP	JUN 16, 1998
020723 001	INIQUIMOD; ALDARA	5349085	SEP 20, 2011	U-172	NCE	FEB 27, 2002
020808 001	IOOIXANOL; VISIPAQUE 270	4278654	JUL 03, 1999			
>ADD>		4278654	JUL 03, 1999			
>ADD>		4278654	JUL 03, 1999			
>ADD>		4278654	JUL 03, 1999			
>ADD>		4278654	JUL 03, 1999			
020808 002	IOOIXANOL; VISIPAQUE 320	5349085	SEP 20, 2011			
>ADD>		5349085	SEP 20, 2011			
>ADD>		5349085	SEP 20, 2011			
>ADD>		5349085	SEP 20, 2011			
>ADD>		5349085	SEP 20, 2011			
020757 001	IRBESARTAN; AVAPRO	4278654	JUL 03, 1999			
020757 002	IRBESARTAN; AVAPRO	5270317	MAR 20, 2011		NCE	SEP 30, 2002
020757 003	IRBESARTAN; AVAPRO	5270317	MAR 20, 2011		NCE	SEP 30, 2002
>ADD>		5270317	MAR 20, 2011		NCE	SEP 30, 2002
040024 001	IRON DEXTRAM; DEXFERRUM	5624668	SEP 29, 2015			
020083 001	ITRACONAZOLE; SPORANOX				I-178	DEC 06, 1999
020657 001	ITRACONAZOLE; SPORANOX				NDP	FEB 21, 2000
019927 001	KETOCONAZOLE; NIZORAL				I-186	MAY 30, 2000
020857 001	LAMIVUDINE; COMBIVIR				NCE	NOV 17, 2000
020406 001	LANSOPRAZOLE; PREVACID				I-195	JUN 17, 2000
>ADD>					I-196	MAY 08, 2000
020406 002	LANSOPRAZOLE; PREVACID				I-197	APR 17, 2000
>ADD>					I-198	JUN 17, 2000
>ADD>					I-195	JUN 17, 2000
>ADD>					I-196	MAY 08, 2000
>ADD>					I-197	APR 17, 2000
>ADD>					I-198	JUN 17, 2000
>ADD>					I-196	MAY 08, 2000
>ADD>					I-197	APR 17, 2000
>ADD>					I-198	JUN 17, 2000
020726 001	LETROZOLE; FEMARA	4978672	DEC 18, 2007	U-203	NCE	JUL 25, 2002
020708 001	LEUPROLID ACETATE; LUPRON DEPOT-3	4652411	NOV 01, 2004		NP	MAR 07, 2000
>ADD>		4677191	JUL 03, 2005			
>ADD>		4728721	MAY 01, 2006			
>ADD>		4849228	JUL 18, 2006			
>ADD>		4917893	NOV 01, 2004			
>ADD>		4954298	NOV 01, 2004			
>ADD>		5330767	NOV 01, 2004			
>ADD>		5476663	APR 17, 2007			
>ADD>		5480656	JAN 02, 2013			
>ADD>		5575987	NOV 19, 2013			
>ADD>		5631020	MAY 20, 2014			
>ADD>		5631021	MAY 20, 2014			
>ADD>		4652441	NOV 01, 2004			
>ADD>		5643607	JUL 01, 2014			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019732 001	LEUPROLIDE ACETATE; LUPRON DEPOT	5631020	MAY 20, 2014			
		5631021	MAY 20, 2014			
		4954298	NOV 01, 2004			
		5480656	JAN 02, 2013			
		5643607	JUL 01, 2014			
020011 001	LEUPROLIDE ACETATE; LUPRON DEPOT	5631020	MAY 20, 2014			
		5631021	MAY 20, 2014			
		4954298	NOV 01, 2004			
		5480656	JAN 02, 2013			
		5643607	JUL 01, 2014			
020517 001	LEUPROLIDE ACETATE; LUPRON DEPOT	5631020	MAY 20, 2014			
		5631021	MAY 20, 2014			
		5643607	JUL 01, 2014			
		4677191	JUL 03, 2005			
		4728721	MAY 01, 2006			
		4849228	JUL 18, 2006			
020517 002	LEUPROLIDE ACETATE; LUPRON DEPOT-4	5631020	MAY 20, 2014			
		5631021	MAY 20, 2014			
		4652411	NOV 01, 2004			
		5476663	APR 17, 2007			
		5480656	JAN 02, 2013			
		5575987	NOV 19, 2013			
		4917893	NOV 01, 2004			
		4954298	NOV 01, 2004			
		5330767	NOV 01, 2004			
		5643607	JUL 01, 2014			
020263 002	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	5480656	JAN 02, 2013			
		5631020	MAY 20, 2014			
		5631021	MAY 20, 2014			
		5631021	MAY 20, 2014			
		4954298	NOV 01, 2004			
		5643607	JUL 01, 2014			
020263 003	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	5480656	JAN 02, 2013			
		5631020	MAY 20, 2014			
		5631021	MAY 20, 2014			
		4954298	NOV 01, 2004			
		5643607	JUL 01, 2014			
020263 004	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	5480656	JAN 02, 2013			
		5631020	MAY 20, 2014			
		5631021	MAY 20, 2014			
		4954298	NOV 01, 2004			
		5643607	JUL 01, 2014			
020263 005	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	5480656	JAN 02, 2013			
		5631020	MAY 20, 2014			
		5631021	MAY 20, 2014			
		4954298	NOV 01, 2004			
		5643607	JUL 01, 2014			
020263 006	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	5480656	JAN 02, 2013			
		5631020	MAY 20, 2014			
		5631021	MAY 20, 2014			
		4954298	NOV 01, 2004			
		5643607	JUL 01, 2014			

NS MAY 30, 2000
D-34 MAY 30, 2000

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	LIPASE;COTAZYM	5489436	FEB 06, 2013		NP	DEC 09, 1999
>ADD>	LOPERAMIDE HYDROCHLORIDE;IMODIUM A-D	5489436	FEB 06, 2013		NC	JUN 26, 2000
>ADD>	LOPERAMIDE HYDROCHLORIDE;IMODIUM ADVANCED	5679376	OCT 21, 2014			
		5248505	JUL 28, 2010			
		5612054	SEP 28, 2010			
	LORATADINE;CLARITIN	4659716	APR 21, 2004	U-142	NCE	APR 12, 1998
>ADD>	LORATADINE;CLARITIN REDITABS	4863931	SEP 15, 2008	U-77		
		4282233	JUN 19, 2002	U-142		
		4659716	APR 21, 2004			
>ADD>	LORAZEPAM;ATIVAN	4808605	NOV 10, 2007	U-194	I-205	SEP 05, 2000
>ADD>	LORAZEPAM;ATIVAN	4808605	NOV 10, 2007	U-194	I-205	SEP 05, 2000
	MESALAMINE;ASACOL	5637320	JUN 10, 2014		I-203	AUG 18, 2000
	METFORMIN HYDROCHLORIDE;GLUCOPHAGE	5637320	JUN 10, 2014		NCE	MAR 03, 2000
	METFORMIN HYDROCHLORIDE;GLUCOPHAGE	5637320	JUN 10, 2014		NCE	MAR 03, 2000
	MIBEFRADIL DIHYDROCHLORIDE;POSICOR	5637320	JUN 10, 2014		NCE	MAR 03, 2000
	MIBEFRADIL DIHYDROCHLORIDE;POSICOR	5637320	JUN 10, 2014		NCE	MAR 03, 2000
	NAPROXEN SODIUM;NAPRELAN	5637320	JUN 10, 2014		NCE	JUN 20, 2002
	NAPROXEN SODIUM;NAPRELAN	5637320	JUN 10, 2014		NCE	JUN 20, 2002
	NEDOCROMIL SODIUM;TILADE	5484926	OCT 07, 2013		I-183	MAR 06, 2000
	NELFINAVIR MESYLATE;VIRACEPT	5484926	OCT 07, 2013		NCE	MAR 14, 2002
	NELFINAVIR MESYLATE;VIRACEPT	5366972	NOV 22, 2011	U-167	NCE	MAR 14, 2002
	NEVIRAPINE;VIRAMUNE	5366972	NOV 22, 2011		NCE	JUN 21, 2001
	NIACIN;NIASPAN				NDF	JUL 28, 2000
	NIACIN;NIASPAN				NDF	JUL 28, 2000
	NIACIN;NIASPAN				NDF	JUL 28, 2000
	NIACIN;NIASPAN TITRATION STARTER PAC				NDF	JUL 28, 2000
	NIACIN;NIASPAN TITRATION STARTER PAC				NDF	JUL 28, 2000
	NICOTINE;NICOTROL	5605897	FEB 25, 2014	U-176	NP	MAY 02, 2000
	OLANZAPINE;ZYPREXA	5605897	FEB 25, 2014	U-176		
	OLANZAPINE;ZYPREXA	5605897	FEB 25, 2014	U-176		
	OLANZAPINE;ZYPREXA	4871865	OCT 03, 2006			
	OLANZAPINE;ZYPREXA	4923892	MAY 08, 2007	U-174		
	OLOPATADINE HYDROCHLORIDE;PATANOL	5116863	MAY 26, 2009			
		5641805	JUN 24, 2014	U-184		
		4636499	MAY 30, 2005			
	OMEPRAZOLE;PRILOSEC	5093342	FEB 02, 2010	U-166		
		5599794	FEB 04, 2014	U-166		
		5629305	FEB 04, 2014	U-188		
	OMEPRAZOLE;PRILOSEC	4636499	MAY 30, 2005	U-166		
		5093342	FEB 02, 2010	U-166		
		5599794	FEB 04, 2014	U-166		
		5629305	FEB 04, 2014	U-188		
	ONDANSETRON HYDROCHLORIDE;ZOFRAN	4753789	JUN 24, 2006	U-44		
		4695578	JUN 25, 2005	U-183		
		5578628	JUN 24, 2006	U-44		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES		
>ADD> >ADD>		019828 001 020262 001	OXITOMAZOLE NITRATE; OXISTAT PACLITAXEL; TAXOL	5670537 5496804 5641803 4721723 4721723 4721723 4721723 4721723 4721723	AUG 03, 2012 MAR 09, 2013 AUG 03, 2012 DEC 29, 2006 DEC 29, 2006 DEC 29, 2006 DEC 29, 2006 DEC 29, 2006 DEC 29, 2006	U-198 U-204 U-198 U-12 U-12 U-12 U-12 U-12 U-12	I-200 ODE I-202 I-150 I-150 I-150 I-150 I-150 I-150 I-150	AUG 18, 2000 AUG 04, 2004 AUG 04, 2000 MAY 07, 1999 MAY 07, 1999 MAY 07, 1999 MAY 07, 1999 MAY 07, 1999 MAY 07, 1999 MAY 07, 1999
>ADD> >DLT>		020031 001 020031 002 020031 003 020031 004 020031 005 020710 001 020710 001	PAROXETINE HYDROCHLORIDE; PAXIL PAROXETINE HYDROCHLORIDE; PAXIL PAROXETINE HYDROCHLORIDE; PAXIL PAROXETINE HYDROCHLORIDE; PAXIL PAROXETINE HYDROCHLORIDE; PAXIL PAROXETINE HYDROCHLORIDE; PAXIL PAROXETINE HYDROCHLORIDE; PAXIL	5114948 4180582 5114948 4180582 5114948 4180582	OCT 19, 2009 FEB 08, 1998 OCT 19, 2009 FEB 08, 1998 OCT 19, 2009 FEB 08, 1998	U-20 U-20	NCE NCE	DEC 29, 2006 MAR 07, 1999 MAR 07, 1999 MAR 07, 1999 MAR 07, 1999 MAR 07, 1999 MAR 07, 1999
>ADD> >DLT>		019385 001	PERGOLIDE MESYLATE; PERMAX	5114948 4180582	OCT 19, 2009 FEB 08, 1998	U-20	NCE	DEC 29, 1997
>ADD> >DLT>		019385 002 019385 003	PERGOLIDE MESYLATE; PERMAX PERGOLIDE MESYLATE; PERMAX	5114948 4180582 5114948 4180582	OCT 19, 2009 FEB 08, 1998 OCT 19, 2009 FEB 08, 1998	U-20 U-20	NCE NCE	DEC 29, 1997 DEC 29, 1997
>ADD> >DLT>		018796 001 020529 001	PILOCARPINE HYDROCHLORIDE; PILOPINE HS PODOFILOX; CONDYLOX	4271143 4680399 5057616 4866812 4866812 4866812 4866812 4866812 4242334 4242334 4242334 4242334 5656296 5656296	MAY 09, 1999 JUL 14, 2004 OCT 15, 2008 DEC 12, 2006 DEC 12, 2006 DEC 12, 2006 DEC 12, 2006 DEC 12, 2006 AUG 02, 2000 DEC 30, 1999 AUG 02, 2000 DEC 30, 1999 AUG 12, 2014 AUG 12, 2014	U-50 U-50 U-50 U-50	MAR 13, 2000 JUL 01, 2002 JUL 01, 2002 JUL 01, 2002 JUL 01, 2002 JUL 01, 2002 JUL 01, 2002	
>ADD> >DLT>		020667 001 020667 002 020667 003 020667 004 020667 005 019568 001 019568 001 020279 001 020279 001 020545 001 020545 002 020701 001 020756 001 019627 002 020639 001 020639 002 020639 003 020559 001	PRAMIPEXOLE DIHYDROCHLORIDE; MIRAPEX PRAMIPEXOLE DIHYDROCHLORIDE; MIRAPEX PRAMIPEXOLE DIHYDROCHLORIDE; MIRAPEX PRAMIPEXOLE DIHYDROCHLORIDE; MIRAPEX PRAMIPEXOLE DIHYDROCHLORIDE; MIRAPEX PREDNI CARBATE; DERMATOP PREDNI CARBATE; DERMATOP PREDNI CARBATE; DERMATOP PROCAINAMIDE HYDROCHLORIDE; PROCANBID PROCAINAMIDE HYDROCHLORIDE; PROCANBID PROGESTERONE; CRINONE PROGESTERONE; CRINONE PROGESTERONE; CRINONE PROPOFOL; DIPRIVAN QUETIAPINE FUMARATE; SEROQUEL QUETIAPINE FUMARATE; SEROQUEL QUETIAPINE FUMARATE; SEROQUEL RANITIDINE BISMUTH CITRATE; TRITEC	4879288 4879288 4879288 5256684 5403830 5407688 5601848 5629297 4686214 4686214	MAR 20, 2007 MAR 20, 2007 MAR 20, 2007 OCT 26, 2010 APR 04, 2012 APR 04, 2012 FEB 11, 2014 MAY 13, 2014 JUL 23, 2008 OCT 30, 2005	NP NP NP NP NCE NCE U-199 U-200 U-201 U-202 U-186 U-100 U-100	JUL 31, 2000 JUL 31, 2000 MAY 13, 2000 JUN 11, 1999 SEP 26, 2002 SEP 26, 2002 SEP 26, 2002	
>ADD> >DLT>		020474 001 020474 001	RIMEXOLONE; VEXOL RIMEXOLONE; VEXOL	4686214 4686214	OCT 30, 2005 OCT 30, 2005	U-100 U-100	NCE NCE	SEP 26, 2002 SEP 26, 2002

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020272 001	RISPERIDONE; RISPERDAL	5158952	OCT 27, 2009	U-90		
020272 002	RISPERIDONE; RISPERDAL	5158952	OCT 27, 2009	U-90		
020272 003	RISPERIDONE; RISPERDAL	5158952	OCT 27, 2009	U-90		
020272 004	RISPERIDONE; RISPERDAL	5158952	OCT 27, 2009	U-90		
020588 001	RISPERIDONE; RISPERDAL	5453425	JUN 11, 2014			
020659 001	RITONAVIR; NORVIR	5616587	JUN 11, 2014	U-190		
020680 001	RITONAVIR; NORVIR	5635523	JUN 03, 2014			
		5648497	JUN 15, 2014	U-190		
		5635523	JUN 03, 2014			
		5648497	JUL 15, 2014			
>ADD>	ROPINIROLE HYDROCHLORIDE; REQUIP				NCE	SEP 19, 2002
>ADD>	ROPINIROLE HYDROCHLORIDE; REQUIP				NCE	SEP 19, 2002
>ADD>	ROPINIROLE HYDROCHLORIDE; REQUIP				NCE	SEP 19, 2002
>ADD>	ROPINIROLE HYDROCHLORIDE; REQUIP				NCE	SEP 19, 2002
>ADD>	SALMETEROL XINAFOATE; SEREVENT				NCE	SEP 19, 2002
020570 001	SAMARIUM SM 153 LEXIDRONAM PENTASODIUM; QUADRAMET	5380922	JAN 10, 2012	U-182		
020570 002	SAMARIUM SM 153 LEXIDRONAM PENTASODIUM; QUADRAMET	5225445	FEB 12, 2008	U-187		
020443 001	SERMORELIN ACETATE; GEREFF	4898724	FEB 06, 2007	U-187		
		4898724	FEB 06, 2007			
>ADD>	SERMORELIN ACETATE; GEREFF				NP	SEP 26, 2000
>ADD>	SERMORELIN ACETATE; GEREFF				NP	SEP 26, 2000
>ADD>	SERMORELIN ACETATE; GEREFF				NP	SEP 26, 2000
019839 001	SERTRALINE HYDROCHLORIDE; ZOLOFT				OOE	SEP 26, 2000
019839 002	SERTRALINE HYDROCHLORIDE; ZOLOFT				OOE	SEP 26, 2000
019839 003	SERTRALINE HYDROCHLORIDE; ZOLOFT				OOE	SEP 26, 2000
019839 004	SERTRALINE HYDROCHLORIDE; ZOLOFT				OOE	SEP 26, 2000
019839 005	SERTRALINE HYDROCHLORIDE; ZOLOFT				OOE	SEP 26, 2000
020231 001	SODIUM FLUORIDE; COLGATE TOTAL				OOE	SEP 26, 2000
019640 001	SOMATROPIN, BIOSYNTHETIC; HUMATROPE				OOE	SEP 26, 2000
019640 004	SOMATROPIN, BIOSYNTHETIC; HUMATROPE				OOE	SEP 26, 2000
020168 001	SOMATROPIN, BIOSYNTHETIC; NUTROPIN				OOE	SEP 26, 2000
020168 002	SOMATROPIN, BIOSYNTHETIC; NUTROPIN				OOE	SEP 26, 2000
020604 003	SOMATROPIN, BIOSYNTHETIC; SEROSTIM				OOE	SEP 26, 2000
020626 001	SUMATRIPTAN; IMITREX				OOE	SEP 26, 2000
020626 002	SUMATRIPTAN; IMITREX				OOE	SEP 26, 2000
020626 003	SUMATRIPTAN; IMITREX				OOE	SEP 26, 2000
020579 001	TAMSULOSIN HYDROCHLORIDE; FLOMAX				OOE	SEP 26, 2000
020600 001	TAZAROTENE; TAZORAC	4816470	DEC 28, 2006	U-72		
020600 002	TAZAROTENE; TAZORAC	4816470	DEC 28, 2006	U-72		
019785 003	TECHNETIUM TC-99M SESTAMIBI KIT; MIRALUMA	4816470	DEC 28, 2006	U-72		
020372 001	TECHNETIUM TC-99M TETROFOSMIN KIT; MYOVIEU	4868216	SEP 19, 2006	U-181		
020372 002	TECHNETIUM TC-99M TETROFOSMIN KIT; MYOVIEU	4731478	OCT 27, 2004			
		4703063	OCT 27, 2004			
		4772475	FEB 27, 2006			
		5089509	FEB 18, 2009			
		5089509	FEB 18, 2009			
>ADD>	TECHNETIUM TC-99M TETROFOSMIN KIT; MYOVIEU	5045302	AUG 14, 2008	U-193		
>DLT>	TECHNETIUM TC-99M TETROFOSMIN KIT; MYOVIEU	5045302	APR 10, 2007	U-193		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019057 001	TERAZOSIN HYDROCHLORIDE;HYTRIN	5504207 5294615	APR 29, 2013 APR 29, 2013	U-165 U-3		
019057 002	TERAZOSIN HYDROCHLORIDE;HYTRIN	5504207 5294615	APR 29, 2013 APR 29, 2013	U-165 U-3		
019057 003	TERAZOSIN HYDROCHLORIDE;HYTRIN	5504207 5294615	APR 29, 2013 APR 29, 2013	U-165 U-3		
019057 004	TERAZOSIN HYDROCHLORIDE;HYTRIN	5504207 5294615	APR 29, 2013 APR 29, 2013	U-165 U-3		
020347 001	TERAZOSIN HYDROCHLORIDE;HYTRIN	5294615	APR 29, 2013	U-3		
020347 002	TERAZOSIN HYDROCHLORIDE;HYTRIN	5294615	APR 29, 2013	U-3		
020347 003	TERAZOSIN HYDROCHLORIDE;HYTRIN	5294615	APR 29, 2013	U-3		
020347 004	TERAZOSIN HYDROCHLORIDE;HYTRIN	5294615	APR 29, 2013	U-3		
020192 001	TERBINAFINE HYDROCHLORIDE;LAMISIL	5010090	OCT 07, 2008		I-180	JAN 21, 2000
020646 001	TIAGABINE HYDROCHLORIDE;GABITRIL	5354760	MAR 24, 2012		NCE	SEP 30, 2002
020646 002	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	OCT 07, 2008		NCE	SEP 30, 2002
020646 003	TIAGABINE HYDROCHLORIDE;GABITRIL	5354760	MAR 24, 2012		NCE	SEP 30, 2002
020646 004	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	OCT 07, 2008		NCE	SEP 30, 2002
020707 001	TILUDRONATE DISODIUM;SKELID	5354760 4876248 4980171	MAR 24, 2012 OCT 24, 2006 APR 06, 2009		NCE	MAR 07, 2002
020676 001	TIOCONAZOLE;VAGISTAT-1	4696949	SEP 29, 2004	U-196	NP	FEB 11, 2000
020497 001	TOREMIFENE CITRATE;FARESTON				NCE	MAY 29, 2002
020136 001	TORSEMIDE;DEMADEX				ODE	MAY 29, 2004
020136 002	TORSEMIDE;DEMADEX				I-206	SEP 09, 2000
020136 003	TORSEMIDE;DEMADEX				I-206	SEP 09, 2000
020136 004	TORSEMIDE;DEMADEX				I-206	SEP 09, 2000
020137 002	TORSEMIDE;DEMADEX				I-206	SEP 09, 2000
020404 003	TRETINOIN;AVITA	4971800	NOV 20, 2007	U-178		SEP 09, 2000
020475 001	TRETINOIN;RETIN-A MICRO	5045317	SEP 03, 2008	U-179		
020468 001	TRIAMCINOLONE ACETONIDE;NASACORT AQ	4690825	OCT 04, 2005	U-134	NP	FEB 07, 2000
074374 001	TRIMETHOPRIM HYDROCHLORIDE;PRIMSOL				I-204	SEP 26, 2000
020326 001	TRIMETREXATE GLUCURONATE;NEUTREXIN	4376858	MAY 09, 2004		I-189	JUN 17, 2000
020719 001	TROGLITAZONE;PRELAY	4572912 5104888 5478852 5457109 5602133	AUG 28, 2004 AUG 28, 2004 SEP 15, 2013 SEP 15, 2013 SEP 15, 2013		NCE	JAN 29, 2002
					I-199	AUG 04, 2000

>ADD>
>ADD>
>ADD>
>ADD>
>ADD>
>ADD>
>ADD>

>ADD>
>ADD>
>ADD>
>ADD>
>ADD>

>ADD>

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020719 002	TROGLITAZONE;PRELAY	4572912	AUG 28, 2004		NCE	JAN 29, 2002
		5104888	AUG 28, 2004	U-163	I-199	AUG 04, 2000
		5478852	SEP 15, 2013	U-164		
		5457109	SEP 15, 2013	U-173		
		5602133	SEP 15, 2013	U-164	I-199	AUG 04, 2000
020719 003	TROGLITAZONE;PRELAY	5457109	SEP 15, 2013	U-173	NCE	JAN 29, 2002
		5602133	SEP 15, 2013	U-163		
		5478852	SEP 15, 2013			
		4572912	AUG 28, 2004			
		5104888	AUG 28, 2004			
020720 001	TROGLITAZONE;REZULIN	5457109	SEP 15, 2013	U-164	NCE	JAN 29, 2002
		5602133	SEP 15, 2013	U-173	I-199	AUG 04, 2000
		5478852	SEP 15, 2013	U-163		
		4572912	AUG 28, 2004			
020720 002	TROGLITAZONE;REZULIN	5104888	AUG 28, 2004	U-173	NCE	JAN 29, 2002
		5602133	SEP 15, 2013		I-199	AUG 04, 2000
		4572912	AUG 28, 2004			
		5104888	AUG 28, 2004			
020720 003	TROGLITAZONE;REZULIN	5457109	SEP 15, 2013	U-163	I-199	AUG 04, 2000
		5457109	SEP 15, 2013	U-164	NCE	JAN 29, 2002
		5602133	SEP 15, 2013	U-173		
		5478852	SEP 15, 2013	U-163		
		4572912	AUG 28, 2004			
		5104888	AUG 28, 2004			
		4830010	MAY 15, 2006			
		4830010	MAY 15, 2006			
		5399578	MAR 21, 2012	U-3		
		5399578	MAR 21, 2012	U-3		
		5612367	MAR 18, 2014	U-189		
		5583152	AUG 22, 2006			
		4873259	FEB 10, 2007	U-168		
		4873259	FEB 10, 2007	U-168		
020617 001	UREA, C-14;PYTEST				NCE	MAY 09, 2002
020617 002	UREA, C-14;PYTEST KIT				NCE	MAY 09, 2002
020487 001	VALACYCLOVIR HYDROCHLORIDE;VALTREX				I-207	SEP 26, 2000
020487 002	VALACYCLOVIR HYDROCHLORIDE;VALTREX				I-207	SEP 26, 2000
020665 001	VALSARTAN;DIOVAN					
020665 002	VALSARTAN;DIOVAN					
020547 001	ZAFIRLUKAST;ACCOLATE					
020471 001	ZILEUTON;ZYFLO					
020471 003	ZILEUTON;ZYFLO					
020458 001	ZINC ACETATE;GALZIN					
020458 002	ZINC ACETATE;GALZIN					

>ADD>
>ADD>

ST. LOUIS COLLEGE OF PHARMACY



3 2201 90036 5673

RM301.45 .A66 1997 Sep Suppl

Approved drug products with
therapeutic equivalence

C:355661 M:174736 O:12937927

Library Use Only

LIBRARY
ST. LOUIS COLLEGE OF PHARMACY
4588 PARKVIEW PL.
ST. LOUIS, MO. 63110

